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Lay Summary 
Trypanosoma brucei, the parasite that causes African sleeping sickness, is 
transmitted from mammals to tsetse flies during its life cycle. To complete this 
transmission, the parasites must transform in the mammalian bloodstream from 
dividing forms, known as slender forms, to non-dividing stumpy forms which are 
able to survive in the harsh environment of the fly gut. As well as facilitating parasite 
transmission, this transformation regulates population growth within the mammal. 
The process involves complex metabolic and shape changes and has long been 
poorly understood at a molecular level. Many genes involved in the process, known 
as posST genes, have recently been identified. However, the interactions between the 
proteins they express and the order in which they act are yet to be elucidated. 
Deletion of specific posST genes in T. brucei prevents transformation to stumpy 
forms. In contrast, excess expression of the same genes enhances stumpy formation. 
Here, deletion of one posST gene is combined with enhanced expression of another 
in various combinations to explore the relationship between different posST proteins. 
This is used to order the pathway in which posST components act. In addition, 
changes in the phosphorylation of every protein in the cell are analysed in response 
to the deletion of two posST components to determine which proteins are affected by 
their absence. Another protein, TOR4, has been shown to inhibit transformation to 
stumpy forms and therefore acts antagonistically to the posST proteins. Expression 
of TOR4 and different posST components were simultaneously blocked to determine 
the effect on stumpy formation. This revealed information about the intersection 
between the stumpy-promoting posST pathway and the stumpy-inhibiting pathway. 
The order in which posST components act was further explored using drugs capable 
of artificially triggering the transition to stumpy forms. These drugs were tested on 
parasites in which expression of various posST genes had been silenced to determine 
if this loss of expression would block the pathway through which the drugs activated 
stumpy formation, thereby generating resistance to the compounds. The results 
provided further insight into the order of components of the posST pathway. One 
drug was tested on a population containing parasites in which expression of every 
gene was separately silenced, and analysis of those which developed resistance was 
used to identify novel genes involved in the stumpy transition. 
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Abstract 
In the mammalian bloodstream, the protozoan parasite Trypanosoma brucei 
undergoes differentiation from proliferative slender forms to arrested, transmissible, 
stumpy forms. This transition is associated with extensive cytological and metabolic 
changes that promote survival in the tsetse midgut, and also influences infection 
dynamics within the mammalian host. A number of genes involved in this 
transformation were recently identified using an RNAi library screen for resistance to 
pCPTcAMP, a membrane-permeable cyclic AMP analogue that induces 
differentiation. These molecules, referred to here as posST (positive mediators of 
STumpy formation), were thereafter validated to regulate the slender to stumpy 
transition, with many of them apparently comprising part of a signal transduction and 
effector pathway. However, it is unknown how these proteins act in relation to one 
another or are ordered within the pathway.  
To this end, null mutants were created for several posST components in 
differentiation-competent pleomorphic trypanosomes and, in this genetic 
background, other members of the predicted pathway expressed to test their ability to 
restore stumpy formation. Analysis of distinct combinations has been used to build a 
preliminary pathway structure model for the signalling events underlying 
trypanosome quorum sensing. In addition, phosphoproteomic analysis of two null 
mutants has revealed downstream signalling effects of two posST kinases, MEKK1 
and YAK.  
A similar extragenic suppression approach was also applied to explore the interaction 
between the identified drivers of stumpy formation and the target of rapamycin 
kinase, TOR4, which has previously been shown to act as a negative regulator of 
stumpy formation in monomorphs. Dual ablation of TOR4 and posST components 
revealed insight into the intersection of stumpy-promoting and stumpy-inhibiting 
pathways. 
Finally, a chemical-genetic approach was used to investigate the posST pathway 
using two differentiation-inducing compounds: the previously studied E667, and 
GKI7, newly identified from a kinase inhibitor set. RNAi lines for different posST 
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components were tested for their ability to undergo development in the presence of 
these compounds. An RNAi library screen using GKI7 identified putative new 
mediators of stumpy formation.  
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1 Chapter 1: Introduction 
 
  




Trypanosoma brucei is a protozoan parasite that is the causative agent of human 
African trypanosomiasis (HAT), or sleeping sickness, in humans and the ruminant 
disease nagana. Transmission between mammalian hosts, where they are found 
extracellularly in the bloodstream, is via the tsetse fly vector, geographically 
restricting disease to the tsetse belt of sub-Saharan Africa. It is an early-branching 
eukaryote of the Kinetoplastid order of motile flagellates. Reflecting its divergent 
evolutionary history, this order is of interest for its many unique features of 
molecular and cellular biology. These include the unusual mitochondrial DNA 
network, the kinetoplast, which gives it its name, as well as the large number of 
important human and veterinary pathogens contained within this order, including T. 
brucei, the Chagas disease parasite Trypanosoma cruzi and Leishmania species 
responsible for leishmaniasis. In addition to its significance as a pathogen and its 
distinctive biology, T. brucei has added value as a research tool due to its genetic 
tractability. The presence of an innate RNA interference (RNAi) system (Ngo et al., 
1998) along with the establishment of a tetracycline-regulated expression system by 
Wirtz et al. (1999) means that genetic manipulations such as targeted RNAi 
silencing, protein overexpression and gene knockouts are commonplace tools in the 
investigation of this unique and important parasite.  
 
 
HAT is caused by two subspecies of T. brucei, T. brucei gambiense and T. brucei 
rhodesiense. Humans are resistant to infection by all other African trypanosome 
species due to the presence of the innate immune molecule apolipoprotein L1 
(ApoL1), which acts as a constituent of two serum complexes, trypanosome lytic 
factors 1 and 2 (TLF-1 and TLF-2) to lyse trypanosomes (Perez-Morga et al., 2005; 
Vanhamme et al., 2003). T. b. gambiense and T. b. rhodesiense differ from each 
other by geographical distribution, rate of disease progression and mechanism of 
serum resistance. As shown in Figure 1.1, T. b. gambiense is found in West and 
central Africa and accounts for over 98% of HAT cases (WHO, 2015). It causes a 
1.1 Trypanosoma brucei 
1.2 HAT 
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chronic infection which may remain asymptomatic for months or years. Its resistance 
to human serum can be primarily attributed to TgsGP, a glycoprotein believed to 
prevent ApoL1 insertion into endosomal membranes (Uzureau et al., 2013). 
However, both reduced ApoL1 uptake, via mutation of the surface receptor through 
which it is endocytosed, and increased ApoL1 degradation, as a result of lowered 
endosomal pH, also contribute (DeJesus et al., 2013; Kieft et al., 2010; Uzureau et 
al., 2013). 
Figure 1.1 Distribution of HAT 2000-2009 (Simarro et al., 2010). 
T. b. rhodesiense, which is found in Eastern Africa, causes a more acute infection 
than T. b. gambiense, with symptoms appearing within a few weeks or months. T. b. 
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rhodesiense also infects animals, particularly livestock, which act as a reservoir for 
the disease (Welburn et al., 2015; Welburn et al., 2001). Serum resistance of T. b. 
rhodesiense is dependent on expression of the serum resistance-associated (SRA) 
protein, which binds to and inactivates ApoL1 (Vanhamme et al., 2003). 
For both rhodesiense and gambiense HAT, the disease can be divided into two 
stages: an early haemolymphatic stage in which the parasites divide within the blood 
and lymph, and a late neurological stage in which they penetrate the blood-brain 
barrier to invade the CNS. This latter stage is invariably fatal if untreated. 
There are currently 5 drugs used for treatment of HAT, all of which have significant 
disadvantages including low therapeutic index and difficulties with complicated 
administration regimes. Early stage infection is treated with pentamidine for T. b. 
gambiense and suramin for T. b. rhodesiense. However, as these compounds cannot 
cross the blood-brain barrier, melarsoprol or eflornithine must be used for late stage 
HAT. Melarsoprol is an arsenic-based compound with severe side effects, including 
reactive encephalopathy, which is fatal in 5-10% of cases. Eflornithine, an 
irreversible inhibitor of the T. brucei ornithine decarboxylase, is better tolerated but 
is ineffective against T. b. rhodesiense. Since 2009, it has been used in combination 
with the nitroheterocyclic compound nifurtimox, previously used in treatment of 
Chagas disease (Priotto et al., 2009). This combination therapy allows for a less 
complex treatment regimen.  
HAT occurs in 36 African countries and is considered a neglected disease. It is 
spread by tsetse flies of the genus Glossina. It predominantly affects rural 
communities with high exposure to these vectors. Disease control primarily involves 
vector control measures, population screening and chemotherapeutic treatment. 
Political disruption of surveillance programs in the second half of the 20th century 
resulted in a resurgence of disease burden. Renewed control efforts led in 2009 to the 
number of recorded cases dropping below 10,000 for the first time in 50 years. In 
2013, 6314 new cases were recorded (WHO, 2015). However, due to the remoteness 
of the most affected populations, it is likely that this figure underestimates the true 
disease burden (Odiit et al., 2005). 
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In addition to the human health consequences of HAT, animal trypanosomiasis, or 
nagana, has a vast economic impact. Cattle in particular can be infected with T. b. 
rhodesiense, T. b. brucei and other Trypanosoma species including Trypanosoma 
congolense and Trypanosoma vivax, resulting in a lethal wasting disease. This places 
a huge constraint on livestock farming across vast swathes of the continent, at an 
estimated economic cost of $1.3 billion dollars per year (Kristjanson et al., 1999). 
 
1.3 Gene expression in trypanosomes 
 
T. brucei is a diploid organism. Its nuclear genome comprises 11 pairs of megabase-
sized chromosomes as well as a small number of aneuploid intermediate 
chromosomes and approximately 100 minichromosomes (Berriman et al., 2005; 
Melville et al., 1998; Wickstead et al., 2004). The different types of chromosomes 
are depicted in Figure 1.2. 
 
 
Figure 1.2 Chromosomal complement of Trypanosoma brucei. 11 pairs of megabase chromosomes 
encode almost all protein-coding genes, which are expressed from polycistronic transcription units 
separated by transcriptional strand-switch regions. Aneuploid intermediate chromosomes and 
minichromosomes contain 177bp repeat regions and are a source of telomeric VSGs. VSGs are 
monoallelically expressed from bloodstream expression sites located at the telomeres of megabase and 
intermediate chromosomes. From Akiyoshi and Gull (2013). 
In contrast to other eukaryotes, T. brucei RNA polymerase I is responsible for 
transcribing not only rRNA but protein-coding genes, specifically the major surface 
proteins of the mammalian bloodstream and insect procyclic forms of the parasite, 
variant surface glycoprotein (VSG) and procyclin respectively (Gunzl et al., 2003). 
VSG is monoallelically expressed from an extensive repertoire of VSG genes found 
in telomeric and subtelomeric regions of the megabase, intermediate and 
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minichromosomes. The VSG coat protects the parasite from the host immune system 
by forming a dense physical barrier at the cell surface and undergoing antigenic 
variation (Cross et al., 2014; Schwede et al., 2011). VSG genes are expressed from 
telomeric bloodstream expression sites (BESs) located at the ends of the megabase 
and intermediate chromosomes. Periodic VSG switching occurs principally by either 
homologous recombination of a new VSG into an active BES or in situ switching to 
a new BES and enables the parasites to evade the humoral immune response 
(reviewed in (Gunzl et al., 2015; Horn, 2014). Procyclins are expressed from 
chromosome-internal positions and comprise 2 distinct classes, EP and GPEET, 
which refer to their respective dipeptide and pentapeptide repeat motifs. GPEET 
procyclin is expressed transiently in early procyclic forms while EP procyclin 
expression is maintained (Vassella et al., 2000). 
 
Figure 1.3 Polycistronic transcription of Trypanosoma brucei genes by RNA pol II. Genes are 
arranged in directional polycistrons separated by strand switch regions characterised by modified 
histones. Mature RNAs are generated from transcribed polycistrons by trans-splicing of a 5’ spliced 
leader RNA cap and polyadenylation of the 3’UTR. From Ouellette and Papadopoulou (2009). 
 
Most other protein-coding genes are arranged into long polycistrons separated by 
strand switch regions (SSRs) on the megabase chromosomes (Berriman et al., 2005; 
Imboden et al., 1987; Siegel et al., 2009). They are constitutively transcribed by 
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trans-splicing of a short spliced leader (SL) RNA to the 5’UTR and polyadenylation 
of the 3’UTR (Lebowitz et al., 1993; Matthews et al., 1994). With the exception of 
the SL RNA promoter (Das et al., 2005), no conventional pol II promoter sequences 
or associated transcription factors have been identified in T. brucei but transcription 
from SSRs appears to be facilitated by an open chromatin state characterised by 4 
histone variants (Siegel et al., 2009). This is summarised in Figure 1.3. Constitutive 
transcription means that regulation of protein expression is apparently exclusively 
post-transcriptional, in particular at the level of mRNA stability, a property often 
conferred by sequences within the 3’UTR (Furger et al., 1997; Haanstra et al., 2008a; 




The trypanosome cell has an elongated shape maintained by a subpellicular array of 
microtubules. This cytoskeletal structure determines the defined positions of the 
numerous single-copy organelles within the cell, as shown in Figure 1.4. 
 
 
Figure 1.4 Structure of the trypanosome cell, showing the positions of the principal organelles and 
cellular features. From Matthews (2005). 
1.4 The trypanosome cell 
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The cell is motile by means of a single flagellum, which originates in the basal body 
and emerges from the flagellar pocket, a membrane invagination at the posterior of 
the cell. The flagellum is anchored along the length of the cell body via the 
cytoskeletal flagellar attachment zone (FAZ) before extending from the anterior. Due 
to the restrictive corset of subpellicular array microtubules adjacent to the plasma 
membrane, the flagellar pocket is the only site of endocytosis and exocytosis within 
the cell (Field and Carrington, 2009). This is of particular consequence in the 
mammalian bloodstream form of the parasite, due to the high expression and rapid 
turnover of the VSG coat required to form a physical barrier to the host immune 
system and clear anti-VSG antibodies at low titres (Engstler et al., 2007). The surface 
coat of 5x106 VSG dimers per cell is completely recycled approximately every 12 
minutes, necessitating a phenomonal rate of endo- and exocytosis through an area 
comprising only 5% of the cell surface area (Engstler et al., 2007; Engstler et al., 
2004).  
The single trypanosome mitochondrion spans the length of the cell. In bloodstream 
forms, its structure and activity are diminished, reflecting a minimal role in energy 
metabolism at this stage, while the elaborated procyclic form contains cristae and has 
a highly active metabolism involving oxidative phosphorylation via the respiratory 
chain (Besteiro et al., 2005). Like many higher eukaryotes, various components of 
the T. brucei respiratory chain are mitochondrially encoded. However, the 
kinetoplast, the mitochondrial genome of the Kinetoplastida, is highly unusual. It 
comprises a giant network of thousands of concatenated circular DNAs, classed as 
maxicircles and minicircles (Shlomai, 2004). Maxicircles encode gene products but 
in many cases these require post-transcriptional processing by addition or deletion of 
uridines. This complex process, known as RNA editing, uses guide RNAs encoded 
on minicircles as templates for the production of functional mRNAs (Sturm and 
Simpson, 1990). The kinetoplast is physically connected to the basal body, and 
therefore the flagellum, via a filamentous structure known as the tripartite attachment 
complex (TAC), which enables faithful segregation of the kinetoplast during cell 
division (Ogbadoyi et al., 2003). 
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Trypanosomes also feature a number of atypical multicopy organelles. They 
compertmentalise glycolysis and other key metabolic pathways within peroxisome-
like organelles known as glycosomes. This compartmentalisation appears to be 
essential for the regulation of glycolysis in the absence of allosteric regulation of 
glycolytic enzymes (Haanstra et al., 2008b; Kessler and Parsons, 2005), and as the 
enzymatic complement of glycosomes varies between different life stages, 
potentially provides flexibility for rapid metabolic adaptation to new nutritional 
environments (Szoor et al., 2014). Acidocalcisomes are acidic organelles in which 
phosphorus, calcium and other cations are concentrated. They were first named in 
trypanosomes (Vercesi et al., 1994) but have since been identified in a wide range of 
organisms (Docampo et al., 2005). Although their precise function remains 
uncertain, roles have been proposed in intracellular regulation of pH, polyphosphate 
levels, calcium levels and osmoregulation (Lemercier et al., 2002; Lemercier et al., 
2004; Rohloff et al., 2004; Vercesi et al., 1994). 
 
 
Cell division in T. brucei requires faithful division and segregation of both the 
nuclear and kinetoplast genomes as well as the various single copy organelles. 
Therefore, the process is tightly regulated and organelle division proceeds in a 
precise order. Overall, it follows the typical eukaryotic program of G0/G1 phase, 
followed by DNA replication in S phase, G2 phase, mitosis and finally cytokinesis. 
Kinetoplast S phase initiates slightly before that of the nuclear genome. Early in G2 
phase, the first detectable morphological event is the duplication of the basal body 
from which the new flagellum forms. The connection of the basal body to the 
kinetoplast via the TAC ensures that this movement also results in segregation of the 
kDNA, prior to mitosis. This sequence of events allows stages of the cell cycle to be 
visualised microscopically using a nucleic acid stain such as 4’,6-diamidino- 2-
phenylindole (DAPI), as cells with a single kinetoplast and nucleus (1K1N) progress 
first to 2K1N and subsequently to 2K2N during G2/M phase. Cytokinesis occurs by 
formation of a cleavage furrow at the anterior of the cell, between the 2 flagella, 
which ingresses towards the posterior, dividing the newly segregated organelles into 
1.5 The trypanosome cell cycle 
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2 new daughter cells. These events are summarised in Figure 1.5. Cell cycle 
regulation and differentiation are closely linked processes in T. brucei, with 
transmissible stages in both mammalian and insect hosts being cell cycle arrested in 
G1/G0 phase. This allows subsequent differentiation upon entry into a new host to be 




Figure 1.5 Cell cycle events in procyclic T. brucei. a) In G1, cells have a single kinetoplast and 
nucleus. b) The basal body divides and a second flagellum outgrows. c) Basal body separation 
leads to segregation of the attached kinetoplast. Cell is now 2K1N. d) Nucleus divides in M phase. 
e) Completion of mitosis produces 2K2N cell. f) Cytokinesis occurs by furrow ingression from 
anterior to posterior of cell. g) Cytokinesis completes with formation of 2 daughter cells, each with 
a single nucleus, kinetoplast and flagellum. From Akiyoshi and Gull (2013). 




Trypanosomes encounter metabolically and immunologically diverse environments 
in the course of their life cycle as they pass from the mammalian bloodstream first to 
the midgut, then proventriculus and finally salivary glands of the tsetse vector. To 
adapt to these changes, they undergo a programmed series of differentiation events to 
distinct life stages, involving changes in morphology, metabolism, gene expression 
and cell cycle status. This process is depicted in Figure 1.6 and described in detail in 
sections 1.6.1 and 1.6.2. 
 
 
Figure 1.6 Life cycle of T. brucei, representing the morphology, location and cell cycle status of each 
developmental stage. From Langousis et al. (2014). 
 
1.6 The trypanosome life cycle 
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1.6.1 The mammalian stages 
Metacyclic trypanosomes enter the dermal connective tissue of the mammalian host 
via the bite of an infective tsetse fly and pass to the bloodstream via the lymphatic 
system. These forms already express a VSG coat for immune evasion but metacyclic 
VSGs represent a distinct, more limited repertoire to those expressed in slender 
forms (Turner et al., 1988a). Metacyclics transform into long slender forms which 
proliferate extracellularly in the bloodstream. In this glucose-rich environment, 
energy is generated by glycolysis and the mitochondrion is relatively repressed. They 
evade the host’s humoral response by VSG switching (see section 1.3) and when 
present at sufficiently high densities undergo differentiation to cell cycle arrested 
transmissible stumpy forms which are competent to infect the tsetse fly (Reuner et 
al., 1997). This transformation is described in detail in section 1.7. 
1.6.2 The tsetse stages 
Bloodstream trypanosomes taken up in a tsetse blood meal enter the insect midgut 
where slender forms die and stumpy forms differentiate to procyclic forms (Turner et 
al., 1988b). This process is described in section 1.8. Procyclic forms are proliferative 
and have an active mitochondrial metabolism in which ATP is generated via 
oxidative phosphorylation, for which proline serves as their primary carbon source 
(Evans and Brown, 1972). They express a surface glycoprotein coat consisting of 
GPEET and EP procyclins. The former is repressed after 7-9 days while EP 
expression persists (Vassella et al., 2000). The parasites cross the peritrophic matrix 
to colonise the ectoperitrophic space and migrate to the proventriculus. Here, cells 
lengthen and arrest before differentiating to epimastigotes via an asymmetric division 
which produces one long and one short daughter cell (Sharma et al., 2008). The long 
cell is believed to die while the short epimastigote moves to the salivary glands and 
attaches to the epithelium via its flagellum. It is here that they differentiate to 
proliferative premetacyclics and then arrested metacyclics expressing a VSG coat. 
Mature metacyclics detach ready for injection into a new mammalian host. The 
salivary glands are also the site of genetic exchange in the parasite, with meiotic 
dividers representing a distinct stage of dividing epimastigotes (Peacock et al., 2011).  
 




It has long been observed in trypanosome infections that parasitaemia follows a 
cyclical wave pattern, a phenomenon generally attributed to the battle between the 
host antibody response and the parasites’ subsequent evasion by switching antigenic 
variant. However, another important contributing factor to this profile is that at high 
densities, T. brucei differentiate to transmissible stumpy forms (Gjini et al., 2010; 
Reuner et al., 1997; Vickerman, 1985). These forms are cell cycle arrested (Shapiro 
et al., 1984), which is important for tightly regulated differentiation, causing the 
subsequent transformation to procyclic form to proceed in a synchronous manner 
(Ziegelbauer et al., 1990). It also serves as an important mechanism of growth 
control in the mammalian host, preventing the parasitaemia from overwhelming the 
host and striking a balance between proliferation and differentiation which enables 
maximum transmissibility. Indeed, it has been shown using the stumpy-specific 
marker PAD1 that stumpy forms dominate chronic infections beyond the first wave 
of parasitaemia (MacGregor et al., 2011).  
Differentiation involves significant morphological and metabolic changes which 
render stumpy forms competent to infect the tsetse fly (Robertson, 1913; Vickerman, 
1965). Morphological rearrangements confer the eponymous stumpy appearance and 
the mitochondrion becomes elaborated in preparation for oxidative phosphorylation 
in the tsetse fly (Vickerman, 1985). The lysosome relocates anteriorly to the nucleus 
(Vanhollebeke et al., 2010) and upregulates its activity (Brickman and Balber, 1994). 
The cells lose mono-allelic control of VSG expression (Amiguet-Vercher et al., 
2004) but are able to use hydrodynamic flow to remove surface-bound 
immunoglobulin more efficiently than slender forms (Engstler et al., 2007) and as a 
result show greater resistance to antibody-dependent complement-mediated lysis 
than their slender counterparts (McLintock et al., 1993). They also show increased 
resistance to acidic and proteolytic stress critical for survival in the tsetse midgut 
(Nolan et al., 2000). Stumpy forms are also characterised by upregulation of a family 
of surface carboxylate transporters known as PAD (proteins associated with 
differentiation), which are responsible for transducing the procyclic differentiation 
1.7 Slender to stumpy differentiation 
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signal (Dean et al., 2009)(see section 1.8). The stumpy enrichment of PAD1 has 
made it an invaluable surface marker for this stage (MacGregor et al., 2014; 
MacGregor et al., 2011; Mony et al., 2014) while PAD2 is upregulated and surface-
localised only at low temperatures (Dean et al., 2009). In general, there is a global 
repression of gene expression in stumpy forms (Brecht and Parsons, 1998). However, 
a number of recent studies which have analysed global expression changes during 
differentiation have found selective enrichment of certain transcripts or proteins 
which are consistent with the changes described above (Capewell et al., 2013; 
Dejung et al., 2016; Gunasekera et al., 2012; Jensen et al., 2009; Kabani et al., 2009; 
Nilsson et al., 2010). Among them are numerous mitochondrial transcripts including 
respiratory complex components and a chloride channel possibly related to elevated 
lysosomal activity (Kabani et al., 2009). Also upregulated are transcripts required for 
procyclic differentiation including members of the PAD family, procyclins and the 
enzyme MSP-B, which is required for VSG cleavage (Capewell et al., 2013; Kabani 
et al., 2009).  
The arrested state of stumpy forms means that the capacity to differentiate is selected 
against over long periods of continuous passage. As a result, the majority of 
molecular research on T. brucei uses so-called monomorphic strains which have lost 
the ability to produce stumpy forms, while differentiation-competent strains known 
as pleomorphs have proved less amenable to culture and genetic manipulation. This 
has long hindered investigation of differentiation and it was the development of 
plate-based in vitro culture system for pleomorphic trypanosomes by Vassella and 
Boshart (1996) which enabled the key discoveries that differentiation is density-
dependent (Reuner et al., 1997) and triggered by a parasite-derived signal, stumpy 
induction factor (SIF), in a form of quorum sensing (Vassella et al., 1997). SIF is a 
low molecular weight factor or factors of unknown identity secreted by the parasites 
which accumulates extracellularly as the parasites proliferate and induces 
differentiation beyond a threshold density. Accordingly, pleomorphic trypanosomes 
can be induced to differentiate by culture in medium conditioned by growth of 
parasites to a high density. In contrast, monomorphic strains are believed to produce 
SIF, but have lost the ability to respond to this signal. Thus although media 
conditioned by dense growth of monomorphic trypanosomes triggers the 
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differentiation of pleomorphic strains, the converse is not true (Vassella et al., 1997). 
Although SIF remains unidentified nearly 20 years after these observations were first 
made, more recent improvements in the culture of pleomorphs and the establishment 
of a stable and efficient transfection system (MacGregor et al., 2013) are facilitating 
significant advancement in elucidating the molecular processes governing 
differentiation. 
Another intriguing aspect of the differentiation process is the role of the second 
messenger cyclic AMP. Vassella et al. (1997) observed that membrane-permeable 
forms of cAMP could mimic the effects of SIF in triggering differentiation to stumpy 
forms and that the molecule was upregulated in response to SIF, implicating cAMP 
as a downstream mediator of SIF. Interestingly, monomorphic parasites can also be 
induced to differentiate in response to membrane-permeable cAMP (Breidbach et al., 
2002), indicating that the factor which confers differential responsiveness to 
differentiation signals between monomorphic and pleomorphic strains operates 
somewhere between SIF and cAMP in the pathway. However, the involvement of 
cAMP is not straightforward. cAMP pathways in trypanosomes are poorly 
understood and appear to have diverged significantly from their mammalian 
counterparts (Gould and de Koning, 2011). Its most common substrate, protein 
kinase A, appears not to be activated by cAMP in this organism (Shalaby et al., 
2001). Furthermore, Laxman et al. (2006) subsequently demonstrated that it is not 
cAMP itself, but its hydrolysis products adenosine and AMP, which are in fact 
responsible for the effects on differentiation.  
 
 
Bloodstream form T. brucei enter the tsetse midgut when ingested in the blood meal. 
Slender forms die while stumpy forms become competent to respond to the 
differentiation signal citrate/cis-aconitate (CCA) and transform to procyclic forms. 
At 37°C, the parasites are insensitive to the micromolar concentrations of CCA 
found in the blood meal (Engstler and Boshart, 2004). However, as mentioned in 
section 1.7, the cold shock encountered upon entering the fly midgut triggers the 
1.8 Stumpy to procyclic differentiation 
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carboxylate transporter PAD2 to be upregulated and relocalised from the flagellar 
pocket to the cell surface (Dean et al., 2009). This acts as a transporter for CCA and 
therefore renders the cell sensitive to the differentiation signal. Within the cell, the 
tyrosine phosphatase TbPTP1 inhibits differentiation (Szoor et al., 2006) by 
dephosphorylating the DxDxT phosphatase TbPIP39 (Szoor et al., 2010). TbPIP39 in 
turn activates TbPTP1, thereby reinforcing its own inhibition. CCA abrogates this 
feedback loop and TbPIP39 is activated and triggers transformation to procyclic 
forms. Its downstream target is unknown. However, it has been shown that TbPIP39 
localises to the glycosomes and that this localization is required for differentiation 
(Szoor et al., 2010). These events are summarised in Figure 1.7. A number of other 
triggers have been shown to induce procyclic differentiation (Rolin et al., 1998; 
Yabu and Takayanagi, 1988). Of these, mild acid treatment has been shown to 
operate through the TbPTP1 signalling cascade, while protease treatment operates 
independently of this pathway (Szoor et al., 2013). 
 
Figure 1.7 Model of the regulation of stumpy to procyclic differentiation. TbPIP39 acts on an 
unknown glycosomal target to trigger differentiation from stumpy to procyclic form. However, this 
action is prevented by dephosphorylation and inactivation by TbPTP1. TbPIP39 activates TbPTP1, 
reinforcing its own inhibition. This feedback loop is abolished by the differentiation signal CCA, 
which is conveyed to the cell via PAD transporters. 
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SIF is believed to initiate stumpy formation via a signalling cascade. However, the 
molecular identity of SIF remains elusive and that of its downstream effectors have 
only recently begun to be revealed. A major breakthrough in the identification of 
such signalling components came from a screen by Mony et al. (2014) of a 
monomorphic RNA interference library. This library takes advantage of the well-
established tetracycline-inducible RNA silencing system in T. brucei and applies it 
on a genome-wide scale, so that within a population of cells every gene is separately 
targeted for RNAi ablation (Morris et al., 2002). Induction of the library under a 
particular selectional condition or in the presence of a specific compound, followed 
by sequencing of the RNAi inserts of the surviving population, can therefore be used 
to identify genes for which silencing confers a selective advantage under those 
conditions (Glover et al., 2015).  This presents a powerful forward genetic screen, 
which has been used to determine essentiality of genes in different parasite life cycle 
stages on a genomic scale (Alsford et al., 2011) and to explore diverse aspects of 
trypanosome biology, including drug action and resistance (Alsford et al., 2012), 
serum lysis (Lecordier et al., 2014) and RNA regulation (Schumann Burkard et al., 
2013).  
 
As discussed in section 1.7, monomorphic trypanosomes are unable to respond to 
SIF but can be induced to differentiate using membrane-permeable forms of cAMP 
and AMP (Laxman et al., 2006; Vassella et al., 1997). Therefore, to investigate 
stumpy formation, the RNAi library was induced in the presence of 8-(4-
chlorophenylthio)-cAMP (pCPTcAMP) or 8-pCPT-2’-O-methyl-5’-AMP (Mony et 
al., 2014). This resulted in the eventual loss of most cells due to differentiation-
associated arrest and the outgrowth of a population in which cAMP/AMP response 
effectors had been silenced. Sequencing of the RNAi loci identified numerous genes 
implicated in the stumpy signalling pathway. This strategy is depicted in Figure 1.8.  
1.9 Molecular components of slender to stumpy 
differentiation 
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Figure 1.8 RNAi library screen used to identify components of stumpy signalling pathway in Mony et 
al. (2014). Genome-wide RNAi silencing was induced with tetracycline and the cells treated with 
pCPTcAMP or 8-pCPT-2’-O-Me-5’-AMP to trigger differentiation, leading to arrest of the uninduced 
(tet-) population. Induced (tet+) cells containing RNAi inserts which silence cAMP/AMP response 
effectors outgrew. The responsible genes were identified by sequencing of RNAi inserts. From Mony 
et al. (2014). 
 
This screen identified numerous components of stumpy formation which are shown 
in Figure 1.9. Although a number of inhibitors of stumpy formation had previously 
been characterised (see section 1.9.4), this cohort, referred to here as posST (positive 
mediators of STumpy formation) represented the first known promoters of 
differentiation. Signal transducers such as kinases and phosphatases as well as 
regulators of gene expression are represented, but their individual roles and 
interactions remain to be characterised in order to construct a defined pathway. 
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Figure 1.9 List of genes identified from RNAi library screen after selection with pCPT-cAMP or 8- 
pCPT-2’-O-Me-5’-AMP (Mony et al., 2014). Columns indicate: 1) target accession no.; 2) specific 
screen(s) in which gene was selected; 3) functional prediction where available; 4) whether gene has 
been tested in independent monomorphic RNAi line; 5) growth characteristics upon RNAi induction 
(1. No verified RNAi competent lines were isolated from several transfections. 2. Slow growth in 
vitro and, to a lesser extent, in vivo. 3. Strong growth inhibition. 4. Weak growth inhibition in vitro or 
in vivo 5. Leaky RNAi in all six lines tested.); 6) ‘SIF res?’ indicates whether RNAi line showed SIF 
resistance and hence reduced stumpy formation in vivo; 7 and 8) whether a reduced fitness (✓) was 
observed in differentiating (7) or procyclic (8) in a genome wide RNAi library screen (Alsford et al., 
2011). From Mony et al. (2014). 
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Tb927.2.1810 AMP ISWI  ݳ ND  ND ݱ ݱ 
Tb927.2.2720  cAMP MEK kinase ݳ ݱ ND ݳ ݱ 
Tb927.2.4020 AMP ubiquitin activating 
enzyme,  
 ݱ ݱ ND 1 ݳ
Tb927.3.4560 cAMP AMPK SNF1 like family 1 ݱ ND ݳ ݳ 
Tb927.4.670  cAMP  hypothetical conserved ݳ ND ND ݳ ݳ 
Tb927.4.3620 both protein phosphatase 1,  ݳ ݳ ݱ 2 ݱ 
Tb927.4.3630 both protein phosphatase 1,  ݳ ݳ ݱ 2 ݱ 
Tb927.4.3640 both protein phosphatase 1,  ݳ ݳ ݱ 2 ݱ 
Tb927.4.3650 both protein phosphatase 1, 
adjacent gene 
 ݳ ݳ ND ND ݳ
Tb927.5.3580 cAMP  phosphoglycerate 
mutase  
 ݳ ݳ ND ND ݳ
Tb927.6.2300 both adenosine kinase, ݳ ݱ ݳ 3 ݱ 
Tb927.6.2360 both adenosine kinase ݳ ݱ ݳ 3 ݱ 
Tb927.7.2100 cAMP  GMP synthase ݳ ݳ ݳ 3 ݱ 
Tb927.7.7160 cAMP  dual specificity 
phosphatase 
 ݳ ݱ ݱ 4 ݳ
Tb927.8.2860 cAMP Hypothetical protein ݳ ݳ ND ݳ  ݳ
Tb927.9.4080 cAMP  hypothetical, conserved  
(HYP 2) 
 ݳ ݱ ݱ 4 ݱ
Tb927.9.7550 both ADSL ݱ ݱ 3 3 ݱ 
Tb927.9.13530 cAMP  hypothetical, conserved ݳ ND ND ݳ ݱ 
Tb927.10.5930  cAMP  NEK protein kinase ݱ 4 ݱ ND ND 
Tb927.10.5940 cAMP  NEK protein kinase ݳ ݳ ݱ 4 ݱ 
Tb927.10.5950 cAMP  NEK protein kinase ݳ ݳ ݱ 4 ݱ 
Tb927.10.12100 cAMP  RNA-binding protein ݳ ݱ ݱ 5 ݱ 
Tb927.10.15020 both YAK protein kinase ݱ ݳ ݱ   
Tb927.10.16120 cAMP   IMP dehydrogenase ݳ ND ND ݳ ݱ 
Tb927.11.290 cAMP  phosphatase and tensin  1 ݳ ND ݱ ݱ 
Tb927.11.300 cAMP  pre-mRNA-splicing 
factor CWC26  like C 
terminus 
 ݱ ݱ ND ND ݳ
Tb927.11.750 
 







Tb927.11.760 cAMP Protein phosphatase 2C ݳ ND ND ݱ ݱ
Tb927.11.1640 cAMP Conserved hypothetical ݳ ND ND ݳ ݳ
Tb927.11.2250 cAMP Conserved hypothetical ݳ ND ND ݳ  ݳ
Tb927.11.3650 both ADSS ݳ ݱ 3 3 ݱ 
Tb927.11.4610 cAMP  protein kinase A 
regulatory subunit 
 ݳ ݱ 3 3 ݳ
Tb927.11.6600 both hypothetical, 
conserved (hyp1) 
 ݳ ݱ ݱ ݳ ݱ
Tb927.11.11470 AMP Mitochondrial SSU 
ribosomal protein, 
putative 
 ݱ ݱ ND ND ݳ








In eukaryotes, protein phosphorylation is a key mechanism of regulation of diverse 
cellular functions. Its importance in signal transduction in T. brucei is indicated by 
the large complement of kinases found in the genome (Jones et al., 2014; Parsons et 
al., 2005) and the widespread changes in phosphorylation between life stages 
revealed by comparative phosphoproteomics (Urbaniak et al., 2013). In addition, 
Jones et al. (2014) were recently able using a kinome-wide RNAi screen to identify 2 
kinases, RDK1 and RDK2 (repression of differentiation kinase), which promote 
bloodstream to procyclic form differentiation. Of particular significance given the 
centrality of cell cycle arrest to stumpy formation, a number of kinases have been 
demonstrated to have roles in the regulation of cell cycle progression (Hammarton et 
al., 2007; Inoue et al., 2015; Jones et al., 2014; Tu and Wang, 2004; Wei and Li, 
2014). Thus, it is unsurprising that the posST cohort included various protein kinases 
(Mony et al., 2014). One of these, a regulatory subunit of protein kinase A (PKA-R), 
was noteworthy for its implication in cellular quiescence in yeast (De Virgilio, 
2012). However, lethality of RNAi silencing of PKA-R in T. brucei precluded its 
validation as a mediator of stumpy formation (Mony et al., 2014). Other identified 
kinases that proved more amenable to validation are described in detail below. 
1.9.1.1 MEKK1 
MAPK signalling transduction pathways are involved in coordinating gene 
expression changes in response to external stimuli. These pathways are ubiquitous in 
eukaryotes and operate in wide-ranging cellular processes and cell types. The 
pathway comprises a three-tiered cascade: a serine/threonine mitogen-activated 
protein kinase kinase kinase (MAP3K) or MAPK/ERK (extracellular signal-related 
kinase) kinase (MEKK) phosphorylates a dual specificity MAP2K/MEK which in 
turn phosphorylates a serine/threonine MAPK (reviewed in (Chang and Karin, 2001). 
This process is depicted in Figure 1.10. A putative MEKK, TbMEKK1 
(Tb927.2.2720), was identified among the posST cohort. As depicted in Figure 1.10, 
it contains a C-terminal MEK kinase catalytic domain as well as 2 predicted N-
terminal transmembrane domains. MEKK1 was detected in a comparative 
phosphoproteomic study by Urbaniak et al. (2013) and showed differential 
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phosphorylation at a number of sites between bloodstream and procyclic forms, 
supporting the hypothesis that this kinase plays a stage-specific role in signal 
transduction.  
 
Figure 1.10 Left: Schematic of TbMEKK1 showing predicted N-terminal transmembrane domains and 
C-terminal kinase domain. Right: Overview of MAPK signalling pathway. 
 
As in other eukaryotes, a number of MAPKs in T. brucei have been implicated in 
growth and differentiation processes. A null mutant of MAPK2 showed delayed 
differentiation to procyclic forms (Muller et al., 2002) while deletion of MAPK5, 
conversely, accelerates stumpy formation in mice (Domenicali Pfister et al., 2006). 
At the second tier, MAP kinase kinase 1 (MKK1) is essential at a different parasite 
life stage, specifically salivary gland colonisation in the tsetse (Morand et al., 2012). 
Recently, Jones et al. (2014) identified the MEKK-like repressor of differentiation 
kinase 1 (RDK1) in a kinome-wide RNAi screen as a negative regulator of 
differentiation to procyclic forms, the only kinase of the uppermost tier of MAPK 
signalling apart from MEKK1 to be explored in relation to parasite differentiation.  
1.9.1.2 NEK 
The never in mitosis A (NIMA)-related kinases, or NEKs, represent a family of 
conserved serine/threonine kinases which function in cell cycle progression (Fry et 
al., 2012). This family is expanded in T. brucei relative to humans (Jones et al., 2014; 
Parsons et al., 2005). Of those so far studied, NEK12.2/RDK2 (repression of 






MEKK1 162kDa  
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differentiation kinase 2) has been found to negatively regulate procyclic 
differentiation (Jones et al., 2014) while NRKA/B exhibits translational upregulation 
in stumpy forms (Gale et al., 1994) and is involved in the initiation of procyclic 
differentiation (Domingo-Sananes et al., 2015). NRKC plays a role in basal body 
separation (Pradel et al., 2006). The posST cohort includes 3 NEK genes 
(Tb927.10.5930, Tb927.10.5940, Tb927.10.5950), found in tandem array on 
chromosome 10 and of near identical sequence, which have been validated in 
pleomorphs as mediators of stumpy formation (Mony et al., 2014). 
1.9.1.3 YAK 
Dual-specificity YAK kinases act as suppressors of proliferation in yeast and 
Dictyostelium (Garrett et al., 1991; Souza et al., 1998). In yeast, YAK1 responds to 
glucose starvation by relocalising to the nucleus where it inhibits cell growth and 
stimulates the stress response (Lee et al., 2008; Moriya et al., 2001). YakA is 
involved in the transition from growth to development in Dictyostelium (Souza et al., 
1998). Correspondingly, silencing of a T. brucei YAK kinase identified in the posST 
cohort (Tb927.10.15020) resulted in decreased cell cycle arrest and reduced 
differentiation to stumpy forms (Mony et al., 2014). YAK1 nuclear localisation and 
consequent activity in yeast is inhibited by phosphorylation by protein kinase A 
(PKA) (Lee et al., 2011). Interestingly, the T. brucei regulatory subunit of PKA, 
PKA-R, was also idenitified in the RNAi library screen, but could not be validated 
due to a severe growth phenotype upon RNAi (Mony et al., 2014). 
1.9.1.4 Adenosine Kinase 
T. brucei lacks a de novo purine synthesis pathway and is therefore dependent on 
salvage from its hosts (James and Born, 1980). One key purine source, adenosine, is 
salvaged by one of two pathways: the two step cleavage-dependent pathway, in 
which it is first cleaved to adenine before phosphoribosylation to adenosine 
monophosphate, and the cleavage-independent pathway in which it is instead 
phosphorylated directly (Vodnala et al., 2008). The enzyme responsible for the latter 
pathway is adenosine kinase (AK) (Luscher et al., 2007; Vodnala et al., 2008). The 
T. brucei genome contains two AK genes (Tb927.6.2300 and Tb927.6.2360). Arising 
from a gene duplication event, the resulting proteins differ by only 4 amino acids and 
in previous experimental studies have been treated as a single product (Luscher et al., 
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2007). AK was among a number of purine pathway enzymes idenitified in the posST 
cohort. Upon further study, many of these showed no role in differentiation, but 
instead appeared to have been selected due to the ability of the analogues to 
complement purine salvage defects (Mony et al., 2014). Unlike these enzymes 
however, it has been previously reported that AK knockdown does not result in any 
growth defect under normal conditions (Luscher et al., 2007). In addition, a potential 
role in stumpy formation is supported by the fact that the product of this enzyme is 
the differentiation induction agent AMP. 
1.9.2 Phosphatases 
As the enzymatic counterparts to protein kinases, phosphatases represent an equally 
important contribution to regulation of cellular processes via dephosphorylation. The 
composition of the T. brucei phosphatome is diverged from that of humans, with an 
expanded complement of serine/threonine phosphatases and reduced tyrosine 
phosphatases (Brenchley et al., 2007). As described in section 1.8, 2 protein 
phosphatases have been demonstrated to be key players in a distinct differentiation 
event, namely the transformation from stumpy to procyclic form. However, a number 
of phosphatases was also included in the posST cohort and are described below. 
1.9.2.1 PP1/PP2A 
The PPP family of serine/threonine phosphatases has been well characterised in 
eukaryotes and is typically subdivided into types 1, 2A, 4, 6, 2B, 5 and 7 (Cohen, 
2002). The T. brucei genome encodes 7 PP1 orthologues (Li et al., 2006). 
Simultaneous knockdown of all 7 results in modest growth inhibition in procyclic 
forms (Li et al., 2006). PP1-3 has been shown to be essential for correct organelle 
positioning in procyclics (Gallet et al., 2013) and is also transcribed directly 
upstream of the largest subunit of RNA pol II, RPB1, leading to speculation that 
RPB1 could be a substrate of the phosphatase (Evers and Cornelissen, 1990). 
Members of a PP1 array, PP1-4,5,6 (Tb927.4.3640, Tb927.4.3630, Tb927.4.3620), 
were identified in the RNAi library screen as posST components. Simultaneous 
knockdown of these genes prevents differentiation (Mony et al., 2014) while 
overexpression of one member enhances stumpy formation (B. Mony and K. R. 
Matthews, unpublished data). TbPP2A (Tb927.3.1240) is essential for growth and 
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cell cycle progression in both procyclic and bloodstream forms (Rothberg et al., 
2014). Interestingly, the related Trypanosoma cruzi PP2A, which shows a high 
degree of homology to the T. brucei protein, has been implicated in the 
differentiation from trypomastigote to amastigote forms of this parasite (Gonzalez et 
al., 2003). Although TbPP2A was detected in the RNAi library screen, this may be a 
consequence of substantial shared homology with the PP1s (Mony et al., 2014).  
1.9.2.2 Dual specificity phosphatase 
Another identified posST phosphatase is the dual specificity phosphatase (DSP) with 
accession no. Tb927.7.7160. It is a kinetoplastid specific DSP with no close 
homology to DSPs of other species (Brenchley et al., 2007) and was previously 
identified as being enriched in stumpy forms in a transcriptomic study (Kabani et al., 
2009). Knockdown of DSP prevents differentiation to stumpy forms (Mony et al., 
2014). 
1.9.3 RNA-binding proteins 
Further downstream in any signalling cascade operate effectors capable of 
modulating gene expression. Due to the reliance of T. brucei on post-transcriptional 
mechanisms of regulation (see section 1.3), it stands that RNA-binding proteins are 
likely candidates for involvement in the stumpy formation pathway. RNA-binding 
proteins have been implicated in developmental progression of other life cycle 
stages, including TbZFP1-3, which are involved in differentiation to procyclic forms 
(Hendriks et al., 2001; Paterou et al., 2006; Walrad et al., 2012), and RBP6, which 
plays a central role in the development of various tsetse life stages (Kolev et al., 
2012). Potential such effectors among the posST proteins include HYP2 and RBP7, 
described below.   
1.9.3.1 Hypothetical protein 2 
Although the function of the hypothetical protein (HYP2; Tb927.9.4080) is 
unknown, as eponymously implied, there is evidence to indicate a role in gene 
regulation. It was shown to upregulate transcripts to which it was artificially tethered 
in a screen for post-transciptional regulators by Erben et al. (2014), although this 
effect may be indirect, as HYP2 has been shown to interact with DRBD3 
(Fernandez-Moya et al., 2012) and MKT1 (Singh et al., 2014), both of which are 
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known to stabilise mRNAs. HYP2 contains a DskA zinc finger motif and a 
nucleotide-binding domain (Mony et al., 2014). In Escherichia coli, DskA is an RNA 
polymerase binding protein which regulates rRNA transcription in response to 
nutritional stress (Paul et al., 2004). Silencing of HYP2 reduces stumpy formation in 
vitro and in vivo (Mony et al., 2014). 
1.9.3.2 RBP7 
RBP7 is encoded by 2 near identical genes, RBP7A and RBP7B (Tb927.10.12090 
and Tb927.10.12100), which each contain a single RNA-recognition motif (RRM). 
RNAi of RBP7 results in reduced responsiveness to the SIF differentiation signal, 
while overexpression of RBP7B accelerates stumpy formation. Transcriptomic 
analysis of these 2 perturbations showed upregulation of a number of histone 
transcripts upon RBP7 depletion, likely reflective of a continued proliferative state, 
whereas overexpression elevated transcripts associated with the procyclic form, 
indicative of preparation for the subsequent differentiation event. RBP7 
overexpression also increased levels of a number of other RNA-binding protein 
mRNAs (Mony et al., 2014).  
1.9.4 Inhibitors of stumpy formation 
Prior to the identification of positive regulators of stumpy formation via the RNAi 
library screen,  a number of inhibitors of this process were already known. A null 
mutant of a zinc finger kinase (ZFK) in a pleomorphic strain showed increased 
stumpy formation in vitro, though not in vivo (Vassella et al., 2001). Similarly, 
ablation of MAPK5 in pleomorphs resulted in premature differentiation both in vitro 
and in vivo (Domenicali Pfister et al., 2006). Crucially, these phenotypes were not 
observed upon ablation of either gene in a monomorphic strain. However, stumpy 
formation can be triggered in monomorphs by RNAi of the TOR kinase TOR4 
(Barquilla et al., 2012). The action of these negative regulators points to the 
influence of 2 opposing forces in regulating differentiation: the stumpy inhibitors 
which act to preserve slender state at low density, and the posST pathway, which 
when released from this inhibition by SIF, activates differentiation. This system 
draws parallels to that of the subsequent development event, in which TbPIP39 
triggers differentiation to procyclic forms but is inhibited by the action of TbPTP1 
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(see section 1.8). It is likely that the components of the conflicting processes operate 
closely together to enable tight regulation of proliferation versus differentiation and it 
would therefore be of interest to study where known stumpy inhibitor proteins 
operate in relation to proteins of the posST pathway. This is explored in this thesis 
via TOR4, which is described in detail below. 
1.9.4.1 TOR4 
The conserved serine/threonine kinases targets of rapamycin (TOR) acts within a 
complex, TORC, to regulate cell growth in relation to environmental conditions and 
energy status. They generally operate during favourable conditions and are 
downregulated upon nutrient depletion (Wullschleger et al., 2006). In T. brucei, 
TOR1 and TOR2 act via TORC1 and TORC2, respectively, to modulate growth in a 
manner analogous to their mammalian and yeast counterparts (Barquilla et al., 2008). 
Specifically, TORC1 regulates such aspects as transcription, translation and 
suppression of autophagy, while TORC2 is implicated in cytoskeletal remodelling, 
endocytosis and cytokinesis. Kinetoplastids are unusual in that they contain 2 
additional TORs which function distinctly from TORC1 and TORC2 signalling 
(Barquilla et al., 2008). TOR3 is involved in regulation of acidocalcisome and 
polyphosphate metabolism (de Jesus et al., 2010). TOR4, meanwhile, forms a unique 
complex, TORC4, which includes proteins not previously associated with TORCs 
(Barquilla et al., 2012). RNAi of TOR4 triggered differentiation to stumpy forms 
while membrane-permeable cAMP or AMP treatment downregulated TbTOR4 
expression. TOR4-depleted monomorphic cells showed many hallmarks of stumpy 
development, including growth arrest, PAD upregulation and cis-aconitate 
hypersensitivity (Barquilla et al., 2012). As these experiments were performed in a 
monomorphic strain, it is unknown if depletion of TOR4 is able to produce the same 
effect in pleomorphs. 
 
The stumpy signalling pathway is of interest not just to our understanding of parasite 
biology but also due to its potential as a novel therapeutic target. In natural 
1.10 Chemical inducers of stumpy formation  
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infections, differentiation to stumpy form occurs at high density, ensuring a 
sustainable and highly transmissible population (MacGregor et al., 2011; Reuner et 
al., 1997). Chemical induction of stumpy formation could be used to achieve arrest 
and clearance of the parasites at sub-transmissible densities. Ablation of negative 
regulators of stumpy formation (Barquilla et al., 2012; Domenicali Pfister et al., 
2006; Vassella et al., 2001) and overexpression of posST proteins (Mony et al., 
2014) have demonstrated the feasibility of targeting the pathway in this manner. In 
addition, the continued elusiveness of the molecular identity of SIF means that in 
vitro studies of differentiation have long relied on membrane permeable forms of 
cAMP and AMP (Laxman et al., 2006; Mony et al., 2014; Vassella et al., 1997), 
highlighting the importance of chemical tools in the investigation of this process.  
To identify novel small molecule inducers of differentiation, MacGregor et al. (2014) 
developed a monomorphic stumpy-specific reporter cell line in which a β-
glucuronidase reporter was fused to the 3’UTR of PAD1. A high-throughput screen 
of 6,764 molecules using this reporter was able to identify DDD00015314 (referred 
to as E667 in this thesis) as a chemical inducer of differentiation in monomorphs and 
pleomorphs. This demonstrated the potential of this reporter for use in subsequent 
high-throughput screens of further compound libraries. In addition, the identification 
of new differentiation regulators presents the possibility of discovery of new 




The aim of this thesis was to study the slender to stumpy signalling pathway in 
Trypanosoma brucei by ordering with respect to one another components known to 
be involved in this process. This objective takes advantage of the recent 
identification of many new proteins involved in stumpy formation and was primarily 
addressed via 3 approaches: 
- Relative positioning of posST proteins via a combinatorial overexpression 
and knockout strategy as well as phosphoproteomic analysis. 
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- Ordering of posST proteins relative to the stumpy inhibitor TOR4 via a 
similar dual genetic silencing approach. 
- Chemical-genetic analysis using small molecules capable of inducing 
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2 Chapter 2: Methods 
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The majority of cell lines used in this thesis are based on T. b. brucei AnTat 1.1 
90:13 (Engstler and Boshart, 2004), a pleomorphic culture-adapted cell line with 
integrated T7 RNA polymerase and Tet repressor constructs to facilitate conditional 
genetic manipulations. The monomorphic 2T1 cell line, in which constructs can be 
specifically targeted to a defined locus containing an incomplete HYG ORF to 
prevent variable position effects (Alsford et al., 2005), was used to generate RNAi 
lines in monomorphs. The RNAi library line based on this strain (Alsford et al., 
2011) was used for the RNAi library screen (section 2.17). Full length and truncated 
MEKK1 fragments were overexpressed in the 427-derived single marker S16 line, 
which expresses a tet repressor and T7 RNA polymerase under the control of 
neomycin (Wirtz et al., 1999). The GUS PAD1 3’UTR reporter line was developed 
from the Lister 427 strain by MacGregor et al. (2014). 
Trypanosomes were maintained in HMI-9 media supplemented with 10% foetal calf 
serum (Life Technologies) and 100U/ml penicillin and streptomycin (Life 
Technologies) at 37°C/5% CO2 (Hirumi and Hirumi, 1989) and grown to densities 
up to 1x106/ml. Cells were counted using a Beckman Coulter Z2 Particle Count and 
Size Analyser. For storage, approximately 2x106 cells at a density of 7x105-1x106/ml 
were resuspended in 1ml 10% glycerol in HMI-9 and frozen at -80°C in cryovials. 
Frozen samples were recovered by thawing rapidly at 37°C, centrifuging at 1000g 
for 5 minutes and transferring to 5ml fresh media. 
All trypanosome infections were performed in MF1 strain mice in the MARCH 
Building, University of Edinburgh. All animal procedures were carried out either by 
myself, Julie Young or Keith Matthews according to the terms of the project and 
personal licenses.  
2.1 Trypanosome strains 
2.2 Trypanosome culture 
2.3 Trypanosome infections 
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Mice were injected with 200µl 25 mg/ml cyclophosphamide (Sigma) 24 hours before 
infection to suppress the immune system. This step was omitted for experiments in 
which only slender parasites were required for harvest. Parasitaemia was monitored 
at 24 hour intervals from 3 days post infection onwards by making a tail snip and 
collecting a blood drop on a slide. Parasitaemia was then estimated microscopically 
according the method described by Herbert and Lumsden (1976). To terminate the 
infection, whole blood was extracted by cardiac puncture using a 2ml syringe 
containing 200 µl 2% citrate. Parasites were purified from whole blood by passing 
through DEAE-cellulose anion exchange resin (Whatman) at pH 7.8. 
2.4.1 DNA extraction 
Genomic DNA was extracted from Trypanosoma brucei using the QIAGEN® 
DNeasy Blood and Tissue kit according to the manufacturer’s instructions. 
2.4.2 PCR 
PCR was carried out in 0.2ml PCR tubes in a Biometra TProfessional Basic Gradient 
Thermocycler. Components and conditions of a typical 25 µl reaction are outlined 
below. 
Components: 
5 µl 5x buffer 
1.5 µl 25 mM MgCl2 
2 µl 2.5 mM dNTPs 
1.25 µl 10 mM Forward primer 
1.25 µl 10 mM Reverse primer 
0.5 µl template DNA 
0.25 µl Taq polymerase 
13.25 µl dH2O 
 
Reaction conditions: 
95°C 5 mins 
2.4 Cloning  
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[95°C 30s 
55°C 30s 
68°C 1 min/kb amplicon] x30 cycles 
68°C 10 mins 
 
All primers used in this thesis were produced by Sigma-Aldrich and are listed in 
Appendix A. 
 
2.4.3 DNA agarose gel electrophoresis 
For the visualisation and separation of DNA fragments, samples were resolved on a 
1% agarose gel in 1x TAE buffer containing 0.5 µg/ml ethidium bromide. The gel 
was cast in a Fisher-brand gel tank and immersed in 1x TAE buffer. DNA samples 
were loaded into the wells alongside a 1 kb DNA ladder for size estimation and 
electrophoresed at 130V until the fragments resolved.  
2.4.4 Restriction digestion 
All restriction enzymes and buffers used were from Promega or NEB. Reactions 
were carried out in an optimum buffer with 10 units of enzyme and incubated at 
37°C (recommended temperature for all enzymes used in this thesis) for a minimum 
of 1 hour. Double digests were carried out simultaneously where a compatible buffer 
for both enzymes was available. 
2.4.5 DNA purification 
DNA was purified from PCR products, restriction digests or agarose gel pieces using 
the NucleoSpin Extract II kit (Machery-Nagel) following the manufacturer’s 
instructions in order to remove salts, primers and other impurities from previous 
reactions which may interfere with downstream processing of the sample. 
2.4.6 Ligation 
PCR products were ligated directly into the pGEM T-Easy vector (Promega) via the 
A/T overhangs. Restriction digested DNA inserts were ligated into expression 
vectors digested with the same enzyme(s) to produce complementary sticky ends. 
Typically ligation reactions were carried out in a 10 µl volume and comprised 1µl 
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10x T4 DNA ligase buffer (Promega), 0.5 µl T4 DNA ligase, 1 µl DNA vector and 
7.5 µl DNA insert. Ligations were incubated at room temperature for 1 hour or 4°C 
overnight. 
2.4.7 Gibson cloning 
Some constructs in this thesis – specifically the overexpression of NEK, YAK and 
MEKK1 with C terminal TY tag in pDEX - were generated by the alternative cloning 
method of the Gibson cloning system (NEB), which enables the assembly of multiple 
overlapping DNA fragments. Primers generating overlap sequences were designed 
using the NEBuilder Assembly tool (http://nebuilder.neb.com) and are listed in 
Appendix A. These primers were used to amplify insert fragments by PCR (section 
2.4.2) while the vector was prepared by restriction digestion (section 2.4.4). The 
assembly reaction comprised 50-100 ng of vector with 2-3 fold excess of each insert 
in a 10 µl volume. 10 µl of 2x Gibson Assembly Master Mix was then added and the 
reaction incubated at 50°C for 15 minutes. 2 µl of the reaction was then transformed 
in NEB 5-alpha Competent Escherichia coli according to the protocol described in 
section 2.4.9. 
2.4.8 Preparation of XL-1 Escherichia coli competent cells 
XL-1 blue cells were used to inoculate 5 ml LB broth. This was incubated at 37°C 
overnight with shaking. This starter culture was then used to inoculate 400 ml LB 
broth, which was divided into 2 x 200 ml cultures in 1L flasks to allow sufficient 
aeration. These were incubated at 37°C shaking until OD600 reached 0.4-0.5, as 
measured on an Eppendorf Biophotometer.  The cells were centrifuged at 2000g for 
10 minutes at 15°C in 8 x 50 ml volumes. Each pellet was resuspended in 25 ml 
sterile ice-cold Buffer RF1 and incubated on ice for 1 hour.  The cells were 
centrifuged at 2000g for 5 minutes at 4°C and resuspended in 8 x 8 ml sterile ice-
cold Buffer RF2.  The competent cells were then aliquoted into 200 μl volumes, snap 
frozen in liquid nitrogen and stored at -80°C. 
Buffer RF1:     Buffer RF2: 
10mM RbCl2     10mM RbCl2 
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50mM MnCl2     10mM MOPS  
30mM potassium acetate   75mM CaCl2 
10mM CaCl2     10% (v/v) glycerol 
10% (v/v) glycerol    pH 6.8 
pH5        
2.4.9 Bacterial transformation 
For transformation, 5 µl of ligation reactions or plasmids were added to 100 µl of 
XL-1 blue E. coli competent cells (prepared as described in section 2.4.8) and 
incubated on ice for 20 minutes. The cells were then subjected to heat shock at 42°C 
for 40s, before addition of 500 µl LB media and incubation at 37°C with shaking for 
1 hour. The cells were then pelleted at 2500g for 90s, resuspended in 100 µl of media 
and spread onto an LB agar plate containing 1 mg/ml ampicillin to enable selection 
of the plasmid. For ligations into pGEM T-Easy, plates were spread with 100 µl 2% 
X-gal (5-bromo-4-chloro-3-indolyl-beta-D-galacto-pyranoside) and 20 µl 0.1M IPTG 
(isopropyl β-D-1-thiogalactopyranoside) prior to addition of cells to screen for 
successful integration of the insert and consequent disruption of the β-lactamase 
gene. Plates were then incubated at 37°C overnight. 
2.4.10 Small scale plasmid preparation  
For preparation of up to 20 µg of plasmid DNA, a bacterial colony was used to 
inoculate 3 ml LB with 1 mg/ml ampicillin. This was incubated at 37°C with shaking 
overnight. The cells were then pelleted at 10,000g for 5 minutes and resuspended in 
100 µl Mini-prep soln I (50mM glucose, 25mM Tris pH8, 10mM EDTA pH 8). 
200µl Soln II (0.2M NaOH, 1% SDS) was added and the sample incubated for 4 
mins at room temperature. 150 µl ice cold Soln III (3M potassium acetate, 5M acetic 
acid) was then added and the sample incubated on ice for 5 mins. It was then spun 
for 10 mins at 10000g and the supernatant transferred to a fresh tube. 2 volumes of 
cold 96% ethanol was added and the sample incubated on ice for 15 minutes. It was 
then spun for 10 mins at 10000g, washed in 70% ethanol and spun again. The pellet 
was air-dried, resuspended in 40 µl water and treated with 100 µg/ml RNase A 
(Sigma) for 5 minutes. 
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2.4.11 Medium scale plasmid preparation 
For preparation of larger quantities of plasmid DNA, DNA was purified using the 
Nucleobond Xtra Midi kit (Macherey-Nagel) according to the manufacturer’s 
instructions.  
2.4.12 DNA sequencing 
DNA sequencing reactions were carried out at the University of Edinburgh’s 
dedicated sequencing facility Edinburgh Genomics (formerly the GenePool). 6 µl 
samples were submitted containing 500 ng DNA and 3.2 µM primer in water. 
Transfection of pleomorphic AnTat 90:13 strains was performed using either cells 
grown in vitro or harvested from mouse blood. In the latter case, whole blood was 
harvested from a mouse showing slender parasitaemia and added to 25 ml HMI-9 + 
10% FCS and allowed to settle for 4-6 hours. 20 ml of this culture was then carefully 
pipetted from the top and transferred to a new flask containing another 20 ml media. 
Any remaining blood was allowed to settle overnight. The following day media was 
then pipetted from the top, transferred to a new flask and used for transfection. 
Transfection of monomorphic strains exclusively used in vitro cultured parasites. 
DNA for transfection was prepared by small or medium scale plasmid preparation as 
described in sections 2.4.10 or 2.4.11 respectively. The plasmid was linearised using 
the relevant restriction enzyme (see section 2.4.4) and purified as in section 2.4.5. 
The purified, linearised plamid was then precipitated by addition of 0.1x volume of 3 
M sodium acetate and 2.5x volumes of 100% ethanol and incubation at -80°C for 
minimum 1 hour. The DNA was then pelleted at 18,000g for 10 minutes at 4°C and 
the supernatant aspirated. The pellet was resuspended in 10 µl water. At least 5 µg 
DNA was used for each transfection. 
2-3x107 parasites at a density of 6x105-1.2x106/ml were centrifuged for 5 mins at 
1000g and washed in TDB (Trypanosome Dilution Buffer – see below). They were 
resuspended in 50-100 µl Amaxa buffer (Lonza) mixed with the DNA. The sample 
was then transferred to a cuvette and electroporated in an Amaxa Nucleofector II 
2.5 Trypanosome transfections 
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using program Z-001 – Free Program Choice. The cells were immediately transferred 
to a flask containing 30ml pre-warmed media and serially diluted 1:10 and 1:100 in 2 
additional flasks. After incubation at 37°C for minimum 6 hours, antibiotic was 
added to each flask for selection of transfectants. Antibiotic concentrations are listed 
in Appendix C. The cultures were plated in 1ml volumes in 24-well plates. Positive 
transfectants were identified microscopically and diluted into antibiotic-containing 
media 4-8 days post transfection.  
Trypanosome Dilution Buffer: 
5 mM KCl 
80 mM NaCl 
1 mM MgSO4  
20 mM Na2HPO4 
2 mM NaH2PO4 
20 mM glucose 
pH7.4 
 
2.6 Growth curves 
 
To measure parasite growth, cells were seeded in triplicate in 24-well plates at a 
concentration of 2x105/ml for pleomorphic cells or 1x105/ml for monomorphic cells. 
In the case of RNAi and overexpression lines, this was done in the presence and 
absence of 1 µg/ml tetracycline (Sigma). Cell density was measured at 24-hour 
intervals using the Beckman Coulter Z2 Particle Count and Size Analyser and diluted 
to prevent growth above a density of 1x106/ml. Cumulative growth rates were plotted 
using GraphPad Prism. 
To test parasite sensitivity to the compounds pCPTcAMP and E667 
(DDD00015314), parasites were treated with or without either 100 µM pCPTcAMP 
(Sigma) or 50 µM E667 (BioFocus) at the outset, or 24 hours after tetracycline 
induction in the case of RNAi lines. Growth was monitored as described above.  
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2.7 Dose response curves 
 
In white-bottomed 96-well plates (Greiner), 150 µl HMI-9 + 10% FCS was added to 
the outermost wells to prevent evaporation from internal sample wells. 50 µl HMI-9 
+ 10% FCS was added to wells B2 to G11. 50 µl media + 4x starting concentration 
of compound was added to wells B2-G2. For E667 and GKI7 (NEU-0001233), a 2-
fold serial dilution of the compound was performed by transferring 50 µl from 
column 2 to column 3, mixing, and repeating along the plate until column 11. In the 
case of pCPTcAMP, 3-fold serial dilutions were similarly performed by transferring 
and mixing 25 µl between columns. This resulted in 50 µl media + 2x compound in 
columns 2 to 10, while 11 was left as an untreated control. 50 µl cells diluted to 
1x104/ml, ± 2 µg/ml tetracycline in the case of RNAi lines, were added to wells B2-
G11 to give 5x104/ml + 1x compound in each well. All cells were tested in triplicate 
for each compound and condition. This plate layout and the concentrations of the 
compounds used are depicted in Figure 2.1. 
The plate was incubated at 37°C/5% CO2 for 72 hours. 10 µl alamarBlue (Bio-Rad) 
was added to each well and the plate was incubated for 4 hours at the same 
conditions. Fluorescence was read using a FLUOstar OPTIMA fluorimeter (BMG 
Labtech) at 544 nM excitation/590 nM emission. Fluorescence values were 
normalised relative to the untreated control and GraphPad Prism was used to plot 
sigmoidal dose response curves with variable slopes (4 parameter non linear 
regression). 
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Figure 2.1 Diagram of concentrations of pCPTcAMP, E667 and GKI7 used in dose response assays 
and column layout in 96 well plate. 
GUS enzyme activity was assayed according to MacGregor et al. (2014). The β-
glucuronidase (GUS) enzyme produces a quantifiable colour change in the 
fluorescent substrate 4-Methylumbelliferyl-β-D-glucopyranosiduronic acid (MUG). 
To test BioFocus-synthesised E667, 427 GUS-PAD1 3’UTR cells were incubated 
with 50 µM of the compound for 48 hours at a starting density of 3x105/ml. Cells 
were counted and 50% v/v substrate/lysis solution (see below) was added to 100 µl 
cells in triplicate in 96-well plates and incubated for 2 hours at 37°C. Absorbance 
was measured with an excitation wavelength of 355 nm and emission wavelength of 
460nm on a BioTek Flx800 Fluorescent Microplate Reader with Gen5 data analysis 
software. For screening of GSK kinase inhibitor (GKI) compounds, 100 µl cells were 
incubated for 24 hours with EC50 concentration of each compound, as determined by 
Diaz et al. (2014). To assay cell density at low volume, 10 µl AlamarBlue was then 
added and incubated at 37°C for 4 hours and fluorescence read as described in 
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as described above. In all cases, 100 µM pCPTcAMP was used as a positive control 
and fluorescence was normalised to cell density, as determined by either 
spectrophotometric count or AlamarBlue assay. 
GUS substrate/lysis solution:  
1mM MUG (Sigma) 




To test the capacity of cells to differentiate to procyclic forms, parasites purified 
from whole blood were resuspended at 3x106/ml in SDM-79 +10% FCS media 
supplemented with 6mM cis-aconitate (Sigma) to induce procyclic differentiation 
and incubated at 27°C/5% CO2. After 0, 4 and 24 hours, 1 ml culture was removed, 
washed and fixed in 2% formaldehyde/0.05% gluteraldehyde for EP expression 
analysis by FACS (see section 2.10). 
Stumpy and procyclic characteristics of trypanosomes were assayed by FACS 
analysis of PAD1 and EP expression, respectively. Samples were prepared in 5ml 
FACS tubes (BD Biosciences). Cells were fixed in 2% formaldehyde/0.05% 
gluteraldehyde at 4°C overnight. Samples were centrifuged at 2000g for 7 minutes, 
washed in PBS and blocked in 200 µl 2% BSA/PBS for 40 minutes or overnight. 
They were centrifuged again and resuspended in primary antibody in 2% BSA/PBS 
for 1 hour or overnight at 4°C. Cells were then washed again and resuspended in 
fluorescently conjugated secondary antibody for 40 minutes at 4°C. The cells were 
washed again and finally resuspended in 500 µl 0.2 µg/ml 4’,6-diamidino- 2-
phenylindole (DAPI)/PBS. Antibody concentrations are listed in Appendix B. 
2.9 Procyclic differentiation assay 
2.10 FACS 
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Samples were processed on an LSRII Flow Cytometer (BD Biosciences). A 
minimum of 10,000 cells were analysed for each sample.  Analysis was performed 
using FlowJo version 9.6.2 (Tree Star). 
To analyse cell cycle status, trypanosomes were smeared on a glass slide, allowed to 
dry and then fixed in cold methanol and stored at -20°C. The slides were washed in 
PBS and stained with 10 µg/ml DAPI/PBS for 2 minutes. They were washed twice 
with PBS and mounted with 50 µl Mowiol (see below). The slides were dried in the 
absence of light and stored at 4°C. 
Mowiol: 
10% (w/v) mowiol 4-88 reagent (Calbiochem catalogue number 475904) 
25% (v/v) glycerol 
100mM Tris-HCl, pH 8.5 
2.5% (v/v) DABCO 
Cell cycle was assessed by counting the number of kinetoplasts and nuclei per cell 
for 250 DAPI stained cells on each slide using a Zeiss Axioskop 2 microscope. 
Trypanosomes in G1 and S phase have 1 nucleus (N) and 1 kinetoplast (K) and after 
S phase division of first the kinetoplast and then the nucleus forms 2K1N and then 
2K2N cells, which represent G2 and post-mitotic phases respectively (Woodward and 
Gull, 1990).  
Morphometric analyses of cell nuclei were performed using ImageJ. The shape 
descriptor function was used to score nuclei for aspect ratio and solidity. At least 100 
nuclei were scored for each condition. 
Aspect ratio = maximum diameter/minimum diameter 
Solidity = area/convex area 
The data was analysed by unpaired t test using GraphPad Prism version 6. P values 
of less than 0.05 were considered statistically significant. 
 
2.11 Microscopic analysis of cell cycle status 
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2.12 Immunofluorescent assay 
 
For immunofluorescent analysis (IFA) of expression, at least 2x105 cells were 
centrifuged at 1000g for 5 minutes, washed in ice-cold PBS and resuspended in 125 
µl ice-cold PBS. 75 µl 8% paraformaldehyde in PBS was added and the tube mixed 
by inverting. The sample was incubated on ice for 10 minutes. 500 µl PBS was added 
and the tube centrifuged at 1000g for 5 minutes. The cells were resuspended in 0.1 M 
glycine/PBS and stored at 4°C. 
8 well 6mm slides (Thermo Scientific) were washed sequentially with hot water, 
ethanol and dH2O and air-dried. In a humid chamber, 15 µl 0.1 mg/ml poly-L-lysine 
(Biochrom) was added to each well. After 15 minutes incubation, the slides were 
rinsed with dH2O and air-dried. 
Samples were resuspended in 15 µl PBS and pipetted onto wells. Slides were 
incubated in a humid chamber for 1 hour to allow the cells to adhere. Excess solution 
was then removed using an aspirator. For intracellular proteins, 0.05% Triton X-100 
was added for 5 minutes. The wells were washed 3 times in PBS and then blocked in 
20% FCS/PBS for 45 minutes. Excess liquid was removed and primary antibody in 
20% FCS/PBS was applied for 1 hour. The wells were washed 5 times and then 
fluorescent dye conjugated secondary antibody in 20% FCS/PBS added for 1 hour. 
Secondary antibody was aspirated and 10 mg/ml DAPI applied for 1 minute. The 
wells were washed 5 times in PBS. The slides were removed from the humid 
chamber and dried for 10 minutes at 37°C, then mounted and dried as described in 
section 2.11. Antibody concentrations used are listed in Appendix B. 
2.13 Western blot 
Lysates were prepared by centrifuging cells at 1000g for 5 minutes, washing in PBS 
and resuspending in Laemmli buffer at 3x105 cells/µl. For PAD1 expression analysis, 
samples were sonicated using a Bandelin Sonorex Ultrasonic bath to reduce 
viscosity. All other samples were incubated at 95°C for 5 minutes. Lysates were 
stored at -20°C until use. 
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Laemmli buffer: 
62.5mM Tris HCl pH 6.8  
10% glycerol  
2% SDS  
0.0025% bromophenol blue  
5% 2-mercaptoethanol 
Protein samples were resolved by SDS polyacrylamide gel electrophoresis using the 
Bio-Rad mini Protean II system. An 8-12% resolving gel (depending on expected 
protein size; see recipe below) was poured between clamped glass plates (1.5 mm 
spacer plate and short plate) to a height of approximately 2 cm below the top of the 
short plate, covered with isopropanol and left to set. The isopropanol was washed out 
and the 5% stacking gel poured to the top of the plate, a comb inserted. Once set, the 
comb was removed and the gel inserted into the gel running apparatus. The tank was 
filled with running buffer (25 mM Tris, 200 mM glycine, 0.1% SDS). 10 µl protein 
(i.e. 3x106 cells) was added to each well alongside Novex sharp prestained Protein 
Standard (Life Technologies) and the gel run at approx. 120V until the bromophenol 
blue dye reached the bottom. 
Resolving gel:     Stacking gel: 
8-12% acrylamide    5% acrylamide 
375 mM Tris pH 8.8    125 mM Tris pH 6.8 
0.1% SDS     0.1% SDS 
0.1% APS     0.1% APS 
0.04% TEMED    0.1% TEMED 
(APS = ammonium persulphate; TEMED = N,N,N’,N’-Tetramethylethylenediamine) 
Protein was transferred from the gel to a nitrocellulose membrane (GE Healthcare) 
using a Bio-Rad Mini Trans-Blot cell according to the manufacturers instructions. 
The tank was filled with cold transfer buffer (25mM Tris, 200mM glycine, 20% 
methanol) and run at 200 mA for 90 minutes while stirring.   
The membrane was blocked at room temperature with agitation for at least 30 
minutes in 5% milk in PBS-0.1% Tween 20 (PBS-T). It was then incubated in 
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primary antibody in 5% milk in PBS-T for minimum 1 hour with agitation and 
washed 3 times in PBS-T.  
Secondary detection of the antibody used one of two systems. The first used 
chemiluminescence. The membrane was incubated in secondary antibody conjugated 
to horseradish peroxidase (HRP) diluted in 5% milk in PBS-T for 1 hour with 
agitation and washed three times with PBS-T. The membrane was placed between 
two sheets of polyethylene and Pierce ECL2 Western Blotting substrate applied for 2 
minutes. Excess liquid was then removed and the membrane and polyethylene placed 
inside a film cassette and exposed to X-ray film (Fujifilm). Exposure time varied 
according to signal strength. The film was developed using a Konica Minolta SRX-
101A developer.   
Alternatively, the signal was visualised using the LI-COR Odyssey system. In this 
case, the secondary antibody was conjugated to a fluorescent dye and diluted in 50% 
Odyssey Blocking Buffer/50% PBS-T. After 1 hour incubation in secondary 
antibody, the membrane was washed twice in PBS-T and once in PBS, and scanned 
using a LI-COR Odyssey imager, which uses an infrared laser to detect fluorescence. 
Southern blotting was used to confirm successful gene deletion and correct 
integration of replacement alleles in null mutants. Probes were prepared using the 
DIG High Prime DNA labelling Kit (Roche) from 1 µg of a double stranded DNA 
template produced by either PCR or restriction digestion, according to the 
manufacturers instructions. 
For each sample, 1 µg of gDNA was digested with the appropriate restriction enzyme 
for minimum 3 hours at 37°C (see section 2.4.4) and run on a 1% agarose gel at 25V 
overnight. The gel was soaked in Depurination Solution (0.25 M HCl) for 15 minutes 
with agitation. It was denatured using Denaturation Solution (1.5 M NaCl/0.5 M 
NaOH) for 2 x 15 minutes with agitation. The gel was rinsed with dH2O and 
neutralised with Neutralisation Solution (1 M Tris, 1.5 M NaCl, pH 7.4) for 2 x 15 
minutes with agitation. 
2.14 Southern blot 
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DNA was then transferred from the gel to a positively charged nylon membrane 
overnight by capillary transfer. A plastic box was placed upside down in a tray filled 
to approx. 2 cm depth with 10x SSC (1.5M NaCl, 150mM tri-sodium citrate). The 
box was covered with filter paper soaked in 10x SSC to form a wick and the gel 
placed on top. Parafilm was used to seal the edges of the tray to prevent evaporation. 
The membrane was pre-soaked in 10x SSC and placed on top of the gel, followed by 
two sheets of filter paper soaked in 2x SSC, a large pile of paper towels and a 
Perspex sheet to ensure even weight distribution. Finally, a 1 kg weight was placed 
on top to add weight. The following day, the membrane was allowed to dry. A 
Stratalinker was used to UV cross-link the membrane at 0.12 joules.  
The blot was pre-hybridised in 10 ml hybridisation buffer (see below) at 42°C for 1 
hour in a hybridisation oven (Techne Hybridiser HB-1D). This was then replaced 
with 7 ml hybridization buffer containing 1 µl DIG-labelled DNA probe denatured 





2% DIG block 
The blot was washed in 2x SSC/0.1% SDS twice for 5 minutes at room temperature 
with agitation. It was then washed in prewarmed 0.5x SSC/0.1% SDS twice for 15 
minutes at 68°C in the hybridisation tube. It was rinsed in maleic acid buffer (100 
mM maleic acid, 150 mM NaCl, pH 7.5) with 0.3% Tween 20 for 1 minute at room 
temperature. The membrane was blocked in 1% DIG block (Roche) in maleic acid 
buffer for 1 hour at room temperature with agitation and then incubated with Anti-
Digoxigenin-AP Fab Fragments (Roche) in 1% DIG block/maleic acid buffer for 30 
minutes. Maleic acid buffer with 0.3% Tween 20 was used to wash the membrane 3 
times for 10 minutes. The blot was soaked in detection buffer (100 mM Tris pH 9.5, 
100 mM NaCl) for 2 minutes and then placed between 2 sheets of polyethylene. 250 
µM CDP-Star chemiluminescent substrate (Roche) in detection buffer was applied to 
the membrane for 2 minutes. Excess substrate was removed and the polythene sealed 
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using a heat sealer before incubation at 37°C for 15 minutes. The blot was then 
exposed to X-ray film and developed as for the Western blot (section 2.13).   
 
For Northern blotting, riborobes were prepared using the DIG RNA labelling Kit 
(SP6/T7)(Roche). The desired sequence was cloned into the pGEM-T Easy vector, 
which contains SP6/T7 promoter sites, and amplified using M13 primers. 1 µg 
purified PCR product was used in the following 20 µl reaction to produce 
digoxigenin-UTP labelled RNA: 
1 µg template DNA 
1x NTP Mix 
5mM DTT  
10U RNase inhibitor 
1x transcription buffer 
40U SP6 or T7 RNA polymerase (SP6 for forward oriented sequences, T7 for 
reverse oriented sequences). 
The reaction was incubated at 37°C for 2 hours, then 20U RNase-free DNaseI added 
and a further 15 minutes incubation at 37°C for 15 minutes to remove any remaining 
DNA. The reaction was stopped by the addition of 20mM EDTA, pH8.0. The sample 
was then precipitated with 2.5 µl of 4 M LiCl and 75 µl of cold 100% ethanol and 
incubated at -80°C for 1 hour. The riboprobe was then centrifuged at 16,500 g for 15 
minutes and washed in 50µl 70% cold ethanol. The pellet was air dried and 
resuspended in 50µl dH2O with 20U RNase inhibitor and stored at -80°C. 
RNA was extracted from Trypanosoma brucei using the QIAGEN® RNeasy kit 
according to the manufacturer’s instructions. For each RNA sample, 1 µg of RNA 
was added to 16 µl RNA gel loading buffer (see below) and incubated at 65°C for 5 
minutes before immediate loading on an RNA gel (see below). The gel was run for 
90 minutes at 150 V. 
 
2.15 Northern blot 
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RNA gel loading buffer:   RNA gel: 
60 % formamide    1.3 % agarose 
20 % formaldehyde    1x MOPS 
1.5x MOPS     1 % formaldehyde 
0.01% bromophenol blue 
1.25% glycerol 
The gel was soaked in 1 µg/ml ethidium bromide in 1x MOPS for 15 minutes with 
agitation and destained twice with dH2O for 30-60 minutes. The rRNA bands were 
visualised and photographed using a Syngene G:box.  
RNA was then transferred from the gel to a positively charged nylon membrane and 
cross-linked exactly as described for Southern blotting (section 2.14). 
The blot was pre-hybridised in 10 ml hybridisation buffer (section 2.14) at 68°C for 
1 hour in a hybridisation oven (Techne Hybridiser HB-1D). This was then replaced 
with 7 ml hybridization buffer containing 1 µl riboprobe, which had been denatured 
for 5 mins at 95°C, and hybridised overnight.  
The blot was washed at 68°C in the hybridisation tube, first in 2x SSC/0.1% SDS 
three times for 30 minutes and then once in 0.5x SSC/0.1% SDS for 30 minutes. It 
was then removed from the tube and rinsed in maleic acid buffer with 0.3% Tween 
20 for 1 minute at room temperature. All subsequent steps were exactly as described 
for the Southern blot in section 2.14.   
2.16 Quantitative RT-PCR  
2.16.1 RNA preparation 
RNA was extracted from Trypanosoma brucei using the QIAGEN® RNeasy kit 
according to the manufacturer’s instructions. Contaminating gDNA was removed 
using Turbo DNase (Ambion). 5 µg RNA was incubated with 1 U DNase in 1x 
Turbo DNase reaction buffer for 30 mins at 37°C. A further 0.5µl DNase was then 
added and the sample again incubated for 30 mins at 37°C. The reaction was then 
incubated for 2 mins at room temperature with 10µl DNase Inactivation Reagent and 
centrifuged for 2 mins at 12000g. Supernatant was transferred to a fresh tube and 
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precipitated with 0.05 volumes of 3M sodium acetate and 3 volumes of 100% 
ethanol for 1 hour at -80°C. The sample was centrifuged for 10 minutes at 12000g at 
4°C, washed in 70% ethanol and the pellet air-dried. Samples were resuspended in 
12 µl RNase-free water. 1 µl was run on an RNA gel (see section 2.15) to check the 
integrity of the RNA.  
2.16.2 Generation of cDNA 
cDNA was synthesised from the DNased RNA using the ThermoScript RT-PCR 
system (Invitrogen). For each RNA sample, a parallel reaction was performed 
without reverse transcriptase (RT-). The following reaction was incubated for 5 mins 
at 65°C to denature the RNA: 
1 µg RNA 
2 µl 10 mM dNTPs 
1 µl (50 ng) Random Hex primers 
Total vol 12 µl 
The following components were added and the 20 µl reaction reverse transcribed 
using the program shown: 
4 µl 5x cDNA synthesis buffer   25°C  10 mins 
1 µl 0.1 M DTT     50°C 50 mins 
1 µl (40 U) RNaseOUT    85°C 5 mins  
1 µl (15 U) ThermoScript Reverse Transcriptase 
1 µl RNase free water 
2 U of RNase H was then added to remove any remaining RNA and the reaction 
incubated at 37°C for 20 mins. 180 µl of nuclease-free water was then added to dilute 
the cDNA 1:10. 
2.16.3 qRT-PCR 
Quantitative reverse transcriptase PCR was carried out on a LightCycler 96 machine 
(Roche) to amplify either TOR4 or ZFP3 mRNA. 25 µl reactions were carried out in 
triplicate. For each cDNA sample, a fourth reaction was also carried out in which the 
corresponding RT- product was substituted for cDNA. A melt curve was added to the 
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end of each qRT-PCR amplification program to ensure amplification of a single 
product. TOR4 transcript abundance was quantified relative to ZFP3 using the 
equation 2-ΔΔCt, where cycle threshold (Ct) refers to the number of cycles at which 
fluorescence passes a set threshold, ΔCt = Ct(TOR4) – Ct(ZFP3) and ΔΔCt = 
ΔCt(test sample) – ΔCt(reference sample) The data was analysed using the 
LightCycler 96 software (Roche). 
Reaction components: 
12.5 µl Power SYBR Green PCR Master Mix (Applied Biosystems) 
1.5 µl 10mM FW 
1.5 µl 10mM RV 
7 µl dH2O 
2.5 µl cDNA  
Reaction Conditions:  
95°C 10 minutes 
[95°C 15 s  
60°C 1 minute] x40 
Melt curve: 60°C - 95°C 0.03°C/s 
 
2.17 RNAi library screen 
2.17.1 Library treatment with GKI7 
A vial containing approx. 1x107 RNAi library cells was thawed and inoculated in 50 
ml HMI-9/10% FCS supplemented with 2 µg/ml blasticidin and 1 µg/ml phleomycin. 
After 24 hours incubation at 37°C/5% CO2, 1x107 cells were frozen in HMI-9 + 25% 
glycerol to replace the stock and the remaining cells diluted to a density of 
2.5x105/ml. 24 hours later, the library was divided into 3 cultures of 2.5x107 cells at 
2.5x105/ml. Genomic DNA was extracted from 1 culture according to section 2.4.1 
to represent the starting population and 1 µg/ml tetracycline was added to another to 
induce RNAi. After 24 hours, the 2 cultures were diluted to a concentration of 
2.5x105/ml, treated with 1.44 µM GKI7 and each divided into 5 x 50 ml volumes. 
Cells were counted every 24 hours and diluted back to 2.5x105/ml in 50 ml volumes 
where required. A minimum of 1.25x107 cells (2.5x105/ml in 50 ml) was 
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continuously present in each culture throughout the experiment. After 10 days, when 
resistant populations had outgrown, genomic DNA was extracted from each replicate 
(section 2.4.1). 
2.17.2 PCR amplification and sequencing 
RNAi fragments were amplified from gDNA from each replicate using RNAi insert 
specific primers Lib3F ATCAAGCTTGGCCTGTGAG and Lib3R 
CCTCGAGGGCCAGTGAG. These primers represent a more effective version of 
the Lib2 primers (E. Rico Vidal, personal communication) described in the published 
protocol by Glover et al. (2015). The products were resolved by gel electrophoresis 
and 6 bands were excised, purified and ligated into pGEM-T Easy. The plasmids 
were transformed and sequenced using M13 primers. 
2.17.3 Ion Torrent sequencing 
Ion Torrent sequencing was carried out at the University of Edinburgh Wellcome 
Trust Clinical Research Facility Genetics Core. PCR products amplified with Lib3F 
and Lib3R primers from 3 induced replicates (tet+1, tet+2, tet+4) and 1 uninduced 
replicate (tet-1) were sequenced. For library preparation, the samples were 
fragmented by Covaris unltrasonication. Each sample was assigned an IonXpress 
barcode and sequenced using an Ion PGM (Thermo), generating 4,158,002 total 
reads, with each sample generating 0.9-1.2 million reads. Subsequent data analysis 
was carried out by Dr. Alasdair Ivens. Quality checking was performed using 
FASTC software, and the output inspected manually  
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Cutadapt software was 
used to identify and remove the Lib3 primer sequences used in amplification 
(parameters: -O 15 -m 100 -n 5 -q 20). Alignments for all cutadapt-processed 
sequences were aligned to the T. b. brucei 927 genome using bowtie2 (version 2.2.7) 
software (parameters: --very-sensitive -p 4 --no-unal). Outputs were stored as 
indexed bam files generated using samtools version 1.3 (http://www.htslib.org/; 
http://samtools.sourceforge.net/).  Read depths at each base were generated  from the 
indexed bam files using samtools and the "depth" parameter. Gene location 
coordinates, extracted from the genome annotation, were stored in bedtools "bed" 
format, and bedtools (v2.23.0) used to extract read counts for each gene, using 
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"multicov -D -bams" parameters (http://bedtools.readthedocs.org/en/latest/ ); read 
counts for each gene in each sample were stored as tab-delimited "Excel" files. Plots 
were generated using R/Bioconductor software (https://cran.r-project.org/; 
https://www.bioconductor.org/). 
 
2.18 Phosphoproteomic analysis 
2.18.1 Cell lysis 
For preparation of phosphoproteomic samples, low binding tips and low binding 
eppendorfs were used. Samples were extracted from 4 replicates each of AnTat 1.1 
90:13, MEKK1 KO and YAK KO cell lines. For each, 2.7x108 cells at 9x105/ml 
were spun at 1000g for 10 mins at 4°C, washed three times in PBS and resuspended 
in 100 µl lysis buffer. The samples were sonicated using a Bioruptor (Diagenode; 10 
cycles of 30s alternating sonication/rest at 18°C).  
Lysis buffer: 
4% SDS 
25 mM Tris(2-carboxyethyl)phosphine (TCEP) (Thermo) 
50 mM N-ethylmaleimide (Thermo) 
M NaCl 
1x PhosSTOP phosphatase inhibitor (Roche) 
10 mM Na2HPO4 pH6 
The samples were then chloroform:methanol precipitated. After 10 minutes 
incubation at 65°C, 400 µl methanol was added and the samples vortexed. 100 µl of 
chloroform was added and the samples vortexed again. 300 µl of ddH2O was added 
and the samples vortexed for 1 minute. They were then centrifuged for 5 minutes at 
9000g and the upper phase aspirated. A further 300 µl of methanol was added and 
the samples vortexed and centrifuged as before. The supernatants were aspirated and 
and the pellets air dried.  
2.18.2 Tryptic digestion 
The pellets were resuspended in 150 µl 8M urea/0.1 M Tris pH8/1 mM CaCl2 and 
quantified by Bradford assay. The protein concentration was determined by 
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comparison to a bovine serum albumin (BSA) standard curve (0.1-2.5 mg/ml). 125 µl 
of Bradford Reagent (Sigma) was added to 2.5 µl protein sample in triplicate in a 96 
well plate and absorbance read at 595 nm using a Fluostar Omega plate reader (BMG 
Labtech). 800 µg of protein for each sample was then diluted with 0.1 M Tris pH8/1 
mM CaCl2 to 1 M urea and 8 µl LysC (Wako) added. The samples were digested 
overnight at 37°C. 8 µg trypsin (Pierce) in 50 mM acetic acid was then added and the 
samples incubated for 4 hours at 37°C. Finally 1 % v/v trifluoroacetic acid was 
added. 
2.18.3 TMT Labelling 
Labelling and mass spectrometry were carried out at the FingerPrints Proteomics 
Facility at the University of Dundee. The samples were divided into 2 separate runs, 
each containing 2 replicates of each cell line. They were purified by solid phase 
extraction and then quantified by bicinchoninic acid assay prior to labeling with 
isobaric tandem mass tags (TMT). The samples were pooled and fractionated into 13 
fractions using hydrophilic interaction liquid chromatography.  
2.18.4 Mass spectrometry 
5% of each fraction was analysed by nLC-MS/MS (nano liquid chromatography-
tandem mass spectrometry) using a Thermo Q-Exactive HF mass spectrometer to 
generate proteomic quantitation. Phosphopeptides were enriched in the remaining 
95% of each fraction and these samples were then also analysed by nLC-MS/MS to 
generate quantitation of phosphopeptides.  
Data analysis was carried out by Dr. Mathieu Cayla. 4,767 and 4,746 proteins were 
detected in the first and second runs, respectively. This was reduced to 3,237 and 
3,128 after exclusion of proteins with a confidence value score less than 20 or TMT 
reporter intensity less than 10,000. 9,265 phosphopeptides from 2,499 proteins were 
identified in the first set and 9,473 phosphopeptides from 2,599 proteins in the 
second set. Phosphopeptides for which protein ratios were not generated were 
excluded from the analysis. Proteins and phosphopeptides for the knockout samples 
were normalised to the mean of AnTat 1.1 90:13 control replicates 1 and 2 for the 
first run and replicates 3 and 4 for the second. Protein ratios were then used to 
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normalise phosphopeptide ratios. All phosphoproteins for which log2 of the 
normalised phosphopeptide ratio was greater than 1 or lower than -1 (i.e. showed 
greater than 2 fold change) and for which a similar effect was not observed when 
comparing AnTat replicates was considered to be differentially regulated. 
2.19  Statistical analysis 
Statistical analysis for all parasitaemia, cell cycle, PAD1 IFA, FACS data collected 
in triplicate was carried out using either Minitab version 15 or GraphPad Prism 
version 6. Where only a single timepoint was analysed, the data was analysed by 
students t test. In the case of multiple timepoints, the data was analysed by general 
linear model with Tukey’s test for multiple comparisons. P values of less than 0.05 
were considered statistically significant. 
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3 Chapter 3: Organising posST components 
within the stumpy formation pathway 
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The recent identification of numerous mediators of stumpy formation via 
pCPTcAMP/AMP treatment of an RNAi library population (Mony et al., 2014)(see 
section 1.9) represents a significant step forward in elucidating a pathway which had 
previously been uncharacterised and opens up countless new avenues for further 
study. While ongoing validation of the posST genes continues to confirm their 
individual roles in differentiation, nothing is known of the contribution of each gene 
to the pathway. An obvious next step in the investigation of these molecules is to 
determine their relationship to each other. It has been shown that silencing of posST 
genes confers a reduced differentiation phenotype, while overexpression increases 
stumpy formation. Therefore, overexpression of one posST gene in a null mutant 
background of a distinct posST gene should provide positional information about the 
relative action of both genes, which will ultimately enable ordering within a 
signalling pathway. Additionally, the abundance of kinases and phosphatases within 
this cohort points to the importance of phosphorylation as a means of signalling in 
stumpy formation. Phosphoproteomic analysis of null mutants of posST kinases can 
therefore offer insight into their respective signalling roles and how these fit with the 
rest of the pathway.  
Mony et al. (2014) were able to validate several hits from the pCPTcAMP/AMP 
RNAi library screen, using individual RNAi lines to demonstrate their involvement 
in stumpy formation. Here, systematic testing of a number of further hits from this 
screen are described. 
3.2.1 Adenosine Kinase 
Adenosine kinase is the enzyme responsible for the cleavage-independent pathway of 
purine salvage in T. brucei (see section 1.9.1.4), in which adenosine is directly 
phosphorylated to form adenosine monophosphate (Luscher et al., 2007; Vodnala et 
3.1 Introduction 
3.2 Validation of posST genes as mediators of 
stumpy formation    
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al., 2008). AK was idenitified in the posST cohort along with a number of other 
purine pathway enzymes. Upon further study, many of these showed no 
differentiation phenotype but were instead selected due to restoration of purine 
balance by the cAMP/AMP analogues (Mony et al., 2014). However, AK differs 
from these enzymes in that RNAi reportedly confers no growth phenotype under 
normal conditions (Luscher et al., 2007). Hence, it was decided to explore the role of 
this molecule in stumpy formation. 
3.2.1.1 AK RNAi confers reduced responsiveness to pCPTcAMP in 
monomorphs 
To generate an AK RNAi line in a monomorphic strain, an RNAi construct was 
generated by cloning 2 complementary 363bp fragments corresponding to both AK 
gene copies, and so capable of forming a stem-loop structure, into a specialised T. 
brucei RNAi vector, pRPaiSL (see map in Appendix D Figure 1). This plasmid was 
transfected into the monomorphic 2T1 bloodstream form cell line which is capable of 
tetracycline-regulated gene expression. 2T1s contain an incomplete hygromycin 
resistance gene within an rRNA spacer locus which is rendered functional by 
successful integration of the pRPa construct (Alsford and Horn, 2008). Transfectants 
were selected with 2.5µg/ml hygromycin. One clone was selected and growth was 
measured for 4 days in cells first either incubated with or without 1µg/ml tetracycline 
to induce the RNAi. Cells were also treated or not treated with 100µM of the 
membrane-permeable cAMP analogue 8-(4-chlorophenylthio)-cAMP (pCPTcAMP) 
after 24 hours to induce differentiation as detailed in section 2.6. Growth was 
measured in 3 technical replicates for each condition. As seen in Figure 3.1A, 
tetracycline has little or no effect on growth in the absence of the analogue. This is 
consistent with the findings of Luscher  et al. (2007), and indicates that AK did not 
emerge from the library screen due to rescue of a purine pathway defect. Upon 
treatment with pCPTcAMP, uninduced cells showed substantial growth inhibition, 
which was partially rescued in the induced cells. This indicates that knockdown of 
AK confers resistance to pCPTcAMP-induced differentiation, validating its original 
selection in the library screen. Figure 3.1B shows confirmation of effective silencing 
of the AK transcript by Northern blot. 
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Figure 3.1 A) Growth curve of monomorphic AK RNAi cells incubated with (tet+) or without (tet-) 
tetracycline and either treated (cAMP+) or untreated (cAMP-) with pCPTcAMP 24 hours post-
induction by tetracycline. AK RNAi results in reduced responsiveness to pCPTcAMP. B) Northern 
blot analysis shows loss of the AK transcript upon RNAi induction. rRNA was used as a loading 
control. 
3.2.1.2 AK RNAi confers reduced responsiveness to pCPTcAMP in 
pleomorphs 
A pleomorphic AK RNAi line was subsequently generated by cloning the same gene 
fragment as for the pRPa plasmid into the pALC14 vector (plasmid map shown in 
Appendix D Figure 2). The plasmid is competent for transfection of the T. brucei 
AnTat 1.1 90:13 cell line expressing the Tet repressor and T7 RNA polymerase. 
Growth in response to pCPTcAMP was measured in puromycin-selected 
transfectants, as for the monomorphs. Figure 3.2 shows that, as in monomorphs, AK 
RNAi confers reduced responsiveness to pCPTcAMP. 
  tet-    1d     2d      3d      
     tet+ 
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Figure 3.2 Growth curve of  pleomorphic AK RNAi cells incubated with (tet+) or without (tet-) 
tetracycline and either treated (cAMP+) or untreated (cAMP-) with pCPTcAMP 24 hours post-
induction by tetracycline. AK RNAi results in reduced responsiveness to pCPTcAMP.  
3.2.1.3 AK RNAi has no effect on responsiveness to SIF in vivo 
To assess responsiveness to SIF in vivo, MF1 mice treated or untreated with 
doxycycline were infected in triplicate with pleomorphic AK RNAi parasites. From 
the third day of infection onward, blood samples were taken and the parasitaemia 
calculated by the rapid matching method (Herbert and Lumsden, 1976). Figure 3.3A 
shows that doxycycline has no statistically significant effect on parasitaemia (p = 
0.448). Blood smears taken from the mice from day 3 of infection onwards were 
stained with DAPI and nuclei and kinetoplast numbers were counted for 250 cells to 
determine their cell cycle position. Trypanosomes in G1 and S phase have 1 nucleus 
(N) and 1 kinetoplast (K) and, after S phase division, of first the kinetoplast and then 
the nucleus forms 2K1N and then 2K2N cells, which represent G2 and post-mitotic 
phases respectively (Woodward and Gull, 1990). The proportion of 1K1N (G1/S 
phase) cells increased from day 3 to day 5 and was not significantly different 
between induced and non-induced samples (p = 0.376), indicating that the parasites 
were arresting at a comparable rate (Figure 3.3B). Loss of the AK transcript was 
confirmed by Northern blot (Figure 3.3C). Thus it appears that, contrary to its in 
vitro phenotype, loss of AK does not prevent differentiation in vivo. Possible 
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explanations for this disparity are explored in Section 3.5.1.  
  
Figure 3.3 AK RNAi has no effect on responsiveness to SIF in vivo A) Parasitaemia of mice infected 
with AK RNAi cells, estimated by the rapid matching method. Data represents 6 mice, 3 treated with 
doxycycline (dox+) and 3 non-induced (dox-). No statistical difference was observed upon RNAi 
induction by general linear model (GLM). B) % 1K1N (representing G1 and S phase) cells throughout 
the course of infection. 250 cells were counted for each sample. No statistical difference was observed 
upon RNAi induction by GLM. C) Northern blot analysis shows upregulation of AK transcript in 
stumpy forms and loss of the transcript upon RNAi induction. rRNA was used as a loading control. 
3.2.2 Protein phosphatase 2A 
The serine/threonine phosphatase TbPP2A (Tb927.3.1240) is essential for growth 
and cell cycle progression in both procyclic and bloodstream forms (see section 
1.9.2.1)(Rothberg et al., 2014).  It was identified in the RNAi library screen as a 
posST component, along with members of a PP1 array, with which it shares 
substantial homology. The involvement of PP1 in stumpy formation has been 
experimentally validated (Mony et al., 2014).  
3.2.2.1 PP2A is essential in monomorphic bloodstream T. brucei  
An RNAi line was generated for PP2A in monomorphic T. brucei as described for 
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doxycycline resulted in severe growth inhibition in both the presence and absence of 
pCPTcAMP. Due to the strong growth defect, this gene was not pursued further in 
pleomorphic cells.  
Figure 3.4 A) Growth curve of monomorphic PP2A RNAi cells incubated with (tet+) or without (tet-) 
tetracycline and either treated (cAMP+) or untreated (cAMP-) with pCPTcAMP 24 hours post-
induction by tetracycline. PP2A RNAi is lethal. B) Northern blot analysis shows loss of PP2A 
transcript upon RNAi induction. rRNA was used as a loading control. 
3.2.3 MEKK1 
The identification of a putative MEKK, TbMEKK1 (Tb927.2.2720), among the 
posST cohort (Mony et al., 2014) was intriguing due to previous implication of 
various MAPK signalling components in growth and differentiation processes (see 
section 1.9.1.1). Supporting a potential stage-specific signalling role, MEKK1 was 
found to be differentially phosphorylated between bloodstream and procyclic forms 
in a comparative phosphoproteomic study by Urbaniak et al. (2013). A monomorphic 
MEKK1 RNAi line had previously been validated as conferring resistance to 
pCPTcAMP (Mony et al., 2014). 
3.2.3.1 MEKK1 RNAi confers modest loss of responsiveness to 
pCPTcAMP in pleomorphs. 
To determine if responsiveness to pCPTcAMP was still dependent on MEKK1 in 
pleomorphic trypanosomes, a MEKK1 RNAi line was generated in the AnTat 1.1 
90:13 strain as for AK (section 3.2.1.2) and treated with pCPTcAMP. MEKK1 RNAi 
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Although this effect was small, it was observed consistently in multiple independent 
experiments in this cell line, although never confirmed in an independent clone. 
 
Figure 3.5 Growth curve of pleomorphic MEKK1 RNAi cells incubated with (tet+) or without (tet-) 
tetracycline and either treated (cAMP+) or untreated (cAMP-) with pCPTcAMP 24 hours post-
induction by tetracycline. MEKK1 RNAi results in modestly reduced responsiveness to pCPTcAMP. 
3.2.3.2 MEKK1 RNAi confers loss of responsiveness to SIF in vivo. 
This cell line was subsequently tested in vivo to assess its response to SIF. The 
parasitaemia of uninduced cells ascended for 4 days post infection and then dropped 
on the fifth day as the population arrested (Figure 3.6A). The parasitaemia was 
significantly higher on day 5 in the presence of doxycycline, indicating that the 
population was undergoing a lower rate of arrest. Further, induced cells contained a 
reduced percentage of 1K1N cells at all timepoints examined (Figure 3.6B), 
supporting a decrease in G1 arrest. However, the 1K1N proportion did increase as the 
infection progressed, indicating that differentiation was not completely eliminated. 
By day 5, parasites in the uninduced population were visibly stumpy in morphology, 
while the induced cells remained morphologically slender (Figure 3.6C). In accord, 
on the same day of infection, PAD1 was low in the induced population relative to 
uninduced cells (Figure 3.6D). However, a low level of expression was still present, 
again suggesting that differentiation was occurring but to a lesser extent. Reduction 
of the MEKK1 transcript in this experiment was confirmed by Northern blot (Figure 
3.6E). Thus it appears that MEKK1 RNAi leads to reduced responsiveness to SIF in  
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Figure 3.6 MEKK1 RNAi confers loss of responsiveness to SIF in vivo. A) Parasitaemia of mice 
infected with MEKK1 RNAi cells, estimated by the rapid matching method. Data represents 6 mice, 3 
treated with doxycycline (dox+) and 3 non-induced (dox-). The parasitaemia was higher for induced 
cells on day 5 of infection. *P<0.05 GLM and Tukey test for multiple comparisons. B) % 1K1N 
(representing G1 and S phase) cells throughout the course of infection. 250 cells were counted for each 
sample. Induced cells have lower 1K1N **P<0.005 GLM. C) Phase contrast images of parasites on 
day 5 of infection. Untreated cells appear stumpy in morphology whereas doxycycline-treated cells 
have remained morphologically slender. D) Western blot analysis of PAD1 expression on day 5 of 
infection. Expression was lower with dox induction. EF-1 was used as a loading control. E) Northern 
blot analysis shows upregulation of MEKK1 transcript in stumpy forms and reduction of the transcript 
upon RNAi induction. rRNA was used as a loading control. 
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vivo, leading to reduced cell cycle arrest, increased parasitaemia and a reduction in 
morphological and PAD expression characteristics associated with stumpy forms. 
However, stumpy formation was still able to proceed at a low level, possibly due to 
incomplete ablation of the MEKK1 transcript.   
3.2.3.3 Generation of a MEKK1 null mutant 
As MEKK1 RNAi cells retained some level of differentiation capacity, albeit 
significantly reduced, a null mutant of this gene was generated to determine the 
effect on stumpy formation when the kinase is completely absent. This was achieved 
by replacing the YFP and TY tags of the pEnT6B-Y and pEnT6P-Y vectors with 
fragments of the 3’ and 5’UTRs of MEKK1 (see vector map in Appendix D Figure 
4). Restriction digestion of these plasmids between the 3’UTR and 5’UTR sequences 
produced 2 linear constructs, containing resistance markers to blasticidin and 
puromycin respectively, which were capable of homologous recombination with, and 
replacement of, MEKK1 alleles. As shown in Figure 3.7A, the pEnT6B-Y construct 
contained external UTR fragments located distal to the ORF relative to the internal 
UTR fragments in the pEnT6P-Y construct. This meant that when the pEnT6B-Y 
construct was transfected into the AnTat 1.1 90:13 strain in the first of 2 sequential 
transfections, it would be expected to delete one allele of MEKK1 including the 
internal UTR fragments. Therefore, when the pEnT6P-Y construct was subsequently 
transfected, it should be able to recombine only with the remaining MEKK1 allele, 
producing a double knockout (dKO) line resistant to both antibiotics. 
After the second round of transfection, a number of double-resistant clones were 
selected. To test for gene deletion, genomic DNA was isolated and PCR carried out 
using primers corresponding to a short fragment of the MEKK1 ORF. As seen in 
Figure 3.7B, the fragment was amplified from parental AnTat 90:13 gDNA and 
every drug-resistant clone except for clone E, in which only primer dimers were 
visible. To confirm that the gene was completely knocked out in this clone, it was 
further tested by Southern blot. Figure 3.7C schematically depicts the fragments 
recognised by 2 DNA probes in parental, single knockout (sKO) and dKO genomic 
DNA digested with PstI. A gene probe was able to detect 2 bands in the parental and 
sKO but not in the dKO, confirming that the gene has been deleted (Figure 3.7D). A 
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second probe to determine correct plasmid integration hybridises to bands of 3 
different sizes in the WT allele, 1st allelic replacement and 2nd allelic replacement 
respectively, thereby conferring parental, sKO and dKO cells each with a unique 
signature and confirming correct integration of the relevant constructs in each case. 
 
Figure 3.7 Generation of a null mutant of MEKK1. A) Schematic of knockout strategy. In the first 
step, a plasmid containing the blasticidin resistance gene was targeted to external portions of the 5’ 
and 3’ UTRs (extUTR) by homologous recombination, thereby replacing both the ORF and internal 
UTRs (intUTR) from one allele. Subsequently, a plasmid containing the puromycin resistance gene 
was targeted to internal portions of the UTRs and could recombine only with the remaining allele so 
that the second copy of the gene was replaced. B) Blast+Puro resistant clones were tested for MEKK1 
deletion by PCR for a 100bp fragment of the ORF, showing successful deletion in clone E (upper 
panel). PCR with primers specific to a region of the HYP2 ORF confirmed gDNA was present in all 
samples (lower panel). KO control is previously verified MEKK1 KO + TOR4 KD clone (see section 
4.5). C) A diagram shows the fragments recognised by 2 Southern DNA probes in the WT allele and 
integrated 1st and 2nd replacement constructs following gDNA digestion by Pst1. D) A gene probe 
complementary to part of the MEKK1 ORF recognises 6815bp and 9448bp fragments in the WT 
allele only, which were present in parental AnTat 1.1 90:13 cells and single knockout (sKO) cells but 
absent in the double knockout (dKO) cells, confirming successful gene deletion. A second probe to 
determine correct integration hybridises to a 6815bp fragment in the WT allele, a 2500bp fragment in 
the 1st allelic replacement and a 2975bp fragment in the 2nd allelic replacement, thereby conferring 
parental, sKO and dKO cells each with a unique signature and confirming correct integration of the 
relevant constructs in each case.  
3.2.3.4 MEKK1 knockout confers loss of responsiveness to SIF in vivo 
The differentiation capacity of the MEKK1 null mutant was tested in vivo. It showed 
uncontrolled proliferation, so that the mice needed to be sacrificed 5 days post 
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infection due to their very high parasitaemia (Figure 3.8A). A loss of G1 arrest was 
supported by a significant reduction in cells with a single nucleus and kinetoplast 
relative to the parental line, although the 1K1N percentage did increase over the 
course of infection, indicating that absence of MEKK1 does not prevent 
differentiation entirely. PAD1 expression was almost completely eliminated in the 
null mutant, with only 8.6 ± 1.8 % expression on the final day of infection, relative to 
60.4 ± 5.2% in the parental line (Figure 3.8C).  
 
Figure 3.8 MEKK1 KO confers loss of responsiveness to SIF in vivo A) Parasitaemia of 6 mice 
infected with parental AnTat (n=3) or MEKK1 KO (n=3) cells, estimated by the rapid matching 
method. The parasitaemia was significantly higher in the KO. B) % 1K1N (representing G1 and S 
phase) cells throughout the course of infection. 250 cells were counted for each sample. KO cells have 
lower % 1K1N. C) % cells expressing PAD1 throughout the course of infection, determined by IFA. 
250 cells were counted for each sample. PAD1 expression was almost abolished in the KO cells. D) % 
EP procyclin expressing cells 4 hours post cis-aconitate treatment. To assess capacity to differentiate 
to procyclic forms, parasites purified from blood 5 days post infection were incubated in SDM-79 
media supplemented with 6mM cis-anonitate at 27°C for 4 hrs and then analysed by FACS. EP 
expression was significantly reduced in the MEKK1KO line. A)-C) *P<0.05,**P<0.005,***P<0.0005 
GLM and Tukey test for multiple comparisons. D) **P<0.005 GLM. 
A B 
C D 
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A key distinction between slender and stumpy forms is that only the latter can 
efficiently differentiate to procyclic forms (Dean et al., 2009; Robertson, 1913). To 
assess the capacity of the null mutant line to undergo this differentiation, parasites 
were purified from blood 5 days post infection and incubated at 27°C in the procyclic 
medium SDM-79 which had been supplemented with 6mM citrate/cis-aconitate 
(CCA) to stimulate differentiation. After 4 hours incubation, the expression of the 
procyclic surface marker EP procyclin was analysed by FACS. EP expression was 
significantly decreased in the null mutant (16 ± 0.1%) relative to the parental line 
(80.3 ± 4.9%)(Figure 3.8D). In agreement with the concurrent large but not absolute 
reductions in cell cycle arrest and PAD1 expression, this indicates that ablation of 
MEKK1 prevents most stumpy formation, but that it is still able to proceed at a low 
level. 
3.2.3.5 Overexpression of full length MEKK1 protein but not the 
catalytic domain alone inhibits cell growth 
In other systems, the N-terminal domain of MEK kinases appears to have a 
regulatory role and has been shown to interact with and repress the C-terminal 
catalytic domain so that overexpression of the C-terminal portion alone in yeast and 
mammalian cells is constitutively active (Mizote et al., 2010; Owen et al., 2013; van 
Drogen et al., 2000). This phenomenon has also been shown to occur naturally in 
human MEKK1, where caspase cleavage releases the active catalytic domain to 
induce apoptosis (Gibson et al., 1999). The possibility that this may also be true for 
trypanosomes raised the intriguing potential for a cell line with constitutively active 
differentiation signal transduction. To this end, 2 cell lines were generated in the 
monomorphic S16 line in which either full length MEKK1 or the catalytic domain 
alone (CatMEKK1) was overexpressed with an N-terminal TY epitope tag to assist 
detection (see vector in Appendix D Figure 5). As seen in Figure 3.9, overexpression 
of full length MEKK1 resulted in growth inhibition. This was as expected as the 
kinase promotes stumpy formation and therefore cell cycle arrest. However, 
CatMEKK1 had no effect on cell growth. 
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Figure 3.9 In vitro growth of monomorphic bloodstream cells was reduced upon overexpression of 
full length MEKK1 but not by the catalytic domain alone (Cat). 
3.2.3.6 Overexpression of full length MEKK1 cannot be detected via the 
N-terminal TY epitope tag  
These cell lines were tested for overexpression using the BB2 antibody which 
recognises the TY epitope tag. Western analysis revealed no detectable expression of 
the TY tagged protein upon induction with tetracycline in the full length MEKK1 
overexpression line (Figure 3.10A). This was unexpected as these cells exhibited 
growth inhibition upon tetracycline induction (Figure 3.9), indicating overexpression 
of a protein which generates a phenotypic response. Equally surprisingly, expression 
of the catalytic domain was clearly detectable at the expected size of 43kDa in the 
CatMEKK1 overexpression line (Figure 3.10A), which showed no growth effect. 
Both of these results were confirmed by immunofluorescence analysis. It appears 
that overexpression of full length MEKK1 inhibits growth but is not detectable via its 
N-terminal tag while its catalytic domain detectably overexpresses but has no 
obvious effect on cell proliferation. 
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Figure 3.10 Overexpression of full length N-terminally TY tagged MEKK1 (FL) cannot be detected 
by BB2 antibody but overexpression of the truncated catalytic domain (Cat) was detectable by A) 
Western blot analysis of FL and Cat – or + tetracycline; EF1 was used as a loading control; or B) 
immunofluorescence analysis.  
3.2.3.7 Overexpression of C-terminally epitope tagged MEKK1 is not 
detectable. 
One possible explanation for the inability to detect TY tagged MEKK1 was that the 
kinase is targeted to a cellular compartment via an N-terminal targeting signal which 
is cleaved upon entry, resulting in loss of the epitope tag. To explore this possibility, 
the overexpression construct was regenerated with a C-terminal TY tag. This plasmid 
was transfected, along with the CatMEKK1 construct, into the pleomorphic AnTat 
1.1 90:13 line. As before, overexpression of the catalytic domain was readily 
detectable via its TY tag but had no effect on cell growth (Figure 3.11). This would 
suggest that overexpression of the catalytic domain in this manner does not result in 
constitutive MEKK1 activity, at least as far as its generation of a detectable 
phenotype is concerned. Possible explanations for this result are discussed in section 
3.5.1. Overexpression of the C-terminally tagged full length protein resulted in 
growth arrest but, as with the N-terminally tagged version, the protein was not 
detectable either by Western or IFA (Figure 3.11). Therefore the inability to detect 
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protein overexpression cannot be simply explained by cleavage of a localisation 
sequence. 
 
Figure 3.11 A) In vitro growth of pleomorphic cells was reduced upon overexpression of C-terminally 
TY tagged full length MEKK1 (FL) but not by the catalytic domain alone (Cat). Cat but not FL can be 
detected by the BB2 antibody by B) Western blot analysis of FL and Cat – or + tetracycline; EF1 was 
used as a loading control; or C) immunofluorescence analysis. 
3.2.3.8 Overexpression of MEKK1 does not increase its transcript level 
but restores it in a null mutant background. 
As MEKK1 overexpression could not be detected at the protein level, the abundance 
of MEKK1 transcript was investigated by Northern blot. As seen in Figure 3.12, 
doxycycline induction does not affect mRNA level in the C-terminally tagged 
MEKK1 overexpression line. However, when the same construct was used to 
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overexpress the protein in the MEKK1 null mutant background, it was able to restore 
detectable MEKK1 mRNA expression, despite complete absence of the transcript in 
the absence of doxycycline. This indicates that the plasmid is capable of generating 
MEKK1 mRNA expression, but is unable either to produce or to sustain a higher 
than endogenous expression level, possibly due to degradation as a consequence of 
the toxic effects of high expression or another regulatory mechanism. 
 
Figure 3.12 Northern analysis showed no increase in MEKK1 transcript level 48 hours after induction 
of overexpression but was able to restore expression in a MEKK1 null mutant background.  
3.2.4 Hypothetical protein 2 (HYP2) 
HYP2 is a posST gene and, although its function is as yet unknown, it is a potential 
candidate as an effector of gene expression changes acting downstream in the stumpy 
formation signalling cascade. The presence of a zinc finger motif (Mony et al., 
2014), interaction with RNA regulators such as DRBD3 (Fernandez-Moya et al., 
2012) and MKT1 (Singh et al., 2014) and its identification in a screen for post-
transcriptional regulators (Erben et al., 2014) all point to a role in the regulation of 
gene expression (see section 1.9.3.1).  
3.2.4.1 Generation of a HYP2 null mutant 
To analyse the loss of HYP2 in a clean genetic background, as for MEKK1 (see 
section 3.2.3.3), the same strategy was used to generate a HYP2 null mutant in the 
AnTat 1.1 90:13 strain. The plasmids were prepared by Eleanor Silvester. After 2 
rounds of transfection and selection, a number of clones were isolated with resistance 
to both blasticidin and puromycin. PCR with internal HYP2 ORF primers 
MEKK1OE         MEKK1OE+MEKK1KO 
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demonstrated that the gene was absent in 3 of these clones. Gene deletion was later 
confirmed in these clones by Southern blot by Eleanor Silvester, who also 
demonstrated that HYP2 knockout confers resistance to SIF in vivo (E. Silvester, 
thesis in preparation). 
 
Figure 3.13 PCRs using internal A) HYP2 and B) RBP7 ORF fragments were used to test for 
successful gene deletion in gDNA from parasites subjected to 2 rounds of allelic replacement. In each 
case, the respective gene was absent in several clones. 
3.2.5 RNA-binding protein 7 (RBP7) 
RBP7 comprises two near identical gene copies, RBP7A and RBP7B, arranged in 
tandem array. It is another potential modulator of gene expression in the 
differentiation pathway due to the presence of an RNA-recognition motif (RRM) in 
each copy. RNAi of RBP7 reduces responsiveness to the differentiation signal, while 
overexpression accelerates stumpy formation. Although transcriptomic analysis of 
these 2 perturbations showed limited widespread expression changes, RBP7 
overexpression increased levels of a number of other RNA-binding protein mRNAs 
(Mony et al., 2014).  
3.2.5.1 Generation of an RBP7 null mutant 
A null mutant of RBP7 was generated in the AnTat 1.1 90:13 strain. This was 
achieved using the same strategy as for MEKK1 and HYP2 (sections 3.2.3.3 and 
3.2.4.1), except that the constructs were targeted to the 5’UTR of RBP7A and the 
3’UTR of RBP7B, in order to delete the two tandemly arranged gene copies 
simultaneously. The plasmids were prepared by Eleanor Silvester. After successive 
transfections with the 2 allelic replacement constructs, a number of clones were 
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tested for the presence of a fragment of the RBP7 ORF. PCR amplification 
confirmed this fragment to be absent in all clones tested (Figure 3.13). Gene deletion 
was later verified by Southern blot (E. Silvester, thesis in preparation).  
3.2.5.2 RBP7 KO confers loss of responsiveness to SIF in vivo 
The SIF response of an RBP7 null mutant cell line was investigated in vivo. As seen 
in Figure 3.14A, the parasitaemia continued to increase throughout the course of the 
infection, showing no sign of arrest. On the final day of infection, RBP7 KO cells 
showed a significantly reduced 1K1N population relative to the parental AnTat 1.1 
90:13 parasites, indicating a failure to undergo G1 arrest (Figure 3.14B). PAD1 
expression was also significantly lower than in wild type cells (Figure 3.14C) and 
when induced to differentiate to procyclic forms, EP procyclin expression was 
almost completely absent in the null mutant, with only 5.9 ± 2.2% expression relative 
to 70.3 ± 2% parental cells (Figure 3.14D). This all points to reduced differentiation 
to stumpy forms in response to SIF. 
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Figure 3.14 RBP7 KO confers loss of responsiveness to SIF in vivo. A) Parasitaemia of 6 mice 
infected with parental AnTat (n=3) or RBP7 KO (n=3) cells, estimated by the rapid matching method. 
B) % 1K1N (representing G1 and S phase) cells 4 days p.i. 250 cells were counted for each sample. 
KO cells have lower 1K1N. C) % cells expressing PAD1 4 days p.i., determined by FACS. PAD1 
expression was significantly reduced in the KO cells. D) Proportions of EP procyclin expressing cells 
4 hours post cis-aconitate treatment. To assess capacity to differentiate to procyclic forms, parasites 
purified from blood 4 days post infection were incubated in SDM-79 media supplemented with 6mM 
cis-aconitate at 27°C for 4 hrs and then analysed by FACS. EP expression was much lower in RBP7 
KO. *P<0.05,**P<0.005,***P<0.0005 GLM. 
3.2.5.3 Overexpression of RBP7 restores differentiation in RBP7 KO in 
vitro 
RBP7 has previously been overexpressed in the AnTat 1.1 90:13 background and 
shown to induce differentiation by Mony et al. (2014). RBP7 was overexpressed in 
the RBP7 null mutant background to determine if this could restore its capacity for 





   
   73 
that exogenously overexpressed RBP7 was able to drive stumpy formation in the 
absence of endogenous protein. This supports the hypothesis that the block in 
differentiation which occurs upon knockout of a posST gene can be overcome by 
overexpressing it. As this would also be expected to be true for any downstream 
effector, it adds credence to the approach of ordering the posST pathway by 
overexpressing posST proteins in distinct posST null mutant backgrounds.  
 
Figure 3.15 A) In vitro growth inhibition upon overexpression of RBP7 was still observed in a RBP7 
null mutant background. B) Northern blot analysis shows overexpression of RBP7 in an RBP7 null 
mutant background upon induction with doxycycline.  
It has been demonstrated for various posST genes that overexpression promotes 
stumpy formation while gene knockout prevents it (sections 3.2.3.4, 3.2.5.2, 3.2.5.3 
and (Mony et al., 2014). It has also been shown in the case of RBP7 that 
overexpression in a null mutant background can restore differentiation capacity 
(section 3.2.5.3). Therefore, overexpression of one posST gene in combination with 
knockout of a distinct posST could be used to elucidate the relationship of the 2 
genes and facilitate ordering of the pathway. As depicted in Figure 3.16, if 
overexpressed posST X is dependent on the deleted posST Y, the parasites would be 
unable to differentiate. This would indicate that, for example, Y acts directly 
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Figure 3.16 Combinatorial knockout and overexpression strategy for ordering posST genes. 
Overexpression of posST X triggers stumpy formation. Knockout of posST Y results in retention of 
slender forms. Combined X OE + Y KO gives possible outcomes: posST X stumpy formation is 
dependent on posST Y and cells remain slender if A) X acts upstream of Y or B) Y is required to 
produce the active form of X. posST X stumpy formation is dependent on posST Y and cells 




















posST X stumpy formation is dependent on posST Y: 
posST X stumpy formation is independent of posST Y: 
A B 
C D 
   
   75 
downstream of X or alternatively is required to produce the active form of X. If, on 
the other hand, X is independent of Y, the parasites would differentiate to stumpy 
forms. This would indicate that Y acts either upstream of X or on a distinct branch of 
the SIF response pathway. 
3.3.1 NEK OE + RBP7 KO: Overexpression of NEK results in 
RBP7-dependent growth inhibition in vitro 
A copy of NEK (Tb927.10.5950) with a C-terminal TY tag was overexpressed in 
AnTat 1.1 90:13 parasites and in the RBP7 KO line using the strategy described for 
overexpression of MEKK1 (section 3.2.3.7). Figure 3.17A shows that overexpression 
of NEK alone resulted in growth inhibition but this effect was completely lost in the 
RBP7 KO background. Interestingly, while both lines showed inducible 
overexpression using an antibody against the TY epitope tag, the level of 
overexpression was much higher in the RBP7 null mutant (Figure 3.17B), in which 
growth was unaffected. Possible explanations for this are discussed in section 3.5.4, 
but it demonstrated that the absence of arrest was not due to a failure to express the 
NEK protein. These results demonstrate that NEK-induced stumpy formation is 
dependent on RBP7 and act as proof of principle that posST overexpression 
phenotypes can be rescued by knockout of a distinct gene. 
 
Figure 3.17 A) In vitro growth inhibition caused by overexpression of NEK was rescued in an RBP7 
null mutant background. B) Western blot analysis using the TY epitope tag specific BB2 antibody 24 
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3.3.2 NEK OE + YAK KO: Overexpression of NEK results in 
YAK-independent growth inhibition in vitro 
NEK was also ectopically expressed in a null mutant of YAK generated by Paula 
MacGregor (unpublished results). Induction of NEK overexpression resulted in 
growth inhibition in both the wild type and the YAK KO cells (Figure 3.18A), 
indicating that NEK mediates differentiation independently of YAK. However, 
western analysis demonstrated that the protein was overexpressed at a much higher 
level in the null mutant line (Figure 3.18B). It is possible that this reflects a partial 
rescue by the YAK KO which necessitates a higher level of NEK overexpression in 
order to produce a similar level of growth inhibition. This possibility is further 
explored in section 3.5.4. However, the observation of growth arrest in the absence 
of YAK strongly indicates that stumpy formation by NEK is not dependent on YAK. 
 
Figure 3.18 In vitro growth inhibition caused by overexpression of NEK was still observed in a YAK 
null mutant background. B) Western blot analysis demonstrated that NEK was overexpressed to a 
higher level in the YAK KO line. EF1 was used as a loading control. 
3.3.3 PP1 OE + RBP7 KO: Overexpression of PP1 results in 
RBP7-independent growth inhibition in vitro 
PP1 has previously been overexpressed in the AnTat 1.1 90:13 background and 
shown to induce stumpy formation (B. Mony and K. Matthews, unpublished results). 
To investigate its pathway position, PP1 was overexpressed in the RBP7 null mutant 
line. Figure 3.19A shows that induction of PP1 overexpression led to immediate 
arrest lasting 48 hours, after which growth subsequently recovered. A Northern blot 
was probed for expression of the PP1 transcript, resulting in the detection of 3 bands. 
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As seen in Figure 3.19B, the lowest of the 3 showed increased intensity 48 hours 
after induction of PP1 ectopic expression in both the AnTat and RBP7 KO lines. This 
was no longer apparent 5 days post induction in the PP1 OE + RBP7 KO line, 
indicating that growth had resumed due to reduced PP1 expression. This suggests 
that in vitro, stumpy formation can be induced by elevated PP1 expression and that 
this is independent of the presence of RBP7.  
 
Figure 3.19 A) In vitro growth inhibition caused by overexpression of PP1 was still observed in a 
RBP7 null mutant background. B) Northern blot analysis of PP1 detects 3 bands, the smallest of 
which (arrow) was increased 48 hours post induction of overexpression. This increase was abolished 
at later timepoints when cell growth had recovered. 
3.3.4 PP1 OE + RBP7 KO: Overexpression of PP1 results in 
RBP7-independent stumpy formation in vivo 
In addition to an in vitro growth analysis, the capacity of PP1 overexpression to 
trigger differentiation in the absence of RBP7 was assessed in vivo. As PP1 
overexpression results in rapid growth arrest in vivo (B. Mony and K. Matthews, 
unpublished results), doxycycline was not introduced until 3 days post infection. This 
resulted in the expected growth inhibition in the PP1 OE line (Figure 3.20A). This 
was also observed in the PP1 OE + RBP7 KO line, showing that PP1 OE induced 
growth arrest independently of the presence of RBP7. Effective PP1 overexpression 
in both lines was confirmed by Northern blot (Figure 3.20C). In the absence of 
doxycycline, the cells appeared slender in morphology on day 4 of infection due to 
the absence of RBP7. However, addition of doxycycline resulted in the presence of 
morphologically stumpy forms (Figure 3.20B), showing that PP1 overexpression was 
able to restore differentiation in this line.  
PO+RK Northern 23.4.15 
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Figure 3.20 PP1 OE restores stumpy formation in RBP7 KO cells in vivo. A) Parasitaemia of mice 
infected with PP1 overexpression and RBP7 knockout cell lines in triplicate, estimated by the rapid 
matching method. Overexpression was induced with doxycycline at 3 days post infection, resulting in 
rapid growth inhibition. A strong growth effect upon induction of PP1 overexpression was also 
observed in the RBP7 null mutant background. ***P<0.0005 t test. B) Phase contrast images of 
PP1OE+RBP&KO parasites on day 4 of infection. Untreated (dox-) cells appear slender in 
morphology whereas doxycycline-treated (dox+) cells were morphologically stumpy. C) Northern blot 
analysis of PP1 detects 3 bands, the smallest of which (arrow) was increased upon overexpression of 
PP1. rRNA was used as a loading control. 
The differentiation status of the parasites 24 hours after induction of PP1 
overexpression was further explored by analysing their cell cycle position. PP1 
overexpression resulted in increased G1 arrest in the RBP7 KO, as determined by a 
19% increase in 1K1N cells (Figure 3.21A). PAD1 expression was also restored, 
although a low level of PAD1 expression was also observed in this cell line in the 
absence of doxycycline. As this was undetectable in the parental RBP7 KO line 
(Figure 3.21B), this indicated that the overexpression was slightly leaky. The PP1 
OE + RBP7 KO population also demonstrated enhanced competence to differentiate 
to procyclic forms and express EP procyclin upon CCA treatment (Figure 3.21C). A 
low level of EP expression was also detected in the absence of doxycycline, again 
likely due to leaky PP1 expression. These results demonstrate that PP1 mediates 
stumpy formation in an RBP7-independent fashion. 
  dox-            dox+          dox-            dox+         AnTat       RBP7KO 
PP1OE               PP1OE+RBP7KO 
A
B C 
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Figure 3.21 Stumpy formation by PP1 was independent of RBP7. A) % 1K1N cells at day 4 p.i. 250 
cells were counted for each sample. An increase in G1 arrest upon PP1 overexpression was still 
observed in the RBP7 null mutant. **P<0.005,***P<0.0005 t test. B) Western blot analysis on day 4 
shows an increase in PAD1 expression upon PP1 overexpression was still observed in the RBP7 null 
mutant. EF1 was used as a loading control. C) Proportions of EP procyclin expressing cells 4 hours 
post cis-aconitate treatment. To assess capacity to differentiate to procyclic forms, parasites purified 
from blood 4 days post infection were incubated in SDM-79 media supplemented with 6mM cis-
aconitate at 27°C for 4 hrs and then analysed by FACS. An increase in EP expression upon PP1 
overexpression was still observed in the RBP7 null mutant. *P<0.05,**P<0.005,***P<0.0005 t test. 
3.3.5 PP1 OE + YAK KO: Overexpression of PP1 results in 
YAK-independent growth inhibition in vitro 
To further analyse the role of PP1 in the differentiation pathway, PP1 was 




   
   80 
resulted in growth inhibition (Figure 3.22A), indicating that this phenotype is 
independent of YAK. Although growth recovered at a later timepoint, this was likely 
due to loss of PP1 overexpression as this was also observed when PP1 was 
overexpressed in the RBP7 null mutant background (section 3.3.3). Indeed, PP1 
overexpression could no longer be detected by Northern blot 4 days post induction 
(Figure 3.22B). Surprisingly, the Northern blot also showed enrichment of the lowest 
band in the uninduced PP1 OE + YAK KO sample. The reason for this is unclear as 
the cells grew normally. 
 
Figure 3.22 A) In vitro growth effect upon overexpression of PP1 was still observed in a YAK null 
mutant background. B) Northern blot analysis of PP1 detects 3 bands, the smallest of which (arrow) 
was increased 48 hours post induction of overexpression. This increase was abolished at later 
timepoints when cell growth had recovered. 
3.3.6 PP1 OE + YAK KO: Overexpression of PP1 results in 
YAK-dependent stumpy formation in vivo 
The capacity of PP1 overexpression to trigger differentiation in the absence of YAK 
was also assessed in vivo. This demonstrated that induction of PP1 overexpression on 
day 3 of infection resulted in rapid growth inhibition both in the AnTat 1.1 90:13 
background and the YAK null mutant (Figure 3.23A). This corresponded to the in 
vitro finding that PP1-induced growth arrest was YAK-independent. However, while 
PP1 OE + YAK KO cells showed an increase in 1K1N upon doxycycline treatment, 
this was modest compared to overexpression of PP1 in the wild type background 
(72.9 ± 1% vs. 97.5 ± 0.5%; Figure 3.23B), indicating that G1 arrest was tempered by 
the absence of YAK. When the harvested parasites were induced to differentiate to 
procyclic forms, PP1 overexpression did not result in an increase in EP expression in 
    tet-              2d+            4d+            tet-              2d+            6d+  
PP1OE+YAKKO                                  PP1OE                           
A B 
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YAK KO cells relative to doxycycline untreated cells (Figure 3.23C), suggesting that 
the population was mainly slender in characteristic. Consistent with this, PAD1 
expression was barely detectable in doxycycline induced PP1 OE + YAK KO 
parasites (Figure 3.23D). Thus it appears that although growth inhibition by PP1 
overexpression is YAK independent, PP1-induced stumpy formation and 
differentiation competence is YAK dependent. The PP1 overexpression growth 
phenotype is more severe than that observed for overexpression of other posST 
proteins and, unlike most of these, it also exhibited growth inhibition upon RNAi 
(Mony et al., 2014). This suggests that, in addition to its role in differentiation, PP1 
also performs a function essential to proliferative slender cells. Therefore, although 
its differentiation function is YAK-dependent, YAK has no involvement in its other 
role in slender forms and as such YAK KO cannot rescue the growth phenotype. 
Northern analysis showed the previously observed upregulation of the lowest PP1 
band in the PP1 OE line (indicated by arrow in Figure 3.23E). However, as observed 
in vitro, this band was upregulated in the PP1 OE + YAK KO line both with and 
without doxycycline. This was not observed in the parental YAK KO line (Figure 
3.23E), which indicates that the PP1 transcript does not accumulate as a consequence 
of the absence of YAK. As the lack of a growth defect in the absence of doxycycline 
also rules out leaky overexpression as an explanation for this observation, the reason 
behind this accumulation is unknown.  
   




   AnTat      YAKKO       dox-         dox+         dox-         dox+ 
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Figure 3.23 Stumpy formation by PP1 in vivo is dependent on YAK. A) Parasitaemia of mice infected 
with PP1 overexpression and YAK knockout cell lines in triplicate, estimated by the rapid matching 
method. Overexpression was induced with doxycycline at 3 days post infection. A strong growth 
effect upon induction of PP1 overexpression was also observed in an YAK null mutant background. 
B) % 1K1N cells at day 4 p.i. 250 cells were counted for each sample. An increase in G1 arrest upon 
PP1 overexpression was diminished in a YAK null mutant. C) % EP procyclin expressing cells 4 
hours post cis-aconitate treatment. To assess their capacity to differentiate to procyclic forms, 
parasites purified from blood 4 days post infection were incubated in SDM-79 media supplemented 
with 6mM cis-aconitate at 27°C for 4 hrs and then analysed by FACS. An increase in EP expression 
upon PP1 overexpression was reduced in the YAK null mutant. A)-C) 
*P<0.05,**P<0.005,***P<0.0005 t test. D) Western blot analysis on day 4 demonstrated that PAD1 
expression upon PP1 overexpression was not observed in the YAK null mutant. EF1 was used as a 
loading control. E) Northern blot analysis of PP1 detects 3 bands, the smallest of which (arrow) was 
increased upon overexpression of PP1. rRNA was used as a loading control.  
Figure 3.24A shows that doxycycline-treated PP1 OE + YAK KO cells appeared 
morphologically slender, which was in agreement with the findings from Figure 3.23 
that PP1-mediated differentiation is YAK-dependent. However, visualisation of these 
cells using a nuclear stain showed that, in many of these cells, the nucleus had an 
unusual elongated, curvy shape. An example is shown in Figure 3.24A. This was 
quantified using 2 shape descriptors: aspect ratio and solidity. Aspect ratio defines 
the length of the object divided by the width, such that an elongated object such as an 
oval will have a higher aspect ratio than a compact object such as a circle. Solidity 
measures the area of an object divided by its convex area and therefore quantifies 
how concave the shape is. Nuclei of doxycycline-treated cells had a significantly 
increased aspect ratio and decreased solidity compared to uninduced controls (Figure 
3.24B), demonstrating that these nuclei were less circular and more elongated and 
concave in shape. This phenomenon has not been observed for PP1 OE alone and 
appears to be specific to the PP1 OE + YAK KO combination, suggesting that these 
cells have characteristics distinct from wild type slender parasites. Possible 
explanations for this phenotype are discussed in section 3.5.3. 
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Figure 3.24 PP1 overexpression affects nuclear shape in YAK null mutant cells. A) Phase contrast 
(upper) and DAPI (lower) images of PP1OE+YAKKO parasites on day 4 of infection. Doxycycline-
treated (dox+) cells appear slender in morphology and have elongated nuclei. B) Quantification of 
nuclear shape changes. Aspect ratio = length/width. Solidity = area/convex area. dox- n=145; dox+ 
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3.3.7 RBP7 OE + YAK KO: Overexpression of RBP7 results in 
YAK-independent growth inhibition in vitro 
Having investigated the role of PP1 relative to both RBP7 and YAK, RBP7 was 
overexpressed in the YAK null mutant line to assess the relationship of these 2 
proteins. Overexpression of RBP7 led to growth inhibition in vitro in the YAK null 
mutant to an even greater degree than in the wild-type background (Figure 3.25A), 
possibly due to a higher level of RBP7 overexpression, as demonstrated by Northern 
blot (Figure 3.25B). This demonstrated that in vitro growth inhibition by RBP7 
overexpression is YAK-independent.  
 
Figure 3.25 A) In vitro growth effect upon overexpression of RBP7 was still observed in a YAK null 
mutant background. B) Northern blot analysis shows upregulation of RBP7 transcript in the presence 
of tetracycline. rRNA was used as a loading control. 
 
3.3.8 RBP7 OE + YAK KO: Overexpression of RBP7 results in 
YAK-independent stumpy formation in vivo 
To explore the genetic interaction between RBP7 and YAK in vivo, Mice were 
infected with RBP7 OE + YAK KO parasites to assess their capacity to differentiate 
to stumpy forms in vivo. Doxycycline was introduced at day 0. In the untreated mice, 
the parasitaemia ascended rapidly whereas growth was significantly reduced upon 
the induction of overexpression (Figure 3.26A). Inducible overexpression of RBP7 
was confirmed by Northern blot (Figure 3.26E). The induction of RBP7 
overexpression also resulted in an increase in G1 arrest, as determined by a 
significantly increased proportion of 1K1N cells (Figure 3.26B). The parasite 
populations in uninduced mice appeared morphologically slender whilst stumpy 
forms were observed upon the overexpression of RBP7 (Figure 3.26C). RBP7  
tet-        tet+       tet-      tet+ 
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Figure 3.26 Stumpy formation by RBP7 in vivo is independent of YAK.  A) Parasitaemia of mice 
infected with RBP7OE+YAKKO cells, estimated by the rapid matching method. Data represents 6 
mice, 3 treated with doxycycline (dox+) and 3 non-induced (dox-). Growth was reduced in dox+. 
***P<0.0005 GLM and Tukey test for multiplie comparisons. B) % 1K1N (representing G1 and S 
phase) cells throughout the course of infection. 250 cells were counted for each sample. Induced cells 
have a higher proportion of 1K1N cells. **P<0.005 GLM. C) Phase contrast images from day 4 of 
infection. Untreated cells appear slender in morphology whereas dox+ cells were morphologically 
stumpy. D) % cells expressing PAD1 throughout the course of infection, determined by IFA. 250 cells 
were counted for each sample. PAD1 expression increases in dox+. ***P<0.0005 GLM. E) Northern 
blot analysis shows upregulation of RBP7 transcript in dox+. rRNA was used as a loading control.  
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overexpression also generated a small but significant upregulation of PAD1 
expression from 0% in the untreated population on days 3 and 4 to 6.8 ±  1.2% and 
9.1 ±  1.4% respectively in the induced parasites (Figure 3.26D). These results 
demonstrated that overexpression of RBP7 induces G1 arrest and differentiation to 
stumpy forms in vivo independently of YAK. 
3.3.9 HYP2 OE + RBP7 KO: Overexpression of HYP2 results 
in RBP7-independent stumpy formation in vivo 
HYP2 has been overexpressed with an N-terminal TY tag in the AnTat 1.1 90:13 
strain and shown to induce stumpy formation by Eleanor Silvester (thesis in 
preparation). The same construct was used to overexpress HYP2 in the RBP7 null 
mutant line. Induction of overexpression generated growth inhibition in vivo (Figure 
3.27A), indicating that this phenotype is RBP7 independent. Although growth 
recovered later in the timecourse (Figure 3.27A), this was likely due to loss of the 
overexpression, which could no longer be detected 5 days post-induction (Figure 
3.27B). Tagged overexpressed HYP2 has an expected size of 142 kDa. However, the 
BB2 antibody detected multiple bands of various sizes. With the exception of 1 non-
specific band, none of these bands were detectable in the tet- samples, suggesting 
inducible expression, and the band pattern was consistent between the HYP2 OE and 
HYP2 OE + RBP7 KO lines (Figure 3.27B). Moreover, the additional bands were 
lost once growth recovered in the HYP2 OE + RBP7 KO line. This would suggest 
that these represent HYP2 or HYP2-derived protein products.   
 
Figure 3.27 A) In vitro growth effect upon overexpression of HYP2 is still observed in an RBP7 null 
mutant background. B) Western blot analysis showed detection of bands of multiple sizes by the BB2 
antibody recognizing the TY tag. EF1 was used as a loading control. 
HO+RK Western 
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The generation of null mutant lines of 2 posST kinases, MEKK1 and YAK, 
presented the opportunity to investigate changes in the phosphorylation profile on a 
global scale resulting from the loss of these proteins by phosphoproteomics, and 
thereby potentially identify downstream substrates. Protein was extracted and 
trypsinised in the presence of phosphatase inhibitors from quadruplicate in vitro 
cultures of slender MEKK1 KO, YAK KO and parental AnTat 1.1 90:13 parasites. 
At the FingerPrints Proteomic Facility at the University of Dundee, these samples 
were labelled with isobaric tandem mass tags (TMTs) and subjected to proteomic 
and phosphoproteomic quantitation by mass spectrometry. This process was carried 
out in 2 separate runs each involving 2 replicates of each cell line. Analysis of the 
data was carried out by Dr. Mathieu Cayla. Ratios were generated for the knockout 
samples relative to the AnTat 1.1 90:13 control replicates and protein ratios used to 
normalise phosphopeptide ratios.  
The proteomic and phosphoproteomic datasets generated showed unexpected results 
for the two kinases investigated. In the first of the two runs, MEKK1 protein was 
unexpectedly detected in the knockout samples. However, it was excluded from the 
analysis due to detection at a reporter intensity of less than the cutoff value of 10,000 
in these samples. In the second run, MEKK1 protein was not detected in any sample, 
although 7 phosphopeptides were attributed to it. Similarly, YAK protein was not 
detected in any sample in the first run. Although it was detected in the second run, it 
did not exceed the cutoff reporter intensity value in any samples. The low level 
detection of MEKK1 and YAK peptides in their respective null mutant lines may be 
due to a limitation of the methodology whereby pooling of the samples after TMT 
labelling and prior to fractionation can lead to co-isolation of peptides of similar 
sizes during mass spectrometry in fractions of high complexity. This issue can also 
lead to ratio compression in quantitation. 
Overall, 105 proteins in the MEKK1 KO line and 176 proteins in the YAK KO line 
were found to have greater than 2-fold differential phosphorylation, of which 61 
were common to both. In many proteins, multiple peptides were affected. These 
changes are depicted in Figure 3.29 and Figure 3.30. As shown in Figure 3.28, a 
3.4 Phosphoproteomic analysis 
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variety of protein classes are represented among the regulated phosphoproteins. As 
well as affecting a large number of hypothetical proteins, both KO lines resulted in 
increased and decreased phosphorylation of numerous kinases, phosphatases and 
RNA-binding proteins, indicating substantial perturbation of signalling pathways. 
The presence of various differentially regulated motor proteins, including many 
dyneins and kinesins, and flagellar proteins suggested effects on transport and 
motility. 
 
Figure 3.28 Differentially phosphorylated proteins grouped according to protein class. 
Loss of MEKK1 affected the phosphorylation status of numerous cellular proteins. A 
number of examples of affected proteins are listed in Table 3.1. 55 proteins showed 
reduced phosphorylation, potentially including direct targets of the kinase, as well as 
proteins in which phosphorylation status is changed due to secondary or indirect 
effects. Notable among these was the posST component NEK, which indicates that 
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NEK likely operates downstream of MEKK1 in the posST pathway. A number of 
other proteins which showed reduced phosphorylation also had predicted roles in 
signal transduction, including 2 putative phosphatase 2C proteins (Tb927.4.4510 and 
Tb927.7.4020) and a predicted TFIIF-stimulated CTD phosphatase (Tb927.10.4180), 
while ZC3H34 (Tb927.10.12330) is a CCCH-type zinc finger RNA-binding protein 
(Kramer et al., 2010) shown to act as a post-transcriptional activator (Erben et al., 
2014), making it a good candidate for a role as a downstream effector in a signalling 
cascade perturbed by loss of MEKK1. A predicted subunit of eukaryotic translation 
initiation factor 3 (eIF-3 beta) also showed reduced phosphorylation. Interestingly, 
according to RNAseq data (E. Silvester, thesis in preparation), eIF-3 beta mRNA is 
enriched 1.8 fold in the stumpy form, a stage associated with widespread repression 
of translation (Kabani et al., 2009).  
Distinct signalling molecules were among the 58 proteins which showed increased 
phosphorylation upon MEKK1 KO (Figure 3.28 and Figure 3.29). One of these was 
the AMPK β subunit Tb927.8.2450, which is particularly intriguing as an α subunit 
of AMPK is a known posST component (Mony et al., 2014). 4 potential regulators 
showed increased phosphorylation. Of these, RBP42 (Tb927.6.4440), which acts on 
transcripts involved in energy metabolism (Das et al., 2012) and DRBD4 
(Tb927.11.14100), were shown to result in post-transcriptional activation of an 
artificially tethered mRNA (Erben et al., 2014). In contrast, RBP12 
(Tb927.10.13540) acted to repress mRNAs (Erben et al., 2014). Silencing of RBP35 
(Tb927.9.12360) resulted in increased fitness during differentiation (Alsford et al., 
2011). A putative C3HC4 zinc finger RING-type protein (Tb927.8.4570) contained 
the most highly upregulated phosphopeptides in both the MEKK1 and YAK KO 
lines. RING finger domain containing proteins are often involved in ubiquitination 
(Lorick et al., 1999).  
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Figure 3.29 Distribution of phosphopeptides showing greater than 2 fold differential phosphorylation 
in MEKK1 KO cells relative to parental AnTat 1.1 90:13 cells. Log2 of the phosphopeptide:protein 
ratio normalised to AnTat controls is shown for each replicate of each phosphopeptide in which the 
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56 proteins showed reduced phosphorylation in the YAK KO line (Figure 3.28 and 
Figure 3.30), and were therefore potential YAK targets. These included two 
predicted PPP phosphatases, one of which (Tb927.4.4510) was also 
dephosphorylated in the MEKK1 KO line. Two paraflagellar rod components 
(Tb927.8.1550 And Tb927.8.6660) also showed reduced phosphorylation. KKT4 
(Tb927.8.3680), a member of the unusual kinetoplastid specific kinetochore proteins 
(Akiyoshi and Gull, 2014), showed both increased and decreased phosphorylation on 
different residues, and was also dephosphorylated in the MEKK1 KO line. 
Interestingly, a NEK kinase, NRKC (Tb927.10.460), was dephosphorylated in the 
absence of YAK. Unlike NEK and NRKA/B (Domingo-Sananes et al., 2015), NRKC 
has not been previously implicated in differentiation, but has been shown to have a 
role in basal body separation (Pradel et al., 2006). 
A much larger cohort of proteins showed enriched phosphorylation in the YAK KO 
line. This included a large complement of motor proteins (6). Phosphopeptides were 
also enriched for six flagellar proteins, including four of the eight FLAM (FLAgellar 
Member) proteins recently identified by proteomic analysis and experimentally 
validated by Subota et al. (2014), which showed distinct suborganellar localisations 
and dynamics. All 4 RNA-binding proteins with increased phosphorylation in the 
MEKK1 KO line showed the same effect in the YAK KO. In addition, the RNA-
binding protein ZC3H34, which was dephosphorylated in the absence of MEKK1, 
showed increased phosphorylation at a different residue in the YAK KO line. The 
mRNA-stabilising factor MKT1 also showed increased phosphorylation. This is 
intriguing as MKT1 has been shown to interact with HYP2 (Singh et al., 2014) and 
also ZC3H20, a zinc finger protein identified in an RNAi library screen for resistance 
to the stumpy inducing compound GKI7 (see section 5.6). A selection of proteins of 
interest showing differential phosphorylation in one or both null mutant lines are 
listed in Table 3.1. 
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Figure 3.30 Distribution of phosphopeptides showing greater than 2 fold differential phosphorylation 
in YAK KO cells relative to parental AnTat 1.1 90:13 cells. Log2 of the phosphopeptide:protein ratio 
normalised to AnTat controls is shown for each replicate of each phosphopeptide in which the value is 
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Accession no. Description MEKK1KO YAKKO Diff 
Tb927.3.5020 Flagellar Member 6 (FLAM6)   + No 
Tb927.4.4510 protein phosphatase 2C, putative - - No 
Tb927.6.640 
kinetoplastid-specific phospho-protein 
phosphatase, putative   - No 
Tb927.6.4770 protein mkt1, putative (MKT1)   + Yes 
Tb927.6.4440 
RNA-binding protein 42 (RNA-binding 
motif protein 42) (RBP42) + + Yes 
Tb927.7.4020 protein phosphatase 2C, putative -   No 
Tb927.8.1550 
paraflagellar rod component, putative 
(PFC3)   - Yes 
Tb927.8.2450 
5'-AMP-activated protein kinase subunit 
beta (AMPKB) + + No 
Tb927.8.3680 kinetoplastid kinetochore protein 4 (kkt4) - -/+ Yes 
Tb927.8.4570 
Zinc finger, C3HC4 type (RING finger), 
putative + + No 
Tb927.8.4780 Flagellar Member 3 (FLAM3) + + Yes 
Tb927.8.6660 
paraflagellar rod component, putative 
(PFC1)   - Yes 
Tb927.8.7950 Flagellar Member 4 (FLAM4)   + No 
Tb927.9.12360 RNA-binding protein, putative (RBP35) + + No 
Tb927.9.5460 
Eukaryotic translation initiation factor 4 
gamma type 2 (eif4g2)   + No 
Tb927.10.460 NIMA-related protein kinase (NRKC)   - No 
Tb927.10.4180 TFIIF-stimulated CTD phosphatase, putative -   Yes 
Tb927.10.5950 NEK kinase -   No 
Tb927.10.11310 
intraflagellar transport protein 57/55 
(IFT57/55)   + Yes 
Tb927.10.12330 
zinc finger protein family member, putative 
(ZC3H34) - + Yes 
Tb927.10.13540 RNA-binding protein, putative (RBP12) + + No 
Tb927.11.9610 
eukaryotic translation initiation factor 3 
subunit 2, putative (eIF-3 beta) -   No 
Tb927.11.14100 DRBD4 (DRBD4) + + No 
Tb927.11.16890 
Tetratricopeptide-like helical domain 
containing protein (FLAM7)   + Yes 
Tb927.3.5310 paraflagellar rod protein   + Yes 
Table 3.1 Selection of proteins showing greater than 2 fold differential phosphorylation in the 
MEKK1 or YAK null mutant lines. Phosphopeptides were either increased (+) or decreased (-).The 
final column refers to whether a reduced fitness phenotype was observed upon differentiation in a 
RIT-seq screen (Alsford et al., 2011). 
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3.5 Discussion 
3.5.1 Involvement of a number of posST screen hits in 
stumpy formation has been clarified. 
To determine the full complement of stumpy signalling molecules which can be 
extracted from the posST RNAi library screen, independent validation of each hit is 
necessary. This had already been carried out for many candidate genes by the 
generation of individual RNAi lines, and in the majority of cases this confirmed that 
silencing of these genes conferred loss of responsiveness to the SIF differentiation 
signal (Mony et al., 2014). In several cases where this phenotype was not observed, 
the hits in question were enzymes involved in purine metabolism and homeostasis. 
Hence, analysis of RNAi lines of adenylosuccinate synthetase (ADSS) and 
adenylosuccinate lyase (ADSL), which are involved in conversion of inosine 
monophosphate (IMP) to AMP, showed growth inhibition which could be alleviated 
by pCPTcAMP treatment. This suggests that these enzymes were selected in the 
screen due to a restoration of purine balance in the parasites by the analogues, 
alleviating growth inhibition. Adenosine kinase is another purine pathway enzyme 
identified in the screen, but unlike ADSS and ADSL, it showed no growth inhibition 
upon RNAi. This is in agreement with observations by Luscher et al. (2007). 
However, AK RNAi did confer loss of responsiveness to pCPTcAMP in both 
monomorphs (section 3.2.1.1) and pleomorphs (section 3.2.1.2). While this initially 
indicated a role in differentiation, no corresponding resistance to SIF could be 
observed when the cell line was analysed in vivo (section 3.2.1.3). This disparity may 
be due to the distinct properties of the pCPTcAMP analogue used in the in vitro 
experiment when compared to the biological activity of SIF. This analogue is 
hydrolysed and dephosphorylated to a corresponding adenosine analogue in culture, 
and therefore rephosphorylation would be required after cell entry (Laxman et al., 
2006). It is possible that this dephosphorylated analogue is recognised by AK, but 
not the enzymes of the alternative cleavage-dependent pathway, such that its action is 
dependent on AK. Hence, while the analogue is prevented at this stage from inducing 
differentiation in AK RNAi induced cells, in vivo, endogenous adenosine could 
circumvent this loss by phosphorylation via the alternative pathway such that 
differentiation remains unaffected. An alternative explanation for these findings is 
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that AK acts in a stage of the cAMP-induced differentiation pathway upstream of its 
intersection with the SIF signaling pathway.  
Another enzyme identified in the screen, PP2A, was independently analysed by 
RNAi in a monomorphic strain (section 3.2.2.1). In accordance with a previous study 
by Rothberg et al. (2014), this resulted in severe growth inhibition which precluded 
further analysis. It is likely that the identification of PP2A resulted from its 
substantial shared homology with validated posST, PP1. 
Mony et al. (2014) determined that MEKK1 RNAi conferred loss of responsiveness 
to pCPTcAMP in a monomorphic strain. Generation of an RNAi line in a 
pleomorphic strain was used to demonstrate a role for the kinase in differentiation in 
vitro (section 3.2.3.2) and in vivo (section 3.2.3.1). This is intriguing as it suggests 
involvement of the MAPK pathway in SIF signal transduction.  
To further investigate the role of MEKK1 in stumpy formation, 2 forms of the kinase 
were overexpressed in pleomorphic trypanosomes: the full length protein and the 
truncated C-terminal catalytic domain. In a number of other systems, expression of 
the latter is constitutively active due to loss of repression by the regulatory N-
terminal domain (Gibson et al., 1999; Mizote et al., 2010; Owen et al., 2013; van 
Drogen et al., 2000). Overexpression of the full length MEKK1 inhibited growth in 
vitro (section 3.2.3.5 and 3.2.3.7), similar to the differentiation-associated growth 
arrest which has been observed upon overexpression of other posST proteins. 
Interestingly, this was observed even in a monomorphic strain, suggesting that 
MEKK1 is able to drive stumpy formation in parasites unresponsive to the SIF 
signal. Surprisingly, despite the growth phenotype, the overexpressed protein could 
not be detected by an antibody to its TY epitope tag (section 3.2.3.6). The result was 
the same when the epitope tag was switched from the N terminal to the C terminal of 
the protein, excluding the possibility that the tag was lost upon cleavage of an N-
terminal targeting signal (section 3.2.3.7). When analysed at the transcript level, 
there was no apparent increase in MEKK1 mRNA upon induction of overexpression. 
However, when the same construct was used to overexpress MEKK1 in a MEKK1 
null mutant background, MEKK1 transcript abundance was restored, though not 
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enriched (section 3.2.3.8). This suggests that MEKK1 can be exogenously expressed 
by the construct, but is unable to increase transcript abundance above endogenous 
levels. This may be an indication of an unknown regulatory mechanism, which is 
discussed further in section 3.5.4. Overexpression of the catalytic domain, in 
contrast, had no effect on growth, but was clearly detectable via its epitope tag 
(section 3.2.3.5). In the absence of kinase assays to determine the activity of the 
truncated protein, it can only be speculated as to whether it is indeed constitutively 
active. However, as constitutive transduction of the differentiation signal would be 
predicted to be antiproliferative, the absence of any growth phenotype indicates that 
this is not the case. This may reflect differences between the trypanosome kinase and 
those of other systems. Another possibility is that the truncated protein is active but 
mislocalised. There are 2 predicted transmembrane domains in the excised N-
terminal portion which may confer targeting essential for protein function. 
CatMEKK1 expression can be detected by immunofluorescence (sections 3.2.3.6 and 
3.2.3.7) but in the absence of detectable full length MEKK1, it is impossible to 
determine whether the staining pattern reflects typical MEKK1 localisation. 
3.5.2 Null mutants of posST genes reduce differentiation in 
vivo and represent a clean genetic background in which 
to carry out further manipulations. 
RNAi has been used to effectively demonstrate involvement of numerous posST 
components in stumpy signalling (section 3.2.3.2)(Mony et al., 2014). However, in 
most cases, some degree of differentiation is still observed. Using RNAi, it is not 
possible to determine whether residual stumpy formation represents a non-absolute 
requirement for the posST component in question for differentiation to proceed or is 
a consequence of incomplete transcript knockdown. It is also problematic to use in 
combination with overexpression to analyse the relative positioning of distinct posST 
proteins. This is because RNAi and overexpression systems may proceed with 
different kinetics but cannot be separately controlled, since both are subject to 
tetracycline induction. The generation of null mutants represents an alternative 
option with the capacity to clarify the absolute requirement of different posST 
components for differentiation and to provide a “clean” background in which to 
execute further genetic manipulations. Fortunately, existing RNAi data indicated that 
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most posST components studied were non-essential, with the notable exception of 
PP1 (section 3.2.3.2)(Mony et al., 2014), making null mutant production feasible. An 
established transfection protocol in the pleomorphic strain AnTat 1.1 90:13 has been 
extensively used in our laboratory for generation of RNAi and overexpression lines 
(MacGregor et al., 2013). However, YAK was the first gene to be successfully 
knocked out in these parasites (P. MacGregor and K Matthews, unpublished), 
demonstrating the feasibility of generating null mutants in this strain using the 
system of sequential allelic replacement outlined in section 3.2.3.3. In this chapter, 
the generation of null mutants of 3 more posST components – MEKK1, HYP2 and 
RBP7 – is described (sections 3.2.3.3, 3.2.4.1 and 3.2.5.1). In vivo, these lines 
proliferate rapidly to high parasitaemia and show dramatically compromised stumpy 
formation. However, the continued increase in the proportion of 1K1N cells 
throughout the course of infection and the appearance of some PAD1 expression at 
later timepoints indicate that a limited level of stumpy formation remains possible in 
the total absence of each of these 3 components (sections 3.2.3.4 and 3.2.5.2; E. 
Silvester, thesis in preparation). The YAK and RBP7 null mutant lines have 
successfully been further modified to overexpress distinct posST components, 
revealing information about the dependency relationships of the signalling pathway 
components, discussed in the following section, while phosphoproteomic analysis of 
MEKK1 and YAK null mutants has provided insight into the downstream effects of 
these signalling molecules, discussed in section 3.5.5.  
3.5.3 Combined overexpression and knockout of posST 
proteins can be used to reveal the organisation of the 
differentiation signalling pathway. 
To explore the dependency relationships between posST components with respect to 
each other, a combinatorial overexpression and knockout approach was used in 
which one posST gene was overexpressed in the a null mutant background of a 
distinct posST gene and the differentiation phenotype analysed, as depicted in Figure 
3.16. First, to demonstrate proof of principle, RBP7 was overexpressed in an RBP7 
null mutant background (section 3.2.5.3). This resulted in growth inhibition in vitro 
similar to the effect observed when RBP7 is overexpressed in a wild type 
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background, demonstrating that stumpy formation could be restored by exogenous 
introduction of RBP7. 
Overexpression of NEK in a wild type background resulted in growth inhibition in 
vitro. This growth defect was completely rescued when NEK was overexpressed in 
the RBP7 null mutant line (section 3.3.1), indicating that stumpy formation by NEK 
is RBP7 dependent. It is likely that RBP7 operates downstream of NEK and that 
NEK is part of a signalling relay which triggers RBP7 to induce expression changes 
related to differentiation. In contrast, the growth defect was retained when NEK was 
overexpressed in the YAK null mutant (section 3.3.2), indicating that stumpy 
formation by NEK is independent of YAK. 
Overexpression of PP1 in the RBP7 null mutant line resulted in growth inhibition in 
vitro as in the wild type background (section 3.3.3). When overexpression was 
induced in vivo, it resulted in a rapid inhibition of the ascending parasitaemia 
accompanied by appearance of morphologically stumpy forms, increased G1 arrest, 
PAD1 expression and capacity to differentiate to procyclic forms (section 3.3.4). 
Stumpy formation by PP1 therefore appears to be independent of RBP7. While it is 
possible that PP1 operates directly downstream of RBP7, this seems unlikely given 
their putative roles in signalling and modulation of expression respectively. An 
alternative hypothesis is that PP1 and RBP7 act on separate branches of the 
differentiation pathway and their actions are therefore independent. A cell line with 
opposing gene modifications – ie. RBP7 overexpression and PP1 knockout – would 
be useful in exploring this hypothesis but unfortunately the apparent essentiality of 
PP1 (Mony et al., 2014) likely precludes successful generation of a knockout using 
this strategy. 
As in the wild type and RBP7 knockout backgrounds, overexpression of PP1 in the 
YAK null mutant background resulted in severe growth inhibition in vitro and in vivo 
(sections 3.3.5 and 3.3.6). In contrast, PAD1 expression in this cell line was 
negligible, and when induced to differentiate to procyclic forms, EP procyclin 
expression was not significantly elevated relative to uninduced parasites. This would 
suggest that PP1-induced stumpy formation is in fact YAK-dependent and that the 2 
proteins act on the same branch of the stumpy signalling pathway. One possibility is 
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that PP1 operates directly upstream of YAK and its action is therefore blocked 
downstream when YAK is absent. An alternative explanation is that PP1 is activated 
by YAK phosphorylation and loss of the latter blocks its action by locking PP1 in an 
inactive form. However, phosphoproteomic analysis of the YAK null mutant showed 
no evidence of changes in the phosphorylation status of PP1 (section 3.4). Another 
question posed by this result is why deletion of YAK blocked differentiation by PP1, 
but not growth inhibition. The growth phenotype observed upon PP1 overexpression 
is more severe than for other posST components, with proliferation completely 
arrested within 24 hours of induction in vivo. In addition, PP1 RNAi results in 
growth inhibition in culture, suggesting it is essential for normal growth of slender 
forms as well as differentiation. One possibility is that PP1 has one function 
unrelated to differentiation which is independent of YAK and a separate YAK-
dependent function in stumpy formation. The discrepancy between the YAK-
dependent differentiation and YAK-independent growth inhibition also highlights the 
importance of in vivo analysis in ordering posST components using this strategy, as 
in vitro evidence alone indicated an entirely different relationship between these 2 
proteins.  
Microscopic examination of DAPI-stained cells revealed that PP1 overexpression in 
the YAK null mutant background also affected nuclear shape. Nuclei in these cells 
were unusually elongated and curved in morphology (Figure 3.24). The reason for 
this phenotype, which is not observed with either PP1 overexpression or YAK 
knockout alone, is unknown. Although the cells have a KN profile similar to that of 
slender cells, this measure of cell cycle only accounts for kinetoplast segregation and 
nuclear division and does not take account of DNA replication. It is unknown if the 
misshapen nuclei contain an atypical quantity of DNA. One possibility is that the 
combined excess of PP1 and absence of YAK locks the cells in a stasis in which 
DNA proliferation proceeds but nuclear division is prevented, resulting in amorphous 
nuclei with multiple genomic copies, although it is worth noting that this morphology 
is also observed in dividing 2K1N and 2K2N cells. This could be explored in future 
by using flow cytometry to quantify DNA content. Another possibility is that the 
morphological rearrangements associated with differentiation to stumpy forms are 
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disturbed by the opposing developmental influences of PP1 overexpression and YAK 
knockout. 
From the above results, it is hypothesised that PP1 acts on the same branch of the 
pathway as YAK, but on a distinct branch to RBP7. Therefore, it would be expected 
that YAK and RBP7 would be positioned on different branches to each other. This 
was explored by overexpression of RBP7 in the YAK null mutant line. Growth 
inhibition in vitro and in vivo and restoration of stumpy formation demonstrated that 
differentiation by RBP7 is YAK independent (sections 3.3.7 and 3.3.8). This is 
consistent with the hypothesis that PP1 and YAK act on a branch of the pathway 
distinct to that of RBP7. 
Overexpression of HYP2 in the RBP7 null mutant line resulted in RBP7-independent 
growth inhibition in vitro. While it could be speculated that HYP2 might therefore be 
found on the pathway branch separate from that of RBP7, the example of the PP1 
overexpression plus YAK knockout line demonstrates that an independent growth 
phenotype does not necessarily equate to an independent differentiation phenotype. 
Hence, this position remains highly tentative until this cell line is tested in vivo.  
A further piece of information regarding ordering of the posST components is 
provided by the phosphoproteomic analysis of the MEKK1 null mutant, which shows 
a significant reduction in phosphorylation of NEK (section 3.4), suggesting that NEK 
is a direct or indirect substrate of MEKK1. This would place MEKK1 upstream of 
NEK and consequently RBP7.  
OE KO Stumpy formation 
PP1 RBP7 PP1 is independent of RBP7 
PP1 YAK PP1 is dependent on YAK 
RBP7 YAK RBP7 is independent of YAK 
NEK RBP7 NEK is dependent on RBP7 
NEK YAK NEK is independent of YAK 
HYP2 RBP7 HYP2 is independent of RBP7 (in vitro) 
Table 3.2 Summary of overexpression (OE) and knockout (KO) combinations of posST components. 
OE promotes differentiation determined to be either dependent or independent of KO gene.  
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Figure 3.31 Model of posST stumpy signalling pathway according to results listed in Table 3.2. 
The results from the numerous overexpression and knockout combinations tested are 
collated in Table 3.2 and enable construction of a model of the posST signalling 
pathway. According to the model depicted in Figure 3.31, the pathway can be 
divided into 2 branches. One branch includes PP1 and YAK in an as yet unknown 
order. It also tentatively includes HYP2 pending in vivo analysis of HYP2 OE + 
RBP7 KO and generation of further combinations including HYP2. PP1 likely also 
performs a separate role in slender forms. On the other branch of the pathway, 
MEKK1 acts upstream of NEK according to phosphoproteomic data, which in turn 
acts upstream of RBP7.  
The pathway described here bears analogy to the signalling networks associated with 
glucose depletion in yeast. Similar to stumpy formation in trypanosomes, this 
response triggers metabolic adaptation to oxidative phosphorylation, G1 arrest and 
widespread transcriptional changes (Brauer et al., 2008; DeRisi et al., 1997). 
Homologues of PP1 and YAK are implicated in this process (Garrett and Broach, 
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(AMPK) and a regulatory subunit of protein kinase A (PKA-R), both identified in the 
posST cohort (Mony et al., 2014) but not investigated in this thesis, act as central 
regulators (Toda et al., 1987; Woods et al., 1994). Yeast Yak1 performs an 
analogous quiescence-promoting role which is at least partially dependent on PKA 
(Garrett et al., 1991; Lee et al., 2011). In contrast to the trypansosome pathway, the 
yeast PP1 Glc7, in conjunction with its regulatory subunit Reg1, inactivates the yeast 
AMPK homologue Snf1 in the presence of glucose, inhibiting energy production by 
alternative carbon sources (Tu and Carlson, 1995). This indicates differences 
between the two systems, as PP1 and AMPK are both positive regulators of 
differentiation in T. brucei (B. Mony and K. Matthews, unpublished results). 
However, given that both systems involve an external signal (glucose depletion/SIF) 
triggering parallel, interconnected signalling pathways which include multiple 
common components and induce multiple common cellular processes, the 
established relationships of the yeast pathway may serve as a useful guide in further 
ordering of the trypanosome pathway. 
Overall, these results validate overexpression and null mutant combinations as an 
effective strategy to identify dependency relationships in the posST signalling 
pathway. The model here can be built on, strengthened and expanded as further 
combinations are tested. Null mutants exist for both HYP2 and MEKK1, relatively 
unexplored via combinations at this point, which should facilitate further 
incorporation of these components into the model. In addition, there exist numerous 
other validated posST components which were not studied in this chapter and are 
excellent candidates for future inclusion.  
3.5.4 A regulatory mechanism controls expression of 
differentiation signalling components? 
A number of posST overexpression lines studied here showed evidence of potential 
limitation of expression levels. Firstly, overexpression of NEK in the RBP7 null 
mutant line showed a far greater level of protein expression than when overexpressed 
in the wild type background (section 3.3.1). As RBP7 knockout completely rescues 
the growth phenotype associated with NEK overexpression and is consequently 
hypothesised to act directly downstream of NEK, it is possible that the enhanced 
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expression level reflects accumulation of upstream pathway components in the 
absence of RBP7. The antibody used to measure expression levels of NEK 
recognises the epitope tag rather than the protein. As such, it can only identify the 
exogenous copy which does not include the endogenous NEK UTRs and it is 
therefore likely that any such accumulation would be mediated via the coding region 
or at a post-translational level. Enhanced NEK expression levels were also apparent 
when NEK is overexpressed in the YAK null mutant background, although growth 
inhibition is still observed in this line (section 3.3.2). Although other lines would 
need to be tested, if repeated it might indicate a general regulatory mechanism which 
limits overexpression in stumpy forms. In this case, NEK overexpression is restricted 
in the AnTat 1.1 90:13 background as a relatively low amount of protein induces 
differentiation. As knockout of RBP7 completely rescues this arrest, the cells remain 
slender and NEK overexpression is consequently unrestricted and is therefore 
expressed to a much higher level. Similarly, overexpression of MEKK1 cannot be 
detected at mRNA or protein level despite its ability to inhibit growth and restore 
transcript detection in a MEKK1 null mutant line (section 3.2.3.8).  
It is possible that T. brucei harbours an intrinsic regulatory mechanism which limits 
posST-mediated stumpy formation to a maximum tolerated level of arrest at low 
density. However, another explanation is that overexpression is downregulated in 
stumpy forms due to the properties of the pDex577-Y plasmid. Sequences 
transcribed from this plasmid are conjugated to the aldolase 3’UTR (see map in 
Appendix D Figure 5). According to RNAseq data, aldolase is downregulated 3.5-
fold in stumpy forms relative to slender forms (E. Silvester, thesis in preparation). 
Work is currently underway to modify the plasmid, replacing the aldolase 3’UTR 
with an actin 3’UTR which remains unchanged during differentiation (E. Vidal, 
unpublished). The new vector should be capable of robust overexpression in stumpy 
forms, a key resource for future posST analyses.  
3.5.5 Phosphoproteomic analysis of null mutants reveals 
downstream effects of MEKK1 and YAK. 
To further investigate the posST signalling pathway, changes in the 
phosphoproteome were examined in null mutant lines of two posST kinases, 
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MEKK1 and YAK. Four replicates of each cell line were subjected to proteomic and 
phosphoproteomic analysis, although the samples were split into two distinct sets of 
two replicates each at the labelling stage. The final dataset showed inconsistencies 
between the two sets, with MEKK1 protein being detected only in the first set of 
replicates and YAK protein detected only in the second, although due to the low 
level of detection, this was later excluded from the analysis. MEKK1 protein was 
detected in the MEKK1 KO samples in the first replicate set, but did not exceed the 
cutoff reporter intensity value and was therefore removed in these samples. YAK 
was not detected above the cutoff value in any samples, indicating low expression in 
slender bloodstream cells. The low level detection of MEKK1 and YAK in their 
respective null mutant lines may be a consequence of the TMT labelling procedure, 
in which the samples are pooled prior to fractionation. If high complexity is retained 
after fractionation, this can lead to co-isolation of peptides of similar sizes during 
mass spectrometry. This issue can also lead to ratio compression in quantitation. As a 
result, it is likely that some proteins with altered phosphorylation status were not 
detected in this analysis and that the effect on others was reduced. 
220 proteins showed a greater than 2-fold change in phosphorylation in one or both 
KO lines, many of which had not previously been implicated in differentiation. 105 
proteins in the MEKK1 KO line and 176 proteins in the YAK KO line were 
differentially regulated, of which 61 proteins were common to both. This indicated 
that both kinases elicit common downstream responses as well as additional effects 
specific to each. One explanation for this is that MEKK1 and YAK act through 
distinct branches of the stumpy signalling pathway which converge later in the 
process. However, it is entirely possible that these kinases have additional roles 
unrelated to differentiation which result in distinct effects. 
The set of differentially phosphorylated proteins included many hypothetical 
proteins, as well as a large number of signalling molecules (Figure 3.28). Numerous 
kinases and phosphatases indicated that signalling cascades were affected in the KO 
lines, while a large representation of RNA-binding proteins and other post-
transcriptional regulators presented potential downstream effectors of these 
pathways. Interestingly, differential phosphorylation was also observed in a large 
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number of motor proteins, including various kinesins and dynein components. While 
kinesins and dyneins are involved in a wide range of cellular processes, the 
concomitant changes in phosphorylation of a substantial set of flagellar proteins, and 
the predicted flagellum localisation of various identified motor proteins, indicated 
that this may be due to effects of MEKK1 and YAK on flagellar processes. Flagellar 
motility is powered by axonemal dynein motors (Langousis and Hill, 2014) while 
kinesins have been implicated in PFR assembly (Demonchy et al., 2009) and 
intraflagellar transport (Kozminski et al., 1995). Flagellum transcripts have 
previously been shown to be enriched in slender forms relative to stumpy forms 
(Jensen et al., 2009). It is possible that the action of MEKK1 and YAK mediates 
deactivation of flagellum formation in arrested stumpy forms. 
The 55 proteins in which phosphorylation decreased in the MEKK1 KO line 
represent a set of potential kinase substrates (Figure 3.29). The most notable of these, 
in terms of posST pathway organisation, was the posST component NEK. The 
relationship between MEKK1 and NEK has not been investigated by combinatorial 
overexpression and knockout. However, this result indicates that NEK acts 
downstream of MEKK1 and may even be directly phosphorylated by MEKK1. 
Collated with the results from the overexpression and knockout combinations, this 
would place MEKK1 upstream of both NEK and RBP7 in the signalling pathway 
(Figure 3.31).  
Other potential effectors of signal transduction which showed reduced 
phosphorylation in the MEKK1 KO line and would therefore be predicted to operate 
downstream of MEKK1 included two predicted phosphatase 2C proteins, a putative 
TFIIF-stimulated CTD phosphatase and the CCCH-type zinc finger RNA-binding 
protein ZC3H34, which was shown to act as a post-transcriptional activator in an 
mRNA tethering screen (Erben et al., 2014). This suggests that loss of MEKK1 has 
substantial effects on downstream signalling pathways, including kinases and 
phosphatases as well as regulators of gene expression. 
Phosphorylation was also depleted in the predicted translation initiation factor 
subunit eIF-3 beta. Translation undergoes global repression during the transition to 
the stumpy form (Brecht and Parsons, 1998). However, comparison of the slender 
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and stumpy transcriptomes by RNAseq (E. Silvester, thesis in preparation) showed 
that eIF-3 beta mRNA was upregulated in the stumpy form. This raises the intriguing 
possibility that this subunit may be involved in activating translation of a subset of 
stumpy-specific transcripts in this life stage.  
Potential substrates of YAK kinase among the 56 proteins which showed reduced 
phosphorylation in the YAK KO line (Figure 3.30) included another NIMA-related 
kinase, NRKC. While NEK has a role in stumpy formation (Mony et al., 2014) and 
NRKA/B is involved in the stumpy to procyclic transition (Domingo-Sananes et al., 
2015), the identification of NRKC as a downstream target of YAK suggests 
extensive involvement of this kinase family in parasite differentiation. The YAK-
dependent role of NRKC may or may not be related to its known function in basal 
body separation in procyclic forms (Pradel et al., 2006). 
The large number of proteins in which phosphorylation increased in one or both null 
mutant lines testified to wide-ranging secondary effects to loss of these kinases. 
These likely include effects of reduced differentiation processes, including increased 
activation of slender-specific proteins, but may also reflect compensatory 
mechanisms whereby cells upregulate alternative pathways to overcome the block. 
Thus the signalling molecules which showed increased phosphorylation have the 
potential to include both positive and negative regulators of stumpy formation.  
This is particularly important to bear in mind in the case of AMPK, which showed 
highly enriched phosphorylation in both KO lines. An α subunit of AMPK, AMPK 
α2, was previously identified as a posST component (Mony et al., 2014). Its position 
in the pathway relative to other posST components has not yet been investigated. In 
mammalian and yeast cells, the β subunit of AMPK acts as a scaffold, binding the 
catalytic α and AMP-binding γ subunits (Woods et al., 1996) The β subunit is 
required for AMPK activation and substrate definition in yeast (Schmidt and 
McCartney, 2000), where as discussed in section 3.5.3, the Saccharomyces AMPK α 
homologue Snf1 plays a central role in the glucose depletion response networks in 
which various other posST homologues are also implicated. In T. brucei, AMPK β 
RNAi has been shown to affect surface glycoprotein expression in response to 
glucose availability in procyclics (Clemmens et al., 2009). The nature of the 
   
   109 
interaction between the α and β subunits of AMPK in T. brucei is unknown. AMPK 
β may regulate AMPK α2 activity in response to MEKK1 KO and YAK KO. This 
could suggest that AMPK acts downstream of both MEKK1 and YAK in the 
signalling pathway. Alternatively, it may act via a distinct arm which is upregulated 
to compensate for the blocked MEKK1 and YAK pathways. 
A putative C3HC4 zinc finger RING-type protein showed the greatest degree of 
increased phosphorylation, with greater than 8-fold phosphopeptide upregulation in 
both the MEKK1 and YAK KO lines. The function of this protein in T. brucei is 
unknown, but RING finger domain containing proteins are often involved in 
ubiquitination (Lorick et al., 1999), which suggests that absence of MEKK1 and 
YAK may affect this process. 
Phosphorylation was increased in numerous RNA-binding proteins. Four of these – 
RBP12, RBP35, RBP42 and DRBD4 – were increased in both the MEKK1 and YAK 
KO lines, and distinct residues of ZC3H34 showed decreased phosphorylation in the 
MEKK1 KO and increased phosphorylation in the YAK KO. This suggests that loss 
of these kinases elicit common gene expression responses. According to a genome-
wide mRNA tethering screen, RBP42 and DRBD4 are post-transcriptional activators, 
while RBP12 represses mRNAs (Erben et al., 2014). RNAi of RBP35 has been 
shown to increase fitness during differentiation while RBP42 regulates transcripts 
associated with energy metabolism, which could suggest that MEKK1 and YAK are 
involved in the metabolic adaptations associated with stumpy formation. One 
regulatory factor which showed increased phosphorylation in the YAK KO line is 
intriguing as it potentially links a number of components potentially implicated in 
stumpy formation via independent approaches. MKT1 stabilises mRNAs through 
interactions with a variety of gene regulators. These include HYP2 (Singh et al., 
2014), ZC3H20, a zinc finger protein identified in an RNAi library screen for 
resistance to the stumpy inducing compound GKI7 (section 5.6), and PAB1-binding 
protein PBP1 (Singh et al., 2014), in which increased phosphorylation was also 
observed in the YAK KO.  
Overall, this analysis has identified many potentially interesting proteins which 
showed differential phosphorylation in the absence of MEKK1, YAK or both, 
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although none have yet been experimentally validated. Hopefully, future analysis of 
these proteins will enable separation of direct substrates from secondary effects, 
validation of proteins involved in stumpy formation and ultimately the identification 
of which differentiation processes are activated by different branches of the 
signalling pathway. 
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4 Chapter 4: Positioning of TOR4 within the 
stumpy formation pathway 
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4.1 Introduction 
In contrast to the posST genes, which positively regulate stumpy formation, a 
number of inhibitors of differentiation are known. Ablation of either ZFK or MAPK5 
has been shown to increase stumpy formation in pleomorphs (Domenicali Pfister et 
al., 2006; Vassella et al., 2001). More recently, an unusual kinetoplastid-specific 
TOR kinase, TOR4, was shown to negatively regulate stumpy formation in a 
monomorphic strain. RNAi of TOR4 in vitro triggered differentiation, as 
characterised by stumpy morphology, G1 cell cycle arrest, upregulation of PAD 
transcripts and an enhanced capacity to differentiate to procyclic forms. In addition, 
membrane permeable cAMP/AMP analogues were found to downregulate TOR4 
expression (Barquilla et al., 2012). Clearly this kinase plays an important role in 
preventing differentiation but it is unknown if it acts via the same pathway as the 
posST genes, and if so, at what point. The differentiation-enhancing phenotype of 
TOR4 RNAi is in effect antagonistic to the reduced differentiation observed upon 
loss of posST proteins. Therefore, dual ablation of TOR4 and a posST protein should 
facilitate ordering of these proteins relative to each other, akin to the combinatorial 
knockout and overexpression approach detailed in the previous chapter, and provide 
insight into how differentiation preventing and promoting mechanisms link. 
 
4.2 TOR4 silencing triggers stumpy formation in vitro 
in pleomorphs, as in monomorphs. 
 
As TOR4 had previously been studied only in a monomorphic strain (Barquilla et al., 
2012), RNAi lines of TOR4 were produced in monomorphic and pleomorphic T. 
brucei to enable comparison of the phenotypes of these strains. To produce the 
monomorphic line, opposing fragments of TOR4 were cloned into the pRPa vector 
and transfected into 2T1s as in section 3.2.1.1 (vector map in Appendix D Figure 1). 
For the pleomorphic line, a single fragment of the gene was cloned between 2 
opposing T7 promoters of the p2T7-177 vector and transfected into the AnTat 1.1 
90:13 line (vector map in Appendix D Figure 3). In both cases, induction of RNAi 
resulted in growth inhibition in culture (Figure 4.1A). Pleomorphic parasites 
analysed 72 hours post induction appeared stumpy in morphology (Figure 4.1B) and 
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expressed the stumpy marker PAD1 (Figure 4.1C). Cell cycle status was analysed by 
scoring kinetoplast (K) and nucleus (N) configuration on DAPI-stained slides (see 
section 3.2.1.3). In both parasite strains, an increase in the proportion of 1K1N cells 
was observed, indicating arrest in G1 (Figure 4.1D). To test the capacity of TOR4 
RNAi cells to differentiate to procyclic forms, cells were transferred to SDM-79 at 
 Figure 4.1 Effect of TOR4 RNAi on monomorphic 2T1s and pleomorphic AnTat 1.1 90:13s in vitro. 
A) Cells grown in the presence of tetracycline (tet+) show reduced growth. B) 72-hour induced 
pleomorphic cells show stumpy morphology. C) Western blot analysis shows expression of PAD1 in 
pleomorphic cells 72 hours after induction. D) DAPI-stained slides scored for kinetoplast (K) and 
nucleus (N) configuration 72 hours post induction show G1 arrest. E) Timecourse of EP procyclin 
protein expression. Parasites cultured in presence or absence of tetracycline for 72 hours were 
incubated at 27°C in procyclic SDM-79 medium with 6mM citrate/cis-aconitate (CCA), which 
induces differentiation to procyclic forms, and analysed by FACS. TOR4 RNAi leads to increased EP 
procyclin expression upon CCA treatment. 
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27°C and triggered to differentiate with cis-aconitate. Expression of EP procyclin 
was then measured by FACS. At all timepoints analysed, EP expression was 
increased when TOR4 RNAi was induced, both in monomorphs and pleomorphs, 
indicating greater differentiation capacity (Figure 4.1E). It appears that TOR4’s role 
in differentiation is shared between monomorphs and pleomorphs, as its silencing in 
a pleomorphic strain results in the appearance of the various hallmark characteristics 
of stumpy forms.   
 
4.3 TOR4 silencing results in premature 
differentiation to stumpy forms in vivo.  
To explore the in vivo role of TOR4, the pleomorphic RNAi line was used to infect 
mice. As seen in Figure 4.2A, mice which were treated with doxycycline show 
reduced parasitaemia. Despite this, the degree of cell cycle arrest in these cells, as 
indicated by the proportion of parasites with a single nucleus and kinetoplast, did not 
significantly differ from the non-induced cells, with the exception of day 5, at which 
point it was lower (Figure 4.2C). This indicates that the cells were arresting at a 
lower parasite density. Likewise, when cells were scored for staining with the 
stumpy-specific marker PAD1, there was no significant difference in expression at 
any timepoint except for day 5 (Figure 4.2D). This suggests that RNAi induced cells 
show characteristics of stumpy forms at low parasitaemia. It would therefore appear 
that loss of TOR4 results in differentiation at low density in vivo.  
   




  Figure 4.2 TOR4 RNAi triggers premature stumpy formation in vivo. A) Parasitaemia of mice 
infected with TOR4 RNAi cells, estimated by the rapid matching method. Data represents 6 mice, 3 
treated with doxycycline (dox+) and 3 non-induced (dox-). TOR4 RNAi induced mice have reduced 
parasitaemia. B) Northern analysis shows decreased TOR4 transcript level 6 days post induction. C) 
% 1K1N (representing G1 and S phase) cells throughout the course of infection. 250 cells were 
counted for each sample. D) % cells expressing PAD1 throughout the course of infection, determined 
by IFA. 250 cells were counted for each sample. ***P<0.0005 GLM and Tukey test for multiple 
comparisons. 
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To investigate the role of TOR4 in relation to the posST kinase NEK, a double RNAi 
line was generated in which both genes were silenced by RNAi. The AnTat 1.1 90:13 
TOR4 RNAi line contains an integrated p2T7-177 construct under the control of 
phleomycin. A corresponding NEK RNAi line was previously produced using the 
pALC14 vector to validate this kinase as a positive regulator of differentiation 
(Mony et al., 2014). As this construct contains a puromycin resistance gene, it could 
be compatibly transfected into the phleomycin-resistant TOR4 RNAi line to generate 
a combined NEK and TOR4 RNAi line. The capacity of this cell line to differentiate 
in vitro was assessed using pCPTcAMP. As shown in Figure 4.3, induction of NEK 
RNAi results in reduced responsiveness to pCPTcAMP, as expected. In contrast, 
TOR4 RNAi results in growth inhibition both in the presence and absence of 
pCPTcAMP, again as expected. NEK+TOR4 RNAi showed a similar growth 
inhibition in response to tetracycline, indicating that it is the loss of TOR4 which has 
the dominant phenotype in vitro. 
 
Figure 4.3 Growth curve of NEK/TOR4 RNAi cell lines incubated with (tet+) or without (tet-) 
tetracycline and either treated (cAMP+) or untreated (cAMP-) with pCPTcAMP 24 hours post-
induction by tetracycline. NEK RNAi cells show resistance to pCPTcAMP. NEK+TOR4 RNAi cells 
show reduced growth upon RNAi induction similar to TOR4 RNAi alone. 
These lines were subsequently analysed in vivo. Consistent with data from Mony et 
al. (2014), the parasitaemia of induced NEK RNAi cells continued to increase 
throughout the infection, showing no signs of arrest while TOR4 RNAi cells were 
unable to reach a high parasitaemia (Figure 4.46A). Each of these lines was 
compared to that of the double NEK+TOR4 RNAi line, in the left 
4.4 Simultaneous RNAi of NEK and TOR4 has 
complex effects on differentiation. 
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Figure 4.46 Effects of combined NEK+TOR4 RNAi on stumpy formation in vivo. A)-C) Data 
from infections with NEK+TOR4 RNAi in the presence of doxycycline is shown relative to NEK 
RNAi (left) and TOR4 RNAi (right) alone. *P<0.05,**P<0.005,***P<0.0005 GLM and Tukey 
test for multiple comparisons. A) Parasitaemia was estimated by the rapid matching method B) % 
1K1N (G1/S phase) cells throughout the course of infection. 250 cells were counted for each 
sample. C) % cells expressing PAD1 throughout the course of infection, determined by IFA. 250 
cells were counted for each sample. D) Northern analysis of RNA 6 days p.i. shows effect of 
doxycycline treatment on NEK/TOR4 transcript level in the respective RNAi cell lines. rRNA was 
used as a loading control.  
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and right panels respectively. The NEK+TOR4 RNAi parasitaemia was significantly 
lower than NEK RNAi, indicating that loss of TOR4 remains capable of driving 
arrest, even in the absence of NEK. Indeed, the profile of the parasitaemia closely 
matched that of TOR4 RNAi until the fifth day of infection. On day 6, however, 
there was an increase in parasitaemia, indicating that the silencing of NEK reduces 
arrest late in infection (Figure 4.46A). NEK+TOR4 RNAi cells also showed a higher 
proportion of 1K1N cells relative to NEK RNAi from days 3 to 5 of infection, 
indicating that the loss of TOR4 was still able to promote G1 arrest in this cell line. 
However, atypically, the percentage of 1K1N cells actually dropped between days 4 
and 5 from 91.1 ± 0.8% to 83.3 ± 0.8%. Again this suggests that the effect of NEK 
RNAi is able to overcome the TOR4 RNAi induced arrest at a later stage of infection 
(Figure 4.46B). The level of PAD1 expression remained low throughout infection in 
NEK+TOR4 RNAi cells, reaching a maximum of 33.3 ± 6.3% on day 6 similar to 
that of NEK RNAi and significantly lower than with TOR4 RNAi at later timepoints 
(Figure 4.46C). It would therefore appear that although loss of TOR4 is able to drive 
cell cycle arrest in the absence of NEK, it is not able to upregulate PAD1. Northern 
analysis confirmed depletion of NEK and TOR4 in their respective single RNAi 
lines. Both transcripts were also present at low abundance in the double RNAi line 
(Figure 4.46D). However, as this was true even in the absence of doxycycline, it 
appears that dsRNA expression may be leaky in these cells. 
4.5 Combined knockout of MEKK1 and knockdown of 
TOR4 has complex effects on differentiation. 
The complex effects on differentiation observed upon simultaneous RNAi of NEK 
and TOR4 may have been influenced by the respective levels of depletion of each 
transcript, as neither was completely silenced (Figure 4.4D). This possibility could 
be overcome by the use of null mutants to eradicate expression completely. As TOR4 
appears to be essential, it is a poor candidate for gene deletion. However, the posST 
kinase MEKK1 is non-essential and was successfully knocked out in the parental 
AnTat 1.1 90:13 strain, as described in section 3.2.3.3. The same vectors were used 
to sequentially delete both alleles of MEKK1 in the TOR4 RNAi line. Successful 
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deletion of the MEKK1 gene and correct integration of both replacement alleles was 
confirmed by Southern blot (Figure 4.5C). 
 
Figure 4.5 Generation of a null mutant of MEKK1 in the TOR4 RNAi line. A) Schematic 
representation of the knockout strategy. In the first step, a plasmid containing the blasticidin resistance 
gene was targeted to external portions of the 5’ and 3’ UTRs (extUTR) by homologous 
recombination, thereby replacing both the ORF and internal UTRs (intUTR) from one allele. 
Subsequently, a plasmid containing the puromycin resistance gene was targeted to internal portions of 
the UTRs and could recombine only with the remaining allele so that the second copy of the gene was 
replaced. B) A diagram shows the fragments recognised by 2 DNA probes in the WT allele and 
integrated 1st and 2nd replacement constructs following gDNA digestion by Pst1. C) A gene probe 
complementary to part of the MEKK1 ORF recognised 6815bp and 9448bp fragments in the WT 
allele only, which were present in the parental TOR4 RNAi cells and the single knockout (sKO) cells 
but absent in double knockout (dKO) cells, confirming successful gene deletion. A second probe to 
determine correct integration hybridised to a 6815bp fragment in the WT allele, a 2500bp fragment in 
the 1st allelic replacement and a 2975bp fragment in the 2nd allelic replacement, thereby conferring 
parental, sKO and dKO cells each with a unique signature and confirming correct integration of the 
relevant constructs in each case.  
The single and double knockouts were analysed in vitro for their capacity to 
differentiate. As shown in Figure 4.6, deletion of either one or both alleles of 
MEKK1 results in decreased responsiveness to the pCPTcAMP signal. However, 
concomitant silencing of TOR4 by tetracycline induction arrests growth in these 
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cells. This indicates that the in vitro growth effect observed upon TOR4 RNAi is 
independent of MEKK1.  
Figure 4.6 Growth curve of MEKK1KO TOR4 RNAi cell lines incubated with (tet+) or without (tet-) 
tetracycline and either treated (cAMP+) or untreated (cAMP-) with pCPTcAMP 24 hours post-
induction by tetracycline. MEKK1sKO TOR4 RNAi and MEKK1dKO TOR4 RNAi cells show 
resistance to pCPTcAMP in the absence of tetracycline and reduced growth upon induction. 
The differentiation capacity of the MEKK1 KO + TOR4 RNAi line was 
subsequently investigated in vivo. In Figure 4.7A, data from infections with induced 
MEKK1KO + TOR4 RNAi parasites were compared to their non-induced 
counterparts in the left panel and to the induced parental TOR4 RNAi line on the 
right. In the presence of doxycycline, MEKK1 KO + TOR4 RNAi parasitaemia 
remains low, showing a similar profile to the induced parental TOR4 RNAi line. In 
the absence of doxycycline, the parasitaemia in the null mutant line increased so 
dramatically that all 3 mice had died by day 5 of infection (Figure 4.7A). This 
suggests that the growth effect observed upon TOR4 RNAi is not dependent on 
MEKK1. MEKK1 KO parasites in which TOR4 RNAi has not been induced showed 
a low proportion of 1K1N cells indicative of a non-arrested population. In the 
presence of doxycycline, this percentage was significantly higher (Figure 4.7B), 
suggesting that TOR4 RNAi leads to G1 arrest even in the absence of MEKK1. 
Uninduced MEKK1 KO + TOR4 RNAi parasites express no detectable PAD1 on the 
days of infection for which data is available. Where the RNAi was induced, 11.2 ± 
2.2% and 19.7 ± 1.6% PAD1 expression was detectable on days 4 and 5 respectively 
but this was significantly lower than in the parental TOR4 RNAi line, which 
expresses 38.4 ± 7.6 % and 57.4 ± 10.2% on the same days (Figure 4.7C). This data 
indicated that, similar to the results seen for the NEK+TOR4 RNAi line, silencing of  
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Figure 4.7 Effects of combined MEKK1 KO + TOR4 RNAi on stumpy formation in vivo. A)-C) Data 
from infections with MEKK1 KO + TOR4 RNAi in the presence of doxycycline is shown relative to 
uninduced (left) and TOR4 RNAi (right) alone. *P<0.05,**P<0.005,***P<0.0005 GLM and Tukey 
test for multiple comparisons. A) Parasitaemia as estimated by the rapid matching method. B) 
Proportions of 1K1N (G1/S phase) cells throughout the course of infection. 250 cells were counted for 
each sample. C) Proportions of cells expressing PAD1 throughout the course of infection, determined 
by IFA. 250 cells were counted for each sample. D) qRT-PCR analysis of TOR4 mRNA 6 days p.i. 
normalised to ZFP3.  
TOR4 is sufficient to promote cell cycle arrest in vivo independent of MEKK1 but 
PAD1 upregulation is MEKK1 dependent. qRT-PCR analysis was used to confirm 
that TOR4 was depleted upon RNAi induction in both parental and MEKK1 KO cell 
lines. In the latter case, this was compared to the uninduced parental TOR4 RNAi 
line, as corresponding data for the null mutant line was unavailable due to death of 
the mice. This analysis also revealed upregulation of TOR4 in stumpy forms relative 
to slender forms (Figure 4.7D). As loss of TOR4 promotes stumpy formation, this 
may affect the degree of transcript depletion observed. 
4.6 Discussion 
4.6.1 TOR4 is an inhibitor of stumpy formation in pleomorphs 
Barquilla et al. (2012) have shown previously that TOR4 negatively regulates 
stumpy formation in monomorphic trypanosomes. Here RNAi is used to demonstrate 
that silencing of TOR4 also induces differentiation in a pleomorphic strain. A 
comparison of monomorphic and pleomorphic RNAi lines highlights that loss of 
TOR4 results in a more pronounced stumpy formation phenotype in pleomorphs, 
which show PAD1 upregulation in vitro not observed in the monomorphic line 
(Figure 4.1C) and enhanced CCA-induced differentiation to procyclic forms (Figure 
4.1E). In vivo, TOR4 RNAi results in reduced parasitaemia (section 4.3). Despite 
this, cells show similar levels of G1 arrest and PAD1 expression to uninduced 
parasites, indicating that loss of TOR4 drives stumpy formation at low cell density. 
The exception to this was on day 5, in which both the proportion of 1K1N and PAD1 
expression levels were significantly lower than in uninduced cells (Figure 4.2). This 
likely represents the point at which the uninduced population reached threshold 
density and the majority of differentiation occurred, leading to a sudden surge in 
arrested, PAD1 expressing cells whereas TOR4 RNAi-induced stumpy formation 
occurs as a more continuous process at sub-threshold parasitaemia. In addition, it is 
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possible that some selection of RNAi resistant parasites occurs in the induced 
population, leading to outgrowth of slender cells, although the observed increase in 
arrested, PAD1-expressing cells from day 5 to day 6 (Figure 4.2) points to continued 
differentiation later in the infection. 
4.6.2 Complex interactions between TOR4 and posST kinases 
NEK and MEKK1 
The relationship of the differentiation inhibitor TOR4 to the components of the 
stumpy promoting posST pathway was investigated using the kinases NEK and 
MEKK1. This was explored first using a double RNAi line in which NEK and TOR4 
were simultaneously silenced. This cell line was used to demonstrate that TOR4 
RNAi induces in vitro growth inhibition independently of NEK (section 4.4). 
Likewise in vivo, the NEK + TOR4 RNAi cells showed reduced growth, although the 
parasitaemia significantly increased on the final day of infection relative to TOR4 
RNAi cells, indicating that NEK RNAi is able to exert a contrary effect on arrest 
only at a late stage of infection. NEK + TOR4 RNAi cells showed increased G1 
arrest relative to NEK RNAi alone. However, these two lines showed similarly low 
levels of PAD1 expression throughout the infection. This indicates that TOR4 RNAi 
induces cell cycle arrest independently of NEK but its upregulation of PAD1 is 
NEK-dependent. As G1 arrest precedes PAD1 expression in the differentiation 
program (MacGregor et al., 2011), this suggests a role for TOR4 in the early stages 
of differentiation, while NEK appears to be implicated in both arrest and later PAD1 
expression components of the process. However, the increase in the NEK + TOR4 
RNAi parasitaemia on the final day of infection suggests that NEK-independent 
growth arrest is lost at this stage. While this may reflect a physiologically dominant 
role for NEK in relation to TOR4 in predominantly stumpy populations, it may 
alternatively be a side effect of the kinetics of RNAi. NEK and TOR4 RNAi may 
proceed with different kinetics due to factors such as the efficiency of their 
respective dsRNA expression systems and differential protein turnover. As with 
TOR4 RNAi alone, it is possible that the growth effect of TOR4 RNAi exerts a 
selective pressure for RNAi escapees, which emerge later in infection as single NEK 
RNAi cells. To complicate matters, TOR4 mRNA shows several-fold upregulation in 
stumpy forms according to qRT-PCR analysis (Figure 4.7D), so the phenotype it 
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induces may in fact counteract its own silencing by upregulating TOR4 transcription 
as the population differentiates. However, this depends on whether cells have been 
driven to irreversible arrest, as TOR4 upregulation would have to occur before the 
point of commitment to be effective in reversing the effect of the RNAi. In a 
comparison of KN counts between TOR4 RNAi and NEK + TOR4 RNAi 
populations, the latter showed a significant decrease in 1K1N cells on day 3, a 
significant increase on day 4, a significant decrease again on day 5 and no change on 
day 6. With unknown variation in levels of each knockdown at these timepoints of 
infection, it can be difficult to interpret which of these differences reflect 
physiological effects and which reflect uneven mRNA silencing, or a combination of 
the two.  
In an alternative approach which attempted to remove some of this variability, both 
alleles of MEKK1 were deleted in the TOR4 RNAi line, providing a constitutively 
MEKK1-negative background in which only TOR4 was under inducible control. As 
with NEK, TOR4 RNAi induced MEKK1-independent growth inhibition in vitro and 
cell cycle arrest in vivo. However, PAD1 expression in the MEKK1 KO + TOR4 
RNAi line was significantly reduced relative to TOR4 RNAi alone. This supports the 
hypothesis suggested by the NEK + TOR4 RNAi phenotype that TOR4 acts early in 
differentiation at the stage of cell cycle arrest, while like NEK, MEKK1 is involved 
in both arrest and later in the process at the stage of PAD1 expression. This is 
summarised in Figure 4.4.8. 
 
Figure 4.4.8 Model of action of stumpy inhibitor TOR4 and posST components MEKK1 and NEK at 
different stages of differentiation. 
This model of TOR4 and posST action makes sense if it is supposed that 
differentiation is controlled by two opposing mechanisms: one responsible for 
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retaining the slender state and the other for inducing stumpy formation. As an 
inhibitor of stumpy formation, TOR4 is likely active in proliferating slender forms at 
low density to prevent initiation of the differentiation process. As such, it is logical 
that it should function in the primary steps, specifically in cell cycle arrest. When 
TOR4 RNAi removes this inhibition, the posST pathway activates the entire 
differentiation program, resulting in the production of PAD1-positive cells. 
However, when MEKK1 or NEK is also removed, G1 arrest proceeds but subsequent 
steps in stumpy formation which require activation by the compromised posST 
pathway do not occur.  
One of many aspects of the intersection of the opposing mechanisms of 
differentiation control which remains to be determined is the role of MAPK5 and 
ZFK, two other kinases which have been implicated in negative regulation of stumpy 
formation. In contrast to TOR4, loss of neither MAPK5 or ZFK has any effect in a 
monomorphic strain (Domenicali Pfister et al., 2006; Vassella et al., 2001). This 
positions them upstream of both TOR4 and the posST components, which were 
identified using a monomorphic RNAi library (Mony et al., 2014). It is unknown if 
ZFK and/or MAPK5 act directly upstream of TOR4 and therefore intersect with the 
posST pathway at the same stage or if they act independently to ensure redundant 
layers of protection against premature differentiation. 
As is the case for numerous posST components, as discussed in section 3.5.3, a TOR 
kinase acts as a central regulator in nutrient signalling in yeast. TORC1 and posST 
component homologues are integrated into a complex signalling network of 
antagonistic interactions. TORC1 has been shown to negatively regulate Yak1 via 
control of  subcellular localisation (Martin et al., 2004; Schmelzle et al., 2004; Zhang 
et al., 2013). Conversely, the yeast AMPK Snf1 represses signalling through the 
TOR pathway (Hallett et al., 2014), a finding also observed in mammalian cells 
(Gwinn et al., 2008; Inoki et al., 2003). The interactions described between TORC1 
and posST component homologues in these signalling networks may offer clues as to 
how slender retention and stumpy induction pathways intersect in T. brucei. 
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5 Chapter 5: Ordering components of the 
stumpy signalling pathway via chemical-
genetic analysis 
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5.1 Introduction 
With the continued elusiveness of the molecular identity of SIF, small molecule 
inducers of differentiation to stumpy forms have long been invaluable as chemical 
tools for in vitro studies of this process. Specifically, membrane permeable forms of 
cAMP and AMP have been used to this end and were integral to the discovery of the 
posST genes. Subsequent validation has shown that individual posST RNAi lines 
show a reduced response to the pCPTcAMP signal. Identification of further 
differentiation inducing compounds with different points of action to cAMP/AMP 
could provide additional information about the organisation of the stumpy formation 
pathway and could even be useful as therapeutic agents, as differentiation at low, 
sub-transmission, parasite densities should lead to population arrest and clearance. 
For example, a small molecule which acts downstream of AMP would be expected to 
select only a subset of posST genes if applied to an RNAi library screen, whereas 
RNAi lines of any posST proteins which act upstream would be fully sensitive to the 
compound. This is represented in Figure 5.1. 
 
Figure 5.1 Organisation of the posST pathway via positioning of stumpy inducing compounds. If 
compound X activates stumpy formation via the posST pathway but downstream of cAMP, RNAi 
cells of all posST components upstream of its action (A, B, C) will retain sensitivity to X and RNAi 
cells of all posST components downstream (D, E, F) will be resistant, revealing A, B and C to act 
upstream of D, E and F in the stumpy signalling pathway. 
D E F 





RNAi of A B C 
sensitive to X 
RNAi of D E F 
resistant to X 
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Using a fluorescent reporter assay for stumpy formation, MacGregor et al. (2014) 
conducted a high-throughput screen for such compounds and were able to identify 
E667 as a small molecule capable of inducing differentiation in monomorphs and 
pleomorphs. Its target within the differentiation signalling pathway remains unknown 
and is explored here via its relation to the posST genes as described above. Given the 
involvement of various kinases in differentiation, kinase inhibitors represent an 
intriguing potential source of downstream stumpy inducers. A recent compound 
screen of a kinase inhibitor library identified a set of small molecules capable of 
inhibiting trypanosome growth (Diaz et al., 2014). Here, this compound set is 
screened for stumpy induction phenotypes. 
The compound DDD00015314 (here referred to as E667) was identified from a high 
throughput screen for developmental phenotypes and shown to induce stumpy 
formation (MacGregor et al., 2014). Due to the inability to commercially source 
E667 which previously hindered further investigation, new chemically identical 
compound was synthesised by BioFocus and tested for differentiation activity using 
the monomorphic GUS-PAD1 3’UTR reporter line. This cell line, in which the 
fluorescent reporter β-glucuronidase (GUS) is conjugated to the stumpy-specific 
PAD1 3’UTR, was used in the original identification of E667 (MacGregor et al., 
2014). Consistent with previous observations, treatment of these cells with newly 
synthesised E667 upregulated reporter activity several fold (Figure 5.2).  
5.2 Validation of E667 as an inducer of stumpy 
formation 
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Figure 5.2 E667 upregulates a PAD1 reporter. A) The monomorphic GUS-PAD1 3’UTR line showed 
an increase in reporter activity after 48 hours treatment with 100 µM pCPTcAMP or 50 µM E667. 
RFU = relative fluorescence units. B) Schematic diagram of the reporter construct from MacGregor et 
al. (2014). 
Diaz et al. (2014) recently identified hundreds of compounds from a 
GlaxoSmithKline kinase inhibitor (GKI) set which effected inhibition of 
trypanosome growth, including 52 for which the chemical structure was disclosed. 
To identify additional compounds capable of inducing stumpy formation, these 52 
compounds were tested for differentiation phenotypes using the GUS-PAD1 3’UTR 
reporter line previously employed.  
for their abili y to induce stumpy repor er activation using an
independent, nonfluorescent CAT reporter-based assay, with
each exhibiting no activity although some of the compounds did
affect cell growth (data not shown; see Fig. S2 in the supplemental
material). Thus, to stringently select for compounds that repre-
sent biologically relevant hits with respect to the phenotypic
screen used, all 112 autofluorescent compounds were excluded
from further analysis, identifying three hits from a primary screen
of 6,764 molecules (Fig. 3B). This apparently low hit rate of 0.04%
highlights the selectivity of the screen for a differentiation-specific
response; a far higher number of compounds (37% in the primary
screen) caused trypanocidal or trypanostatic growth effects (as
measured by alamarBlue assay), probably through multiple spe-
cific and nonspecific cellular mechanisms.
Reporter and phenotypic confirmation of screen outputs.
Relative to 100 !M 8-pCPT-cAMP, the three hit compounds
identified were able to activate the GUS reporter gene at levels
between 58% and 77% at 50 !M (Fig. 3C). Each compound also
caused a decrease in alamarBlue activation, indicative of a reduc-
tion in population growth of between 31% and 123%, where
100% inhibition is that caused by 100 !M 8-pCPT-cAMP
(Fig. 3D). Of the hree compounds, DDD00070762 and
DDD00070827 were structurally related (Fig. 3B), and the third
was chemically distinct.
Of the two related compounds identified, compound
DDD00070762 was chosen for validation and follow-up analysis.
This compound demonstrated a 77% activation level of the GUS
reporter activity during screening (Fig. 3C) and also caused re-
duced population growth as measured by an alamarBlue assay
(Fig. 3D). For validation, 427 CAT-PAD1 3= UTR GUS-Const 3=
UTR cells were used that have the CAT reporter gene under PAD1
3=UTR control linked to a constitutively expressed GUS reporter
(this provides a measure of constitutive gene expression in the
presence of the compound in addition to stumpy-specific expres-
sion changes within the same cell line) (16). Treatment of these
cells with 50 !M compound DDD00070762 stopped population
growth within 24 h (Fig. 4A) and caused upregulation of CAT
reporter gene expression after 24 and 48 h (Fig. 4B). This result
confirmed that DDD00070762 promoted stumpy-specific re-
porter gene expression in an independent, non-fluorescence-
based assay, validating the results of the high-throughput screen.
It was also observed, however, that the control GUS reporter gene
FIG 1 Regulation of GUS reporter gene expression by the PAD1 3= UTR. (A) Schematic representation of the pHD617 GUS-PAD1 3= UTR reporter construct
used to create the 427 GUS-PAD1 3= UTR cell line used for compound screening. This vector was modified from those described in MacGregor et al. and
Biebinger et al. (16, 24). Also shown are the pHD617 CAT-PAD1 3=UTR and pHD617 GUS-Const 3=UTR reporter constructs previously used to create the 427
CAT-PAD1 3= UTR GUS-Const 3= UTR cells (16), which are utilized in this study for follow-up analysis. The vector integrates into the ribosomal spacer locus
via a ribosomal integration site sequence (RITS). (B) Monomorphic bloodstream form T. brucei cells transfected with the pHD617 GUS-PAD1 3=UTR construct
(427 GUS-PAD1 3=UTR cells) showed an increase in GUS reporter activity when treated with 10 !M 8-pCPT-2=-O-Me-cAMP. Treatment with 0.5% (vol/vol)
DMSO had no effect on reporter activity. Error bars represent standard errors of the means (n " 3).Puro, puromycin; Hygro, hygromycin.
Phenotypic Compound Screening in Trypanosoma brucei
March 2014 Volume 13 Number 3 ec.asm.org 415
A B
5.3 Kinase inhibitor library screen for stumpy 
induction pheno ype  
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Figure 5.3 Primary screen for differentiation effects of GKI compound set. GUS-PAD1 3’UTR 
reporter line cells were incubated with EC50 conc. of each compound for 24 hours and % activation 
calculated relative to pCPTcAMP upregulation (set at 100% activation). Threshold for selection 
(dotted line) was set at 53%.  
The level of upregulation of the fluorescent reporter caused by incubation with 
pCPTcAMP was set at 100% activation and any compounds which resulted in >53% 
activation were selected for further analysis, according to the selection parameters 
used in MacGregor et al. (2013). Six compounds met this criterion (Figure 5.3). 
RBP7 is predicted to act relatively far down in the posST pathway (section 1.9.3.2) 
and is therefore likely to be necessary for the action of any drug which drives 
differentiation via this pathway. In consequence, the six GKI compounds selected 
from the primary screen were subsequently screened for reduced activity in the 
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Figure 5.4 Inhibition of RBP7 KO by GKI compounds relative to parental AnTat 1.1 90:13. Cells 
were treated with EC50 compound conc. for 24 hours and growth inhibition determined by Alamar 
blue assay. 
As expected, the RBP7 null mutant cells showed reduced sensitivity to pCPTcAMP, 
with only 60% inhibition relative to the parental line. Reduced sensitivity was also 
observed for five of the six GKI compounds tested (7, 21, 31, 41, 52; Figure 5.4), 
supporting roles for them as activators of stumpy formation. 
Of the GKI compounds tested, NEU-0001233, referred to here as GKI7, showed both 
the highest degree of activation of the PAD1-specific reporter, at 108% (Figure 5.3), 
as well as the lowest relative inhibition of RBP7 null mutant parasites (Figure 5.4). It 
was therefore selected for further analysis. Further supporting its differentiation 
promoting activity, treatment of pleomorphic AnTat 90:13 parasites with GKI7 
resulted in G1 arrest, as denoted by a significant increase in 1K1N cells (Figure 
5.5A), and upregulation of PAD1 protein (Figure 5.5B).  
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Figure 5.5 GKI7 induces stumpy formation in the pleomorphic AnTat 1.1 90:13 strain. Cells were 
treated with 1.44 µM GKI7 for 24 hours. A) % 1K1N (representing G1 and S phase) cells throughout 
the course of infection. 250 cells were counted for each sample. **P<0.005 t test. B) Western blot 
analysis of PAD1 expression. EF-1 was  used as a loading control. 
To examine if E667 and GKI7 act via the posST pathway to activate stumpy 
formation, and to determine the point of their respective actions within this pathway, 
several posST RNAi lines were tested for sensitivity to these compounds. 
GKI7 PAD1 




5.4 Sensitivity of posST RNAi lines to E667 and GKI7 
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Figure 5.6 Growth curve of posST RNAi cells treated with pCPTcAMP or E667 24 hours post-
induction by tetracycline.  
Six posST RNAi lines were tested for sensitivity to E667. Induction of RNAi had no 
effect on the sensitivity to E667 in any of these lines (Figure 5.6). However, several 
lines also showed very limited resistance to pCPTcAMP, suggesting that the level of 
in vitro differentiation resistance previously observed in Mony et al. (2014) may be 
diminished. As this could potentially mask subtle phenotypes at a single compound 
concentration, their sensitivity to each compound was instead analysed using a range 
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Figure 5.7 Growth of PP1 RNAi cells 72 hours post treatment with stumpy-inducing compounds, 
determined by alamarBlue assay. 100% indicates density of untreated cells. 
As seen in Figure 5.7, induction of PP1 (Tb927.4.3640, Tb927.4.3630, 
Tb927.4.3620) RNAi resulted in an increase in the concentration of pCPTcAMP 
required to elicit a response. This was in accordance with previous observations that 
PP1 RNAi confers loss of responsiveness to pCPTcAMP (Mony et al., 2014). 
Modest dose-dependent shifts were also observed for both E667 and GKI7 (Figure 
5.7), indicating that growth inhibition by both compounds is moderated by PP1.  
Figure 5.8 Growth of RBP7 KO cells relative to parental AnTat 1.1 90:13 cells 72 hours post 
treatment with stumpy-inducing compounds, determined by alamarBlue assay. 100% indicates density 
of untreated cells. 
Due to poor regulation of dsRNA expression in the RBP7 (Tb927.10.12090 and 
Tb927.10.12100) RNAi line (Mony et al., 2014), the RBP7 null mutant line was 
tested instead and compared to the parental line. In this case, clear resistance to all 3 
compounds was observed (Figure 5.8). Intriguingly, the cells were completely 
resistant to E667, and cell density actually increased at high concentrations of the 
compound. This demonstrated that both E667 and GKI7 act in an RBP7-dependent 
manner. 
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Figure 5.9 Growth of DSP RNAi cells 72 hours post treatment with stumpy-inducing compounds, 
determined by alamarBlue assay. 100% indicates density of untreated cells. 
The dual specificity phosphatase (DSP) Tb927.7.7160 was another posST component 
identified in the screen by Mony et al. (2014) and a role in stumpy formation has 
been subsequently validated (B. Mony and K. Matthews, unpublished). DSP RNAi 
showed no effect on the cells response to E667 or GKI7, suggesting that the 
compounds act independently of the phosphatase. However, this interpretation was 
complicated by the absence of any effect of pCPTcAMP in this experiment, contrary 
to previous observations by Mony et al. (2014).  
 
Figure 5.10 Growth of MEKK1 RNAi/KO cells 72 hours post treatment with stumpy-inducing 
compounds, determined by alamarBlue assay. 100% indicates density of untreated cells. 
RNAi 
KO 
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The involvement of MEKK1 in drug action was tested using both RNAi and null 
mutant lines. While loss of MEKK1 had no effect on GKI7 sensitivity, it actually 
increased sensitivity to E667 (Figure 5.10).  
 
Figure 5.11 Growth of HYP2 RNAi/KO cells 72 hours post treatment with stumpy-inducing 
compounds, determined by alamarBlue assay. 100% indicates density of untreated cells. 
HYP2 RNAi led to the expected decreased sensitivity to pCPTcAMP. It also showed 
decreased sensitivity to GKI7, while sensitivity to E667 was unaffected (Figure 
5.11). While this would suggest that stumpy induction by GKI7, but not E667, is 
HYP2-dependent, this was not supported when the experiment was conducted on the 
HYP2 null mutant line, which showed no difference in sensitivity to GKI7 (Figure 
5.11; lower panel). 
RNAi 
KO 
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Figure 5.12 Growth of YAK RNAi/KO cells 72 hours post treatment with stumpy-inducing 
compounds, determined by alamarBlue assay. 100% indicates density of untreated cells. 
Loss of YAK had no effect on sensitivity to any of the 3 compounds tested (Figure 
5.12). This was unexpected as YAK RNAi had previously shown a pCPTcAMP 
resistance phenotype (P. MacGregor and K. Matthews, unpublished), but as observed 
for several other posST RNAi lines, this appears to have been lost in this assay. 
 
Figure 5.13 Growth of NEK RNAi cells 72 hours post treatment with stumpy-inducing compounds, 
determined by alamarBlue assay. 100% indicates density of untreated cells. 
RNAi 
KO 
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NEK RNAi had no effect on sensitivity to any of the compounds (Figure 5.13). As 
for many other posST RNAi lines discussed above, it is difficult to interpret the 
relevance of NEK to the actions of E667 and GKI7 as no phenotype was observed 
for pCPTcAMP, which is known to induce stumpy formation via NEK (Mony et al., 
2014). 
Overall therefore, only PP1 and RBP7 showed resistance to E667 and GKI7. For the 
other posST genes an absence of resistance was complicated by a concomitant lack 
of resistance to pCPTcAMP. 
5.5 Rapid generation of resistance to E667 
Treating an RNAi library population with E667 would allow a more comprehensive 
identification of the downstream effectors of the compound. Previous experiments 
with E667, carried out on the monomorphic GUS-PAD1 3’UTR reporter line and the 
pleomorphic AnTat 1.1 90:13 line, used a concentration of 50 µM as standard 
(MacGregor et al., 2014). Therefore, E667 was tested at this concentration on an 
RNAi library population (Lib2) to determine its effect on growth. 
 
Figure 5.14 Growth effect of E667 on RNAi library (Lib2), GUS-PAD1 3’UTR and AnTat 1.1 90:13 
cell lines at 50 µM (upper panel, 3 replicates) and 250 µM (lower panel, 6 replicates). Growth 
inhibition of monomorphic strains was modest at 50 µM but resistance was rapidly generated at 250 
µM. 
50 µM  
250 µM  
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At 50 µM, E667 had only a modest effect on the uninduced RNAi library population 
relative to the AnTat 1.1 90:13 strain (Figure 5.14), consistent with previous findings 
that its effect is less pronounced in monomorphic than pleomorphic trypanosomes 
(MacGregor et al., 2014). As this level of inhibition would be insufficient for 
effective selection of resistant RNAi cells, the concentration was increased to 250 
µM. This concentration resulted in immediate growth arrest in both monomorphic 
strains. However, several replicates rapidly recovered and resumed normal growth 
within 2-6 days of drug addition. It therefore appears that E667 is not suitable for 
analysis by RNAi library screening as the cells were able to rapidly develop 
resistance to the compound in the absence of RNAi induction. When 250 µM E667 
was tested on pleomorphic trypanosomes, the cells exhibited an immediate and 
sustained growth arrest. However, 1 replicate recovered growth 12 days after 
induction and was able to grow continuously at a normal rate in 250 µM E667. This 
resistance required continuous drug selection to be maintained as when E667 was 
removed for 12 days and then reintroduced, the cells died (data not shown). Hence, 
the resistance to the drug selection was not stable over time. 
Unlike E667, GKI7 was found to effectively inhibit the library population at the 
concentration used in previous experiments i.e. 1.44 µM, the EC50 defined by Diaz et 
al. (2014). To identify downstream effectors of the compound, the RNAi library was 
induced and subsequently treated with GKI7, resulting in growth arrest. Growth 
gradually resumed in RNAi induced replicate populations from 5-6 days after 
treatment. Unexpectedly, this also occurred in non-induced replicates, albeit the 
effect was delayed by approximately 48 hours (Figure 5.15). This could represent 
outgrowth of resistant cells, or outgrowth of leaky RNAi lines silencing genes 
required for GKI7 action. 
5.6 An RNAi library screen identifies putative GKI7 
effectors    
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Figure 5.15 Growth of RNAi library cells treated with 1.44 µM E667 24 hours post induction with 
tetracycline (tet). 5 replicate flasks were analysed in independent assays to provide sufficient library 
coverage.  
After 10 days drug treatment, gDNA was isolated from all treated replicates of the 
RNAi library, both induced and uninduced, and RNAi inserts amplified by PCR. As 
seen in Figure 5.16, a continuous smear was observed in a sample isolated at the 
outset of the experiment due to the presence of a genome-wide representation of 
RNAi inserts. However, a more specific banding pattern was observed for the GKI7-
treated samples, indicating selection of a narrower range of RNAi cells. While this 
was partially true for uninduced replicate samples, in which distinct bands were 
visible, a greater degree of selection was evident in the RNAi induced replicates 
which showed a still more specific profile with far fewer bands. In addition, the 
banding pattern was similar between replicates, indicating that GKI7 treatment had 
selected for RNAi of many of the same gene fragments independently. 
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Figure 5.16 RNAi insert amplicon profiles from gDNA of RNAi library cells 10 days post GKI7 
treatment. Induced (tet+) replicates show a greater degree of selection. Bands indicated by white 
arrows were excised and identified by sequencing.  
Six amplified RNAi inserts, indicated by white arrows in Figure 5.16, were purified 
from the gel, cloned into the pGEM T Easy vector (Promega) and sequenced. They 
were found to correspond to five T. brucei genes, listed in Table 5.1. In agreement 
with hypothetical roles in GKI7-induced stumpy formation, two of these, an N-
terminal synaptojanin orthologue and zinc finger protein ZC3H20, showed reduced 
fitness upon differentiation in a RIT-seq screen by Alsford et al. (2011). 
Synaptojanin is an inositol phosphatase implicated in endocytic recycling (Guo et al., 
1999) while ZC3H20 is a zinc finger protein which has been shown to act as a post-
transcriptional activator (Erben et al., 2014), and interacts with MKT1, a factor 
associated with numerous components involved in post-transcriptional regulation 
(Singh et al., 2014). MKT1 has also been shown to interact with HYP2 (Singh et al., 
2014) and showed enriched phosphorylation in the YAK KO line (section 3.5.3). 
Also included were the methyltransferase MTQ1, which corresponded to two distinct 
amplified RNAi fragments, as well as two hypothetical proteins. 
 
Starting              tet+ replicate no.                              tet- replicate no.  
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No. Accession no. Function Additional information Diff? 
1 Tb927.6.2520  Hyp  No 
2 Tb927.10.14400  Hyp Identified in kinome (Urbaniak et al., 2012).  No 
3 Tb927.7.3490  synaptojanin 
(N-term) 






Tb927.10.9860  MTQ1 S-adenosylmethionine-dependent 
methyltransferase. Yeast MTQ1 methylates 
translational release factor Mrf1p. Non-
essential. 
No 
5 Tb927.7.2660 ZC3H2O Identified in an silico screen for CCCH-type 
zinc finger proteins (Kramer et al., 2010). 
Post-transcriptional activator (Erben et al., 
2014). Interacts with MKT1 (Singh et al., 
2014). 
Yes 
Table 5.1 List of genes from the GKI7 RNAi library screen identified by purification and sequencing 
of RNAi insert specific PCR products. Numbers correspond to the band labels in Figure 5.16. The 
final column refers to whether a reduced fitness phenotype was observed upon differentiation in a 
RIT-seq screen (Alsford et al., 2011). 
To allow comprehensive identification of selected RNAi fragments, PCR products 
for 3 induced replicates and 1 uninduced replicate were subject to Ion Torrent 
sequencing. RNAi insert amplification primers were identified and trimmed and 
reads aligned to the T. brucei TREU 927 genome. A map of read density is shown 
for all chromosomes in Figure 5.17A. Consistent with the band pattern observed in 
Figure 5.16, the uninduced replicate showed a greater degree of random widespread 
mapping at low read density across the genome, indicating reduced specificity 
relative to the induced samples, although a number of peaks of high read density in 
the induced samples were also present in the uninduced. Possible explanations for 
this pattern are discussed in section 5.7.4. Some peaks, such as that at 
Tb927.10.14400, appeared to be common between induced replicates, while others, 
such as at RBP7A, were specific to a single replicate, suggesting that parasites 
silencing these genes were not selected in the other replicates sequenced. This 
indicated incomplete genomic coverage of the RNAi library population within single 
replicates, although the use of multiple replicates should provide maximum coverage 
overall. As each replicate was therefore liable to contain unique hits, the top 20 hits 
for each RNAi-induced replicate were selected, giving a collated total set of 31 
genes. As 4 of these corresponded to only 2 unique sequence targets, this gave a final 
list of 29 hits, which are listed in Table 5.2. The alignment of reads to each of these 
genes is depicted in Appendix F Figure 1. The overlap between the 3 sets is depicted 
in Figure 5.17B. 13 hits are common to all replicates. 
   
   144
 
Figure 5.17 Ion Torrent sequencing of RNAi insert specific PCR products from GKI7 RNAi library 
screen. A) Read density of sequenced replicates aligned to the TREU 927 genome. Pink dotted lines 
denote divisions between chromosomes. Chromosome numbers are indicated at the top of each graph. 
A=11_02; B=11_03; C=11_LHfork; D=11_RHfork. Accession numbers of the highest peaks are 
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Accession no. Description R1 R2 R4 All Diff 
Tb927.10.14400 hypothetical protein, conserved  2 1 1 Yes No 
Tb927.6.2520 hypothetical protein, conserved  1 2 3 Yes No 
Tb927.7.3490 synaptojanin (N-terminal domain), putative  - - 2 No Yes 
Tb11.v5.0205/ 
Tb927.10.6130 
hypothetical protein, conserved (gene 
copies)  3 5 9 Yes Yes 
Tb927.9.4190 fatty acyl CoA syntetase 1  - 3 - No Yes 
Tb927.3.5190 hypothetical protein, conserved  5 4 6 Yes Yes 
Tb927.10.12090 RBP7A - - 4 No Yes 
Tb927.3.3000 PIFTC3 6 7 5 Yes Yes 
Tb927.7.2660 ZC3H2O 7 - - No Yes 
Tb927.3.5530 Tb-292 membrane associated protein  8 - - No No 
Tb927.7.5620 SET domain containing protein, putative 9 - - No No 
Tb927.9.12490 hypothetical protein, conserved  10 - - No No 
Tb927.7.5210 
Putative phosphatase/protein of unknown 
function DUF89 - 8 7 No No 
Tb927.6.3220/ 
Tb11.v5.0720 
hypothetical protein, conserved, post 
transcriptional activation (gene copies) 11 12 8 Yes No 
Tb927.11.17610 
variant surface glycoprotein (VSG), 
frameshifted and point mutation  - 9 19 No No 
Tb927.8.5280 TbMRPS34 13 17 13 Yes No 
Tb927.5.3160 protein kinase, putative  16 10 16 Yes No 
Tb927.11.12470 hypothetical protein, conserved  15 11 14 Yes Yes 
Tb927.7.1640 
Mitochondrial LSU ribosomal protein, 
putative 14 - - No No 
Tb927.7.4440 
NAD dependent epimerase/dehydratase 
family, putative 16 - - No No 
Tb927.5.3330 hypothetical protein, conserved  - 18 12 No No 
Tb927.2.3320 65 kDa invariant surface glycoprotein  18 - - No Yes 
Tb927.3.3010 hypothetical protein, conserved  20 14 18 Yes No 
Tb927.3.3020 actin-like protein, putative  19 15 17 Yes No 
Tb09.v4.0072 
variant surface glycoprotein (VSG, 
pseudogene), putative - 16 - No Yes 
Tb927.9.2220 SUMO1/Ulp2, putative  - - 15 No No 
Tb927.4.240 
retrotransposon hot spot protein (RHS, 
pseudogene), putative  - 19 - No No 
Tb927.11.1680 vesicular-fusion protein SEC18, putative  - - 20 No No 
Tb927.10.4790 hypothetical protein, conserved  - 20 - No Yes 
              
Table 5.2 List of genes from the GKI7 RNAi library screen identified by Ion Torrent sequencing of 
RNAi insert specific PCR products including the top 20 hits for each induced replicate. Ranking of 
each gene is shown for each induced replicate in columns 3 to 5. The final column refers to whether a 
reduced fitness phenotype was observed upon differentiation in a RIT-seq screen (Alsford et al., 
2011). Highlighted rows: previously identified by cloning; known posST component; yellow and 
green pair gene copies; pseudogenes. 
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Of the genes previously identified by sequencing in the pGEM-T Easy vector, reads 
aligning to hypothetical proteins Tb927.6.2520 and Tb927.10.14400 were highly 
abundant in all 3 induced replicates sequenced while reads from synaptojanin and 
ZC3H20 were abundant only in replicates 4 and 1 respectively. This matched the 
PCR product profile shown in Figure 5.16. Surprisingly, MTQ1 was not detected by 
Ion Torrent sequencing, despite being independently identified from cloning of two 
distinct PCR fragments.  
Of the known posST components, RBP7A was the fourth highest hit in replicate 4. 
This is in agreement with the dose response analysis shown in Figure 5.8, in which of 
all the posST RNAi and KO lines tested, the RBP7 null mutant most convincingly 
showed decreased sensitivity to GKI7. None of the other posST components studied 
were identified, suggesting that stumpy formation by GKI7 follows a pathway 
largely distinct to that induced by cAMP, but that both involve the action of RBP7. 
Also identified were numerous genes of wide-ranging predicted functions not 
previously implicated in stumpy formation. The inclusion of metabolic enzymes fatty 
acyl-coA synthetase 1 (Tb927.9.4190) and a putative member of the NAD dependent 
epimerase/dehydratase family (Tb927.7.4440) likely relates to the metabolic changes 
which occur during differentiation in preparation for survival in a new host. 
Tb927.7.4440 is predicted to be upregulated in stumpy forms according to a recent 
proteomic study (Dejung et al., 2016). The presence of two components of 
mitochondrial ribosomes (Tb927.8.5280 and Tb927.7.1640) may also reflect the 
upregulation of mitochondrial activity in stumpy formation prior to uptake by the 
tsetse. Tb927.8.5280 is also predicted to be upregulated in stumpy forms (Dejung et 
al., 2016). Similar to the cAMP-responsive posST pathway, the cohort includes 
signalling components including a putative kinase (Tb927.5.3160) and putative 
phosphatase (Tb927.7.5210). The kinase is upregulated both in stumpy forms and 
during subsequent differentiation to procyclic forms, while the phosphatase is 
upregulated during procyclic differentiation (Dejung et al., 2016). There are also a 
number of candidates which could potentially be involved in regulation of 
expression. This includes epigenetic regulation, in the case of Tb927.7.5620, which 
contains a SET domain associated with lysine methyltransferases (Dillon et al., 
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2005), and the predicted SUMO protease SUMO1/Ulp2 (Tb927.9.2220). In addition, 
the hypothetical protein Tb927.6.3220 was implicated in post-transcriptional 
activation when artificially tethered to a reporter mRNA (Erben et al., 2014). 
Curiously, three pseudogenes were also selected. It is possible that these transcribe 
non-protein coding RNAs with regulatory roles. RNAi of one of these, the VSG 
pseudogene Tb09.v4.0072, was previously found to reduce fitness upon 
differentiation in a RIT-seq screen (Alsford et al., 2011). Additional hits included an 
actin-like protein (Tb927.3.3020), an intraflagellar transport protein (Tb927.3.3000) 
and various hypothetical proteins.  
As independent validation of individual RNAi lines has yet to be completed for any 
of the above hits, their involvement in stumpy formation remains hypothetical. RNAi 
of some transcripts may select for resistance to GKI7 by mechanisms distinct from 
differentiation. As such, the selection of the putative vesicular fusion protein SEC18 
(Tb927.11.1680) may reflect reduced uptake or increased export of the compound 
via vesicular transport. A 65 kDa invariant surface glycoprotein (Tb927.2.3320) was 
also selected. RNAi of another ISG, ISG75, was selected for resistance to suramin 
and resulted in reduced binding of the drug (Alsford et al., 2012). Interestingly, 
ISG65 was downregulated upon RNAi of RDK1, which promotes bloodstream to 
procyclic differentiation (Jones et al., 2014). 
5.7 Discussion 
5.7.1 Identification of a GKI7, a compound capable of 
inducing stumpy formation. 
MacGregor et al. (2014) previously developed a monomorphic reporter line in which 
the PAD1 3’UTR was conjugated to the β-glucuronidase reporter to use in high-
throughput screening assays for stumpy-inducing compounds. This reporter line was 
used to identify E667, a small molecule capable of inducing differentiation in 
monomorphic and pleomorphic trypansosomes, demonstrating its efficacy as a 
phenotypic screening tool and the value of its use in the screening of further 
compound libraries. The subsequent identification of potent inhibitors of 
trypanosome growth from a kinase-targeted library by Diaz et al. (2014) provided an 
excellent compound set for such analysis. 52 small molecules were tested for 
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upregulation of the PAD1 reporter, of which 6 resulted in greater than 53% reporter 
activation relative to pCPTcAMP (Figure 5.3). GKI7 resulted in the greatest level of 
activation and was selected for further analysis. Subsequent validation in a 
pleomorphic line demonstrated that this molecule caused G1 arrest and upregulation 
of the PAD1 protein (Figure 5.5). Again, this validated the effectiveness of the 
reporter assay in the identification of stumpy-inducing small molecules which can be 
used both as research tools and potentially as novel therapeutics. Although only 
GKI7 was analysed further in this thesis, the other five compounds also merit 
subsequent validation. As the tested compound set was previously selected for 
potency of growth inhibition, GKI7 was capable of triggering differentiation at a 
substantially lower concentration (1.44 µM) than E667 (50 µM) and thus represents a 
useful tool for future analysis. 
5.7.2 Sensitivity to E667 and GKI7 of posST RNAi and KO 
lines. 
E667 and GKI7 have been shown to induce stumpy formation but it is unknown if 
they act via the same pathway as cAMP and, if so, at what point on this pathway. If 
either compound acts on a posST component downstream of cAMP, RNAi silencing 
of those components downstream of this action would confer resistance to the 
compound while any which acts upstream would remain sensitive (Figure 5.1). RNAi 
lines for 6 posST components (PP1, DSP, MEKK1, HYP2, YAK and NEK) were 
tested for sensitivity to E667 at 50 µM (Figure 5.6). RNAi did not appear to confer 
resistance in any case. However, contrary to previous observations by Mony et al. 
(2014), many of these lines concurrently showed little or no resistance to 
pCPTcAMP. To negate the possibility that subtle resistance phenotypes were being 
masked at a single drug concentration, the sensitivity of posST RNAi and null 
mutant lines to pCPTcAMP, E667 and GKI7 were instead analysed using a range of 
concentrations and dose response curves generated. For many cell lines tested, 
resistance to pCPTcAMP still was not observed. This was unexpected as the posST 
components were originally selected for resistance to pCPTcAMP upon RNAi 
silencing and this was validated in each independent RNAi line (Mony et al., 2014). 
In addition, all cell lines recently tested in vivo still effectively reduce stumpy 
formation in response to SIF (K. McWilliam and K. Matthews, unpublished). It is 
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possible that the loss of the cAMP resistance phenotype was due to adaptation of the 
cells in culture over time. As any such adaptation may also affect the response to 
other stumpy-inducing compounds, it complicated interpretation of E667 and GKI7 
sensitivity analyses. RNAi of DSP, MEKK1, YAK and NEK all had no apparent 
effect on sensitivity to either compound, indicating that they operate independently 
of these proteins. HYP2 RNAi resulted in a modest decrease in sensitivity to GKI7 
but this was not replicated in the HYP2 null mutant line. PP1 RNAi also showed a 
modest decrease in sensitivity to pCPTcAMP, E667 and GKI7. The most obvious 
effect, however, was observed in the RBP7 null mutant line, which showed a 
substantial reduction in sensitivity to pCPTcAMP and GKI7 and was completely 
resistant to E667. This indicated that stumpy formation by both E667 and GKI7 is 
dependent on RBP7, which is consistent with the prediction that this protein acts 
relatively low down in the pathway. This could indicate that these compounds 
activate the posST pathway at a position low down in the signalling cascade or 
alternatively that they activate an alternative stumpy formation pathway which 
converges with the cAMP-responsive posST pathway at or above RBP7. However, 
the muted response to pCPTcAMP of various posST RNAi and KO lines means that 
the possibility cannot be excluded that E667 and/or GKI7 act higher up in the posST 
signalling pathway but that the effects of these manipulations were masked by 
adaptation of the parasites. 
5.7.3 Cells rapidly generate resistance to E667 
An RNAi library screen offers a more global approach to identifying downstream 
effectors of stumpy-inducing compounds, as was used for pCPTcAMP/AMP (Mony 
et al., 2014). However, in the case of E667, a high concentration of drug (250 µM) 
was required to sufficiently inhibit the uninduced monomorphic RNAi library cells 
and, in most replicates, growth resumed within 2-6 days of drug treatment (Figure 
5.14). This rapid development of resistance in the absence of RNAi induction 
precluded the use of an RNAi library screen to identify components responsive to 
this compound.  
Treatment of pleomorphic AnTat 1.1 90:13 cells with an equivalent concentration of 
E667 resulted in a higher degree of growth inhibition relative to monomorphic cells 
   
   150
(Figure 5.14). However, after 12 days of treatment with 250 µM E667, one of six 
replicates tested in this cell line developed resistance to the compound and growth 
was restored to wild type levels. Although this cell line was able to grow 
continuously in the presence of the compound, the resistance phenotype was lost 
when drug pressure was removed for 12 days. This indicated that the cells developed 
resistance via an adaptation which arises in independent replicates, is not cell line 
specific and can be both acquired and lost rapidly. It is currently unknown if resistant 
cells display cross-resistance to other differentiation signals. The E667 resistant 
AnTat 1.1 90:13 cell line may prove a useful tool in future studies of this kind. 
5.7.4 RNAi library screen with GKI7 reveals putative novel 
differentiation factors. 
GKI7 was found to effectively inhibit the RNAi library population at the 
concentration used for all previous experiments (1.44 µM). So in order to 
comprehensively identify downstream effectors of this compound, the RNAi library 
was induced and treated with GKI7. A resistant population gradually outgrew in all 5 
replicates and amplification of RNAi inserts showed selection of specific RNAi 
fragments, with the majority of replicates showing a similar profile (Figure 5.16). 
Unexpectedly, a resistant population also outgrew in the uninduced replicates, 
although this effect was delayed by approximately 48 hours relative to the replicates 
in which RNAi had been induced (Figure 5.15). The amplified RNAi insert profile of 
these cells showed a less specific profile than in the induced replicates with a far 
greater number of bands present (Figure 5.16) and a greater degree of widespread 
random mapping to the genome at low read density by Ion Torrent sequencing 
(Figure 5.17). However, the visibility of distinct bands indicated that some degree of 
selection had occurred for specific RNAi inserts in the absence of tetracycline, 
possibly due to leaky dsRNA expression. Indeed, a number of hits identified in the 
induced replicates by Ion Torrent sequencing were also highly abundant in the 
uninduced replicate sequenced. An alternative explanation for the emergence of a 
resistant population in the absence of induction is that either GKI7 or by-products of 
GKI7 are mutagenic, leading to background genomic mutations unrelated to RNAi.  
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RNAi inserts of the selected parasites were identified, first by sequencing of distinct 
amplified bands cloned into the pGEM-T Easy vector, and then more 
comprehensively by Ion Torrent sequencing. PCR products for 3 induced replicates 
and 1 uninduced replicate were subject to the latter method. The hits identified by 
each method were in good agreement, with four out of five cloned genes appearing 
as top hits in the Ion Torrent dataset and variation between replicates consistently 
reflected.  
A number of hits showed very high read density in one of the replicates sequenced 
but were low or absent in others, indicating that parasites silencing certain genes 
were selected in some replicates and not others. For example, Tb927.7.3490 was 
cloned from a PCR band only visible in induced replicate 4. When sequenced by Ion 
Torrent, read density for this gene was the second highest for that replicate but this 
was more than 300 fold lower in the other replicates sequenced. For this reason, the 
top 20 hits were calculated for each replicate sequenced as many genuine hits may be 
unrepresented in some replicates due to incomplete genomic coverage within a single 
replicate. Alsford et al. (2011) reported that the library included 5 RNAi targets per 
gene in an uninduced population. While maintenance of the library at >5x106 cells 
and use of >1x107 cells for each replicate should be sufficient to sustain this level of 
complexity, it is likely that complexity has been lost over time due to growth and 
passage of the cells in our lab. This may have been exacerbated by the progressive 
dilutions entailed in the 48 hour period between thawing of the cells and induction of 
the library (see section 2.17). Overall, this should be resolved by the use of multiple 
replicates to increase genomic coverage.  
Collation of these hits gave a total of 29 candidate genes. It is possible that some of 
these genes may be false positives due to sequence homology with the RNAi insert 
primers. Glover et al. (2015) recommended filtering reads using construct-specific 
tags internal to the sequences used in amplification to confirm construct as opposed 
to genomic origin. This step was not included in the analysis presented in this thesis. 
However, a preliminary analysis which did detect and remove construct tags 
produced an identical list of candidate genes with only very minor variations in the 
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ranking positions of a few genes, which would indicate that all 29 candidates were 
identified from genuine RNAi fragments.  
The 29 candidates include many novel genes not previously implicated in stumpy 
formation with a wide range of predicted functions. 11 of these showed reduced 
fitness upon differentiation in a RIT-seq screen (Alsford et al., 2011). Included were 
the metabolic enzymes fatty acyl coA synthetase 1 and a putative NAD dependent 
epimerase/dehydratase, as well as two mitochondrial ribsome components, which 
may reflect the altered energy metabolism and upregulated mitochondrial activity in 
the stumpy form in preparation for transmission to the tsetse vector. Also present 
were a number of potential gene regulators, including a hypothetical protein and a 
zinc finger protein (ZC3H20) both shown to result in post-transcriptional activation 
when tethered to a reporter transcript (Erben et al., 2014). Interestingly, a number of 
hits had putative roles in chromatin remodelling. These include a predicted SUMO 
protease and a protein containing a SET domain, associated with lysine 
methyltransferases (Dillon et al., 2005). These could be involved in the loss of mono-
allelic control of VSG expression associated with stumpy forms (Amiguet-Vercher et 
al., 2004; Navarro and Gull, 2001), which involves delocalisation of polymerase I 
from the expression site body (ESB) containing the active VSG expression site 
(Barquilla et al., 2012), as SUMOylation has been shown to positively regulate VSG 
expression at the ESB in slender forms (Lopez-Farfan et al., 2014). Another hit 
identified by PCR product cloning was the predicted S-adenosylmethionine-
dependent methyltransferase MTQ1, although this was not found by Ion Torrent 
sequencing. 2 predicted kinases and a predicted phosphatase also indicated the 
involvement of signal transduction in relaying the GKI7 response. 
A number of hits had putative functions in endocytic and vesicular transport 
processes. These include an N-terminal synaptojanin orthologue and putative 
vesicular fusion protein SEC18. It is possible that RNAi of these genes confers 
resistance to GKI7 independently of stumpy formation pathways, for example via 
decreased uptake or increased export of the compound. However, RNAi of the 
synaptojanin orthologue results in reduced fitness upon differentiation (Alsford et al., 
2011), supporting a role in stumpy formation. ISG65 was also identified in the 
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screen. It is possible that this could be involved in binding and uptake of the 
compound as RNAi of another ISG, ISG75, was selected for resistance to suramin 
due to reduced binding of the drug (Alsford et al., 2012). However, a role specific to 
the differentiation process is supported by the fact that ISG65 was downregulated 
upon RNAi of RDK1, which promotes bloodstream to procyclic differentiation 
(Jones et al., 2014). 
The inclusion of 3 pseudogenes among the screen hits indicated the involvement of 
non-protein factors in the response to GKI7. One of these, the VSG pseudogene 
Tb09.v4.0072, has previously been implicated in differentiation due to reduced 
fitness in the RIT-seq screen (Alsford et al., 2011). It is possible that these 
pseudogenes transcribe ncRNAs with regulatory functions.  
RBP7A was also identified in the screen. This was in agreement with previous 
results which showed that the RBP7 null mutant line was less sensitive to GKI7 
(Figure 5.4 and Figure 5.8), supporting the hypothesis that stumpy formation by 
GKI7 is dependent on RBP7. In contrast, none of the other posST components were 
detected, indicating that GKI7 acts independently or downstream of these proteins, as 
depicted in Figure 5.18. The number of novel hits identified would favour the option 
that GKI7 induces differentiation via a pathway distinct to pCPTcAMP and that the 
two pathways converge upstream of RBP7. 
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Figure 5.18 Alternative models of stumpy formation induced by cAMP or GKI7. Left: cAMP and 
GKI7 induce distinct stumpy signalling pathways involving different effectors. The pathways 
converge upstream of RBP7. Right: Alternatively, GKI7 induces the same stumpy signalling pathway 
as cAMP, but acts upstream of RBP7 and downstream of other posST components.  
The identification of so many genes that had not previously been implicated in 
stumpy formation, and which may operate in a distinct arm of the pathway to those 
previously studied, represents an intriguing prospect for future analysis. All of these 
hits remain to be independently validated. Stumpy signalling can then be further 
explored by examining the interactions between these novel components and also 
their relationship to the actions of the cAMP-responsive posST components, 
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6 Chapter 6: Summary and future directions 
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The differentiation of Trypanosoma brucei, from proliferative slender forms to 
arrested, transmissible, stumpy forms in the mammalian bloodstream involves 
extensive morphological and metabolic adaptations in preparation for uptake by the 
tsetse fly vector. The signalling pathway which transduces the unindentified parasite-
derived stumpy induction factor signal to produce these adaptations remained 
uncharacterised until Mony et al. (2014) carried out an RNAi library screen for 
resistance to the stumpy inducing molecules pCPTcAMP and pCPTAMP. This 
identified a cohort of positive mediators of stumpy formation (posST), many of 
which were individually demonstrated to be involved in differentiation in vitro and in 
vivo. How these proteins function together to drive stumpy formation remains 
unknown and this thesis aimed to order known components of the process within the 
signalling pathway. 
 Firstly, the organisation of the pathway was explored using knockout and 
overexpression combinations of distinct posST components in pleomorphic 
trypanosomes to determine the dependency relationships between these proteins. The 
effect on differentiation of these manipulations was analysed for numerous 
combinations, in particular those involving the posST components PP1, RBP7, YAK 
and NEK, revealing a pathway structure predicted to divide into two separate 
branches with PP1 and YAK acting via one arm and NEK and RBP7 through the 
other (Figure 3.31). This demonstrated simultaneous knockout and overexpression to 
be an effective method of elucidating the organisation of the stumpy signalling 
pathway. Future use in further combinations will not only allow the incorporation of 
additional components into the model, but will enable corroboration of the predicted 
positions of those components already investigated in multiple combinations and 
clarification for components such as HYP2 and MEKK1, which have been tested in 
fewer combinations to date and for which positioning remains tentative. 
Further contributions to the proposed pathway organisation came from the 
phosphoproteomic analysis of two posST kinases, MEKK1 and YAK (section 3.4). 
The first was that NEK is dephosphorylated in the MEKK1 null mutant line, which 
indicated that MEKK1 acts upstream of NEK. This placed MEKK1 on the branch of 
the signalling pathway containing NEK and RBP7 (Figure 3.31). It would be 
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interesting to explore by enzymatic assay whether MEKK1 directly phosphorylates 
NEK and how this affects its activity. However, recombinant expression of MEKK1 
could prove complicated, based on the difficulties experienced in its overexpression 
(sections 3.2.3.6 and 3.2.3.7). The second contribution is that phosphorylation of 
AMPK β is increased, indicating that activity of the known posST component 
AMPK α2 may either be regulated downstream of MEKK1 and YAK or alternatively 
can be independently upregulated to compensate for the loss of these kinases. While 
these changes remain to be independently validated, and involvement of many of the 
proteins affected in differentiation remains hypothetical, the differences observed 
between MEKK1 KO and YAK KO raises the interesting possibility that global 
analysis of the downstream effects of these signalling components could be used to 
identify which differentiation processes are activated by different branches of the 
pathway, as both kinases affected phosphorylation of proteins involved in a wide 
range of cellular processes.  
A number of inhibitors of stumpy formation have also been identified previously 
(Barquilla et al., 2012; Domenicali Pfister et al., 2006; Vassella et al., 2001). The 
relationship between differentiation promoting and differentiation inhibiting 
mechanisms was explored using a pleomorphic TOR4 RNAi line. TOR4 RNAi had 
previously been shown to trigger stumpy formation in vitro in a monomorphic line 
(Barquilla et al., 2012) and this phenotype was also observed in a pleomorphic line 
(Figure 4.1). RNAi induction also resulted in stumpy formation at low parasite 
density in vivo (Figure 4.2). Ablation of posST components in combination with 
TOR4 RNAi was used to explore the dependency relationships between positive and 
negative regulators of stumpy formation. TOR4 RNAi in conjunction with either 
NEK RNAi or MEKK1 KO resulted in growth inhibition in vitro and in vivo (Figure 
4.3 and Figure 4.6). TOR4 RNAi still caused cell cycle arrest independently of either 
posST component but was unable to upregulate PAD1 expression (Figure 4.4 and 
Figure 4.7), indicating that this process is dependent on MEKK1 and NEK. This 
indicated that TOR4 acts at an early stage of differentiation to inhibit cell cycle 
arrest, while MEKK1 and NEK are implicated in both arrest and later stages of the 
process including PAD1 expression (Figure 4.4.8). These results support the model 
proposed by Mony et al. (2015) in which stumpy formation is regulated by two 
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opposing mechanisms, in which TOR4 and other inhibitors of differentiation act to 
retain the slender state, while the posST components activate stumpy formation. The 
slender retention mechanism, including TOR4, would be predicted to be active in 
slender forms at low density in blocking the initial stages of differentiation, including 
cell cycle arrest. This inhibition is removed upon TOR4 RNAi, and the posST 
pathway activates the entire differentiation program. 
It would be interesting to further explore the intersection of these two opposing 
mechanisms in differentiation. However, this would likely require a change in 
strategy from the TOR4 RNAi + posST RNAi/KO combinations used here. TOR4 
RNAi does not offer the “clean” genetic background provided by posST null mutant 
lines in which to perform further genetic manipulations. TOR4 RNAi line infections 
proceeded with complex kinetics, possibly in part due to temporal variablility in the 
level of silencing, and this complicated analysis when used in combination with 
RNAi/KO of other genes. Although the growth phenotype observed upon TOR4 
RNAi suggests that it is essential and therefore not amenable to knockout, Vassella et 
al. (2001) were able to successfully delete both alleles of another stumpy inhibitor, 
ZFK, in a pleomorphic strain, despite this resulting in a similar slow growth 
phenotype to TOR4 RNAi. 
The organisation of the stumpy signalling pathway was further interrogated using 
chemical-genetic analysis. The identification of small molecules capable of inducing 
stumpy formation at low density has potential both in the discovery of novel 
therapeutics and for use as chemical tools in the investigation of the process. 
MacGregor et al. (2014) identified one such compound, E667, using a stumpy-
specific reporter line to screen a compound library. This reporter line was used here 
to screen 52 compounds selected for trypanosome growth inhibition (Diaz et al., 
2014), identifying a further six compounds capable of inducing stumpy formation 
(Figure 5.3), one of which, GKI7, was selected for further analysis (Figure 5.5). 
Nothing is known about the mechanism by which either E667 or GKI7 induce 
stumpy formation: whether they act at the same point of the stumpy signalling 
pathway to cAMP, or indeed whether they act via the same pathway at all. A 
compound which acts via the posST pathway, but at a point downstream of cAMP, 
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would offer an invaluable tool to investigate ordering of the pathway, as known 
components could essentially be phenotypically separated into two subsets using 
RNAi/KO lines: downstream components which confer resistance to the compound, 
and those upstream or on separate branches, for which sensitivity would be retained 
(Figure 5.1).  
Genes involved in resistance to E667 and GKI7 were therefore investigated using a 
combination of individual posST RNAi and KO lines and RNAi library screens. The 
first approach was hindered by the fact that many of these lines appeared to have lost 
resistance to pCPTcAMP, possibly due to adaptation through culture, which 
complicated interpretation for many cell lines. However, the PP1 RNAi line showed 
a modest reduction in sensitivity to both E667 and GKI7 (Figure 5.7), and the RBP7 
KO line showed clear resistance to both compounds (Figure 5.8), indicating that 
E667 and GKI7 action is dependent on RBP7 and possibly PP1. Resistance to GKI7 
was more comprehensively explored using an RNAi library screen, which identified 
mainly genes not previously implicated in differentiation (Table 5.1 and Table 5.2). 
The exception was RBP7, consistent with the result observed using the RBP7 KO 
line. As no other posST components were identified, this would suggest that GKI7 
induces stumpy formation via a largely separate pathway to cAMP involving distinct 
components, but that the two pathways converge upstream of RBP7. This supports 
the hypothesis that RBP7 is a central regulator of differentiation which acts far down 
in the signalling pathway. In addition, this screen has identified many potential novel 
mediators of stumpy formation which remain to be validated using individual RNAi 
lines. 
It was not possible to carry out an RNAi library screen to identify genes involved in 
resistance to E667 as the parasites rapidly and consistently developed resistance to 
the compound in the absence of tetracycline and were again able to proliferate 
normally (Figure 5.14). A pleomorphic line similarly developed resistance to the 
compound. Although these cells grew at a rate comparable to untreated parasites, 
continuous drug pressure was required to maintain resistance. This indicated that T. 
brucei are easily able to generate resistance to E667 via a mechanism which can be 
both acquired and lost rapidly. The E667 resistant pleomorphic line may serve as a 
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useful tool in future studies of stumpy formation pathways. It would be interesting to 
explore its competence to differentiate in response to other signals such as 
pCPTcAMP and SIF. 
While mapping the signalling pathway mediating differentiation to stumpy forms is 
still in its very preliminary stages, the work described here provides a valuable 
framework upon which subsequent analyses can be built and existing predictions 
corroborated, as well as validating strategies which will facilitate this work. It has 
also identified many potential novel mediators of stumpy formation to be 
individually analysed and ultimately incorporated into an increasingly characterised 
pathway. 
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Appendix A: Primers 
Nomenclature guide: 
F/FW – forward; R/RV – reverse 
MKD – monomorph knockdown; PKD – pleomorph knockdown 
OE – overexpression 
KO – knockout 
5/3 ext/int – external/internal 5’/3’UTR;  
2300 – AK; 1240 – PP2A; 2720 – MEKK1; 1930 – TOR4 
GC – Gibson cloning (see section 2.4.7) 
RNAi primers for pRPa constructs: 
MKD2300F (XbaI/BamHI) TCTAGAGGATCCAGTTTGTATCACCGGCAAGG  
MKD2300R (XhoI/SmaI) CTCGAGCCCGGGCTTGCAATCTCCTCGACACA  
MKD1240F (XbaI/BamHI) TCTAGAGGATCCCGAAAGTATGGCAGTGCAAA  
MKD1240R  (XhoI/SmaI) CTCGAGCCCGGGGCACGAGCAATTGTTTTCAA  
MKD1930F (XbaI/BamHI) TCTAGAGGATCCCTGCAGACGTATCTCGACCA  
MKD1930R (XhoI/SmaI) CTCGAGCCCGGGCTTTGAAAAGACCTCCAGCG  
RNAi primers for p2T7-177 constructs: 
PKD1930F (BamHI/HindIII) GGATCCAAGCTTCTGCAGACGTATCTCGACCA  
PKD1930R  (XhoI/XbaI) CTCGAGTCTAGACTTTGAAAAGACCTCCAGCG 
RNAi primers for pALC14 constructs: 
PKD2300F  (BamHI/HindIII)  GGATCCAAGCTTAGTTTGTATCACCGGCAAGG  
PKD2300R (XhoI/XbaI) CTCGAGTCTAGACTTGCAATCTCCTCGACACA  
PKD2720F (BamHI/HindIII) GGATCCAAGCTTTTATGTAATGCAGCGAAGCG  
PKD2720R (XhoI/XbaI) CTCGAGTCTAGAACCGTTGTCACGCTTATTCC  
Overexpression primers for pDEX 577-Y constructs: 
MEKK1OE FW (SpeI)  ACTAGTCCCTTCGCGGCAAAT 
(for N-terminal TY tagged copy) 
CatMEKK1OE FW (SpeI)  ACTAGTTCTTACACGTTGGGGCG 
MEKK1OE RV (BamHI) GGATCCCTAAACAACTCCCTGATCACCA 
MEKK1OECtTY GC Pt1FW GTATGGACCTCTCTAGAAACAACTCCCTGATCACC 
MEKK1OECtTY GC Pt1RV GTGCAAGTAATGGTGCTATTAGCAGTG 
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MEKK1OECtTY GC Pt2FW AGCACCATTACTTGCACCCGAAGAGC 
MEKK1OECtTY GC Pt2RV AGTAAAATTCACAAGCTTATGATGCCCTTCGCGGCAAAT 
NEKOE FW GC (XbaI)         GTATGGACCTCTCTAGACAATCCAAGAACCTCCTGTATTTTC 
NEKOE RV GC (HindIII)      AGTAAAATTCACAAGCTTATGATGTCGTCAACGGATGCAATG 
182 (YAK GC Pt1 FW) (SpeI)  TCACACTAGTACGTTGTGAGTATACCTG 
179 (YAK GC Pt1RV)  TCGGTGATCCCTCAATGGTACCAACCCATAC 
178 (YAK GC Pt2 FW)  TACCATTGAGGGATCACCGAATGGTATATACGTGTG 
175 (YAK GC Pt2 RV) (SpeI) ACCAAAAAGTAAAATTCACAAGCTTATGGACGCTGACGAG 
       GGC 
Knockout primers for pEnT6B-Y/pEnT6P-Y constructs: 
MEKK1 KO internal UTR primers: 
2720KO 5U F (SpeI)  ACTAGTTTATCAGGGGGTTCGAG 
2720KO 5U R (BamHI) GGATCCGGGTGGTCACCTGCTC 
2720KO 3U F (HindIII) AAGCTTGAATATATGTAAAAGGGAAGAAGG 
2720KO 3U R (SpeI)  ACTAGTCGATTACCCTCTTCCCC 
MEKK1 KO external UTR primers: 
MEKK1 5extF (SpeI)  ACTAGTGTACGTCATTTGCTCCATT  
MEKK1 5extR (BamHI) GGATCCGGGTGGTCACCTGCTC 
MEKK1 3extF (HindIII) AAGCTTGAATATATGTAAAAGGGAAGAAGG 
MEKK1 3extF (SpeI)  ACTAGTCGATTACCCTCTTCCCC 
RNAi library primers: 
Lib3F    ATCAAGCTTGGCCTGTGAG 
Lib3R    CCTCGAGGGCCAGTGAG 
qRT-PCR primers: 
TOR4qF   ACTGCATGGACAAGCAAGTG 
TOR4qR   TCAGCAATAACAGGCACGAG 
17 (ZFP3qF)   CAGGGGAAACGCAAAACTAA 
19 (ZFP3qR)   TGTCACCCCAACTGCATTCT 
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Appendix B: Antibody concentrations 
 
rabbit α-PAD1 (Eurogentec)    Western 1:1000 
       IFA  1:1000 
       FACS  1:200 
mouse α-EF1 (Millipore)    Western 1:7000 
mouse α-EP procyclin (VH Bio)   FACS  1:500 
mouse α-BB2 (in house)    Western 1:20 
       IFA  1:2 
α-rabbit-HRP (Sigma)    Western 1:1000 
α-mouse-HRP (Sigma)    Western 1:7000 
α-rabbit IRDye 800CW (LiCor)   Western 1:7500 
α-mouse IRDye 800CW (LiCor)   Western 1:7500 
α-rabbit IRDye 680 (LiCor)    Western 1:7500 
α-mouse IRDye 680 (LiCor)    Western 1:7500 
α-rabbit Alexa fluor 488 (Life Technologies) IFA  1:1000 
α-mouse Alexa fluor 488 (Life Technologies) IFA  1:1000 
α-rabbit Cy5 (Jackson ImmunoResearch)  FACS  1:1000 
α-mouse FITC (Sigma)    FACS  1:1000 
 
Appendix C: Drug concentrations 
 
Drug 2T1 427/S16 AnTat 1.1 90:13 
Hygromycin 2.5 2 0.5 
G418  - 2.5 2.5 
Phleomycin 0.5 2.5 1.5 
Puromycin 0.2 0.5 0.5 
Blasticidin 2 - 10 
Tetracycline 1 1 1 
Table 1 Table of drug concentrations used for selection and maintenance of T. brucei in culture. 
Concentrations are in µg/ml. 
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Appendix D: Plasmid maps 
pRPa 
 
Figure 1 pRPa vector map. RNAi construct for T. brucei 2T1 cell line containing the terminal 
component of a hygromycin resistance gene (HYG) and RRNA spacer sequences for targeting to 
RRNA locus containing the remaining portion of HYG and the complete puromycin resistance gene 
(PAC) on chromosome 2a in 2T1 cells. Correct integration generates an intact HYG ORF under the 
control of the EP procyclin promoter and deletes the PAC ORF. Within, a stem-loop component, in 
which the ‘loop’ is a 468-bp lacz fragment, contains unique cloning sites, shown in the upper panel, to 
facilitate insertion of sense and antisense gene fragments for RNAi targeting. This component is under 
the control of an RRNA promoter and a tet operator which represses expression of the stem-loop RNA 
in the absence of tetracycline and allows expression on its presence. From Alsford and Horn (2008). 
 
  




Figure 2 pALC14 vector map. RNAi construct suitable for T. brucei lines with integrated expression 
cassettes for T7 polymerase and a tet repressor  (Bochud-Allemann and Schneider, 2002). The 
plasmid contains a puromycin resistance gene (PuroR) under the control of a T7 promoter and rRNA 
spacer sequence to enable targeting to RDNA locus. To enable RNAi, a stem-loop component 
contains unique cloning sites to facilitate insertion of sense and antisense gene fragments either side of 
the stuffer region for RNAi targeting. This component is under the control of a procyclin promoter 
and a tet operator which represses expression of the stem-loop RNA in the absence of tetracycline and 
allows expression on its presence. 
  





Figure 3 p2T7-177 Wickstead map. RNAi construct suitable for T. brucei 427 and AnTat 1.1 90:13 
lines with integrated expression cassettes for T7 polymerase and a tet repressor (Wickstead et al., 
2002). The plasmid contains a phleomycin resistance gene under the control of an rDNA promoter and 
177bp repeat sequences to enable targeting to the transcriptionally silent mini-chromosomes. The 
RNAi component is flanked by opposing T7 promoters to enable double-stranded RNA synthesis and 
tet operators to repress its expression in the absence of tetracycline. 
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MEKK1 KO pEnT6B-Y 
 
 
Figure 4 Constructs for generation of MEKK1 null mutant line. External fragments of the 3’UTR and 
5’UTR of MEKK1 were cloned into the pEnT6B-Y plasmid (Kelly et al., 2007) replacing the YFP 
and TY tags (extMEKK1pEnt6B-Y). Internal fragments of the 3’UTR and 5’UTR of MEKK1 were 
cloned into the pEnT6P-Y plasmid (intMEKK1pEnT6P-Y). Linearisation of the first plasmid using 
SpeI between the 3’UTR and 5’UTR fragments and transfection into AnTat 1.1 90:13 cells enabled 
recombination of the entire construct, including the BlastR gene, into the MEKK1 locus. SpeI 
linearisation of the intMEKK1 pEnT6P-Y plasmid then produced a PuroR containing construct 
capable of recombination only with the remaining MEKK1 allele. 
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Figure 5 pDex577-Y constructs used for overexpression of MEKK1. The MEKK1 ORF was cloned 
into the pDex577-Y plasmid, which facilitates tetracycline-inducible expression from an EP promoter 
(Kelly et al., 2007), using either BamHI and SpeI restriction sites to produce an N-terminal TY 
epitope tag or HindIII and XbaI to produce a C-terminal TY tag, replacing the vector’s YFP tag in 
both cases. In the final construct, the catalytic domain (Cat) of MEKK1 was cloned into pDex577-Y 
using BamHI and SpeI restriction sites to produce an N-terminal TY tag. NotI was used to linearise all 
3 constructs. 
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Appendix E: Ion Torrent Read Alignments  
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Figure 1 Read densities from Ion Torrent sequencing of RNAi insert specific PCR products aligned to 
individual genes identified as top hits in the GKI7 RNAi library screen. S007=tet+ R1; S008=tet+ R2; 
S009=tet+ R4; S010=tet- R1. Top strand graphs show transcription form left to right and bottom 
strand graphs show transcription from right to left. 
 
